Factors Affecting Blood Loss In Liver Surgery For Colorectal Metastases by Pathak, Samir
   
i 
 
 
Factors Affecting Blood Loss In Liver Surgery For Colorectal Metastases 
 
 
Volume 1 
 
Mr Samir Pathak 
Submitted in accordance with the requirements for the degree of 
Doctorate of Medicine  
 
The University of Leeds 
 
Department of General Surgery, St James’s University Hospital 
 
May 2017  
   
ii 
 
 
The candidate confirms that the work submitted is his/her own and that appropriate credit has 
been given where reference has been made to the work of others. 
 
 
This copy has been supplied on the understanding that it is copyright material and that no 
quotation from the thesis may be published without proper acknowledgement. 
 
Assertion of moral rights: 
The right of Mr Samir Pathak to be identified as Author of this work has been asserted by 
him in accordance with the Copyright, Designs and Patents Act 1988. 
 
© 2016  The University of Leeds and Mr Samir Pathak 
   
iii 
 
 Acknowledgements 
This research has been carried out by a team which has included (Professor Giles Toogood, 
Mr K Raj Prasad, Mr D Miskovic as supervisors and Dr S Brown, Ms Cath Moriarty, Ms L 
Brown, Mr A Hakeem, Dr A AlDuwaisan and Mr Khoyratty as co-investigators).  
The RCT (Chapter 6) was funded by a grant from the Research for Patient Benefit (RfPB) 
arm of the NIHR.  
Specifically I would like to thank the following: 
Professor Giles Toogood for offering me the chance to work in Leeds and for providing 
excellent mentorship through some difficult times. 
Mr Raj Prasad for giving me an opportunity to do this project and for ensuring that my time 
in research amounted to me submitting this thesis.  He always encouraged out of the box 
thinking 
Mr Danilo Miskovic for his detailed reviews of my work and support. 
Dr Emad Salib for his patience, help and expertise with statistical analysis. 
Ms Cath Moriarty and her team for being so supportive, particularly after my time in Leeds 
was completed. Without her, the RCT would not have completed recruitment 
My research colleagues (Amit Nair, Rajiv Dave, Alan White, Tom Pike, John Hutchinson, 
Jim Tiernan, and Adam Peckham-Cooper) and all my other clinical colleagues in Leeds- we 
were all in it together! 
I would also like to thank the wider faculty, staff and other colleagues in the Department of 
Hepatobiliary Surgery and Transplant at St. James’s University Hospital Leeds.  
   
iv 
 
I would also like to thank the Ray of Hope Charity whose funding has allowed me (and 
several others) to complete this work 
Several other friends and colleagues have helped me during the five years since I started my 
thesis both in terms of encouragement and in other pursuits. I would like to make particular 
mention of Mr Jonathan Rees, Mr Neil Smart and Mr Quentin Nunes.  
Lastly, I would like to thank my family whose guidance and well wishes have always been 
with me. Particular thanks to my Brother in Law, Avin Rabheru for his help in formatting! 
   
v 
 
 Abstract 
ABSTRACT 
Introduction 
Peri-operative blood loss and blood transfusions are associated with poorer short- and long-
term outcomes in patients undergoing hepatectomy. Various techniques are utilised to 
decrease blood loss though these may also cause an Ischaemia-Reperfusion Injury (IRI). The 
aim of this thesis was to identify factors which predispose to intra-operative bleeding during 
liver surgery and to identify methods to decrease blood loss without increasing the likelihood 
of post-operative liver dysfunction 
Methods 
In order to address the aim of this thesis, several studies are performed: 
1. A systematic review examining non-surgical methods to decrease blood loss. Primary 
outcome measures included peri-operative blood loss and transfusion requirements. The 
secondary outcome measure was occurrence of IRI. The review was performed according to 
the PRISMA guidelines for systematic reviews.  
2. A retrospective database analysed the association between blood transfusion and survival. .  
Uni- and multivariate analysis were performed.  
3. A pilot single blinded, randomised control trial (RCT) was undertaken comparing the 
Pringle manoeuvre (standard) versus Portal Vein clamping.  
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Results  
1.  Seventeen studies were included in the systematic review. In 8 studies (n=894) 
pharmacological methods and in another 9 studies (n=679) anaesthetic methods to 
decrease blood loss were investigated. In 3 trials potential benefits of anti-fibrinolytics 
were demonstrated. Six anaesthetic trials demonstrated potential roles for low central 
venous pressure, acute normovolaemic haemodilution, autologous blood donation 
techniques and choice of inhalational anaesthetic agent employed.  
Six hundred and ninety patients were included in this study. Median follow-up was 33 
months. Sixty-four (9.3%) patients required a peri-operative RBCT. Red cell 
transfusion was a predictor for decreased OS (median 41 vs 49 months, p=0.04). 
However, on multivariate regression analyses pre-operative chemotherapy, post-
operative complications and Clinical Risk Score (CRS) were independently associated 
with reduced overall survival, though RBCT was not. There was no association 
between RBCT and recurrence free survival ( median 15 vs 17 months, p=0.28) 
2. The main findings of the RCT were that it was technically feasible to perform isolated 
portal vein clamping in patients and to recruit patients into the trial. However, a larger 
RCT will be needed to obtain definitive evidence on the role of PVC in hepatic 
resections in the future 
 
Conclusions 
There is potential for use of non-surgical techniques to decrease peri-operative bleeding in 
liver surgery.  RBCT is not independently associated with poorer survival although it may be 
a surrogate marker for more advanced disease.  The RCT confirms that isolated portal vein 
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clamping is technically feasible and it was possible to recruit into the trial; a multi-centre 
RCT is required to assess the role of isolated portal vein clamping surgery for colorectal liver 
metastases. 
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1 Introduction 
1.1 Colorectal Cancer 
 
Colorectal cancer (CRC) is the third most common cancer in the world after breast and 
prostate cancer, with nearly 1.4 million new cases annually and the most common 
gastrointestinal cancer (Haggar and Boushey 2009) (Kingham, Correa-Gallego et al. 2015). 
In the UK 41,112 new cases of colorectal cancer are diagnosed each year, with a 10 year 
survival rate of  57% (UK 2009).  
However, the prognosis of breast and prostate cancer is relatively good with more than 4 out 
of 5 people surviving. In contrast, CRC has an all cause of mortality in 1 out of 3 patients 
with the disease (http://www.cancer.org/Cancer/ColonandRectumCancer/index 2011) 
Colorectal mucosal tumourigenesis is relatively slow with 90% of new cases being in the 
over 50 age group, and 94% of deaths also being in this age group. The incidence of CRC has 
been increasing but the overall mortality has been decreasing over the last 20 years (Jemal, 
Clegg et al. 2004). The decreased incidence is likely to be due to the early detection of 
invasive disease via colonoscopy and faecal occult blood tests and improved multi-
disciplinary management, as well as removal of adenomatous polyps, preventing adenoma-
carcinoma sequence progression (Selby, Friedman et al. 1992, Kronborg, Fenger et al. 1996) 
(Jemal, Clegg et al. 2004).  
Patients with early lesions experience 5-year survival rates of up to 90%, in contrast to those 
with widely disseminated metastatic disease at presentation who have five year survival rates 
of  < 10% (Nordlinger, Sorbye et al. 2008).  
Colorectal cancer is a multifactorial disease process, with aetiology encompassing genetic 
factors, environmental exposure and also inflammatory conditions of the gastrointestinal tract 
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(Deen, Silva et al. 2016). These lead to molecular and genetic events leading to 
transformation from adenomatous polyps to overt malignancy, characterized by Vogelstein 
and Fearon (Vogelstein, Fearon et al. 1988) . CRC is believed to result from a complex 
interaction between inherited susceptibility and environmental factors (Cooper, Squires et al. 
2010). Observational studies suggest that the development of CRC may be linked to obesity, 
smoking, high alcohol intake, high calorie intake, high intake of red meats and a low 
consumption of fruits, vegetables and fibres (NICE 2004). Risk of CRC is also increased in 
patients with inflammatory bowel disease, with the relative risk increasing dependent on 
disease duration and severity. (Eaden, Abrams et al. 2001) 
From a genetic point of view, a family history of CRC (particularly with a first degree 
relative diagnosed under the age of 45 years) is associated with an increased risk of CRC 
development (Hall, Finan et al. 1994). Approximately 5% of cases are associated with either 
familial adenomatous polyposis (FAP) or hereditary non-polyposis CRC. FAP causes 
approximately 1% of all CRCs and is caused by a mutation in the adenomatous polyposis coli 
gene. Patients with FAP may develop hundreds of polyps within the large bowel and by the 
age of 40, if they have not already had a colectomy, the majority would have developed CRC 
(Bishop and Hall 1994). Hereditary non-polyposis CRC is caused by a dominantly inherited 
alteration in one of a number of repair DNA mismatch repair genes; therefore it also conveys 
a slightly higher risk for the development of other cancers too. (Aaltonen, Salovaara et al. 
1998)   
Of those patients with colorectal cancer, 20-25% (8 – 10,000 in the UK) have CRLM present 
when their primary tumour is detected.  A further 40-50% of patients develop CRLM within 
three years of their prior bowel surgery (Weiss, Grundmann et al. 1986, Geoghegan and 
Scheele 1999, Mueller, Broering et al. 2002).  
   
3 
 
1.2 Surgery for Colorectal Liver Metastases 
Liver resection is the only treatment that offers potential cure in patients with colorectal liver 
metastases (CRLM). Five year survival rates of 40% in large prospective series and up to 
67% in highly selected cases are reported, particularly if surgery is combined with 
chemotherapy (Hadden, de Reuver et al. 2016).  
At presentation approximately only 20% of patients with CRLM have resectable 
disease(Martinez, Puig et al. 2007). However, the use of chemotherapy and more recently 
molecularly targeted agents, have been employed to downsize CRLM converting inoperable 
to potentially operable disease (Cunningham, Humblet et al. 2004, Bipat, van Leeuwen et al. 
2005, Grabowski, Mueller-Koch et al. 2005, Gervasini, Garcia-Martin et al. 2007, Martinez, 
Puig et al. 2007, Zech, Korpraphong et al. 2014). 
 In contrast median survival without treatment for metastatic colorectal; cancer is typically 
eight months from presentation(Mueller, Broering et al. 2002) and only 3 – 5% of patients 
survive to five years (Schnitzbauer, Lang et al. 2012, Ratti, Schadde et al. 2015, Rosok, 
Bjornsson et al. 2016). 
 
1.3 A Brief History of Liver Surgery 
Liver surgery for metastatic disease  has only become widespread in the last thirty years 
although the anatomy of the liver was first describe almost 500 years ago by Glisson in 1654 
(Foster 1991, Mueller, Broering et al. 2002). The first planned liver resection, removing a left 
sided liver tumour, was undertaken in 1887 by Carl von Langenbuch (Hardy 1990) and a 
number of further attempts at liver resection were then reported in both the USA and Europe 
in the 1880’s.  
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James Hogarth Pringle was an Australian born surgeon who practised in Scotland. In 1908, 
he published a case series where he proposed that when blood was issued from the fractured 
liver, it might be possible to temporarily control the bleeding by occluding the portal vein in 
the free edge of the foramen of Winslow (Pringle 1908).  This technique has allowed liver 
surgery to expand as a specialty, alongside other concurrent advancements in anaesthetics, 
particularly since the early 1990s (Wong, Hamady et al. 2008) 
 
 However, this was followed by a more than 60 year hiatus in this field (Foster 1991). The 
lack of accurate imaging, effective blood transfusion, modern anaesthesia and lack of critical 
care all contributed to this gap as without these technological developments, operative risk 
particularly from bleeding were too high.  
Following experiences with hepatic trauma during World War 2 and improvements in 
anaesthetic expertise, liver surgery was revisited in the 1950’s. These developments were also 
supported by a better understanding of the hepatic anatomy, particularly the patterns of 
hepatic vascular inflow and outflow as originally described by Glisson (Hardy 1990, Foster 
1991). However, the major expansion of liver surgery to what we see today only began in the 
1990’s (Kopetz, Chang et al. 2009).  
 
1.3.1 Liver Anatomy 
 
Although improving technology has helped the evolution of liver surgery, knowledge of the 
internal anatomy has also significantly improved outcomes. This is largely due to the work of 
French surgeon and anatomist Claude Couinaud, who published his work in 1957 (Abdel-
Misih and Bloomston 2010). He demonstrated that hepatic functional anatomy is based on 
vascular and biliary relationships rather than external surface anatomy 
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The liver is located in the right upper quadrant of the abdomen and is the largest organ in the 
human body typically weighing between 1200g and 1500g. It is suspended from the anterior 
abdominal wall by the falciform ligament and the round ligament and from the diaphragm by 
peritoneal reflections known as the triangular and coronary ligaments.  Macroscopically the 
liver is divided in to two lobes and anatomical resections are based on this anatomy (Abdel-
Misih and Bloomston 2010, Strasberg and Phillips 2013, Guerra, De Gaetano et al. 2017) 
1.3.2 Liver Surgery 
 
The majority of liver resections undertaken in the UK are due to colorectal liver metastases 
(CRLM) (Farid, Prasad et al. 2013). Resections are also performed for other, both benign and 
primary malignant hepatobiliary tumours such as cholangiocarcinomas, hepatocellular 
carcinomas, neuroendocrine tumours and live-related or -unrelated donation for 
transplantation and for trauma (Tsim, Frampton et al. 2010, Farid, Prasad et al. 2013).  
Liver surgery previously carried significant risk however developments in surgical and 
anaesthetic techniques have resulted in a typical mortality risk for all comers of 1-3%. These 
developments have also resulted in some improvements in short term morbidity and mortality 
(Melendez, Arslan et al. 1998, Jarnagin, Gonen et al. 2008, Agrawal and Belghiti 2011). 
However, reported morbidity in spite of these advances is still high ranging from 19.7% to 
52.5% in elderly patients (Nagano, Nojiri et al. 2005, Mazzoni, Tocchi et al. 2007, de Liguori 
Carino, van Leeuwen et al. 2008, Mann, Neal et al. 2008, Adam, Frilling et al. 2010, Reddy, 
Barbas et al. 2011). Complications include respiratory events such as pneumonia (5.5 – 
17.9%), cardiac events (arrhythmias and infarctions; 7.6%), abdominal (2.3 – 7.8%) and 
wound collections (3.6 - 7.4%). Less common complications included thromboembolic 
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events (pulmonary embolus and deep venous thrombosis; (1.0 – 3.5%), bile leaks (5.3-5.5%) 
and rarely liver failure (1.4-3.0%) (Cannon, Martin et al. 2011, Reddy, Barbas et al. 2011).    
The lack of consensus as to how to grade surgical complications led to widespread variability 
in reporting outcomes and hampered surgical evolution. The Clavien-Dindo classification 
was developed for use in all fields of surgery to be simple and reproducible. It is how the 
majority of hepatobiliary studies grade their complications (Clavien, Barkun et al. 2009). 
 
 
1.3.3 Indications and Contraindications to Liver Surgery 
 
Liver resection for CRLM is safe and feasible in many patients and with normal liver 
parenchyma a functional residual liver volume (FRV) of as little as 20% can be safely 
tolerated although complications, particularly hepatic impairment are a significant risk 
(Kanas, Taylor et al. 2012). A more conservative approach is taken if patients have received 
chemotherapy or significant hepatic steatosis is present when a post-operative functional liver 
remnant of 30–60% is desirable. In patients with cirrhosis only relatively small volumes of 
liver can be resected and a functional liver remnant of 50 - 70% or more is optimal to 
minimise the risk of liver insufficiency (Charnsangavej, Clary et al. 2006).  Those patients 
who demonstrate an adequate FRV would typically proceed to liver surgery without or 
without chemotherapy depending on the clinical presentation.  
Anatomical resection over the years has been the standard modality of resection for 
hepatocellular carcinoma to achieve adequate tumour free margin (Spelt, Andersson et al. 
2012) . For CRLM, a parenchymal sparing approach is being increasingly adopted keeping in 
mind chemotherapy induced hepatotoxicity and the need for repeat liver resection as an 
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option in multimodal treatment of recurrent colorectal liver cancer (Gold, Are et al. 2008). 
This paradigm shift in management of CRLM from ‘what comes out’ to ‘what stays in’ has 
led to non-anatomical resections/parenchyma preserving surgery being increasingly utilised. 
Several studies, comparing anatomical and non-anatomical liver sparing surgery have 
published conflicting results with some showing better survival with  anatomical resections 
(DeMatteo, Palese et al. 2000), whilst others showed no difference (Kokudo, Tada et al. 
2001, Lalmahomed, Ayez et al. 2011) although, a recent meta-analysis comparing the 2 
techniques has shown that margins and oncologic outcomes were comparable (Sui, Cao et al. 
2012) 
 
1.3.4 Neoadjuvant Chemotherapy 
 
The past decade has seen the criteria for resectability in CRLM being extended with 
more patients being eligible for hepatectomy with curative intent. However, a small future 
liver remnant volume (FLR) is associated with significant morbidity and mortality (Azoulay, 
Castaing et al. 2000, May, Talenfeld et al. 2013). It is therefore critical to leave a sufficient 
volume of liver coupled to the functional capacity of the underlying liver (Shindoh, Tzeng et 
al. 2013). Several strategies have been implemented to increase the FLR including portal vein 
embolization, portal vein ligation and two-stage hepatectomies (Abulkhir, Limongelli et al. 
2008, Popescu and Alexandrescu 2012, Lam, Laurence et al. 2013, van Lienden, van den 
Esschert et al. 2013).  
Pre-operative chemotherapy has also been used to increase the pool of patients 
amenable to resection. Current treatment algorithms classify patients with liver only CRLM 
as being resectable, borderline resectable or unresectable. The borderline resectable category 
facilitates chemo-responsiveness to be established, as well as identifying patients with 
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aggressive tumour biology (Adam, Delvart et al. 2004). Furthermore micro-metastatic disease 
can also be treated. 
Patients previously considered unresectable are now being considered for curative therapy 
with a recent phase III trial demonstrating that a 60% response rate in such patients with 15% 
going on to have R0 resections (Falcone, Ricci et al. 2007). Biological therapies and 
molecular targeting have also played key roles in advancing management for patients with 
Stage IV CRC, with response rates for unresectable liver disease approaching 70% 
(Folprecht, Gruenberger et al. 2010). An aggressive line of management in patients with 
unresectable metastatic disease is therefore now justified with studies showing five year 
survival rates for patients who are “chemo-converted” to resectability being the same as 
patients who were initially considered resectable (Adam, Avisar et al. 2001, Adam, Delvart et 
al. 2004, Lam, Spiro et al. 2012, Jones, Hamann et al. 2014). Furthermore, the addition of 
monoclonal antibodies against the epidermal growth factor receptor (EGFR), such cetuximab, 
have facilitated response rates of up to 80% in the treatment of liver metastases (Hurwitz, 
Fehrenbacher et al. 2004).  
  
Regimen-specific liver injury may be caused by neoadjuvant chemotherapy, which 
adds further complexity to the timing of such therapies. The use of 5-FU, leucovorin and 
irinotecan may predispose to development of steatosis (and hence, bleeding) and oxaliplatin 
use may cause sinusoidal obstruction syndrome (Wagman 2013). Such injury may increase 
surgical risk and therefore by default, overall prognosis. Hence utilisation and timing of 
chemotherapy needs careful evaluation, particularly in this cohort of patients. 
(Hurwitz, Fehrenbacher et al. 2004) 
 
   
9 
 
1.4 Significance of bleeding in CRLM surgery 
 
Despite recent advancements, intra- and postoperative hepatic bleeding remains an important 
operative risk with negative impact on short-term outcomes resulting from organ 
hypoperfusion (Kooby, Stockman et al. 2003, Ibrahim, Chen et al. 2006, Shiba, Ishida et al. 
2013, Sui, Onyeji et al. 2016). In addition, there is increasing some evidence that the need for 
blood transfusions also results in poorer long-term survival in surgical oncology (Parrott, 
Lennard et al. 1986, Little, Wu et al. 1990, Tartter 1992, Panagopoulos, Karakantza et al. 
2008, Wang, Jiang et al. 2015, Cata, Lasala et al. 2016). Attempts to explain this observation 
include host immunosuppression due to the transfusion resulting in decreased tumour 
surveillance and earlier recurrence (Kooby, Stockman et al. 2003), a condition termed 
transfusion-related immune modulation (TRIM) (Cata, Wang et al. 2013, Youssef and 
Spitalnik 2017). Mechanisms for TRIM include suppression of cytotoxic cell and monocyte 
activity, release of immunosuppressive prostaglandins, inhibition of interleukin-2 (IL-2) 
production, and increase in suppressor T-cell activity (Vamvakas 2002{van Twuyver, 1991 
#103, Sui, Onyeji et al. 2016)}. The immunosuppressive effects of allogeneic blood 
transfusion were even used therapeutically to reduce renal allograft rejection before effective 
immunosuppressant drugs became available (van Twuyver, Mooijaart et al. 1991) 
It is also worth considering the circumstances in which patients are given blood transfusions 
peri-operatively which may also influence survival. These include preoperative nutrition and 
functional status, the presence of preoperative anaemia, tumour type and stage, degree of 
resectability, duration and type of anaesthesia, amount of blood loss, perioperative stress 
response, and the presence of postoperative complications.  
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Furthermore, tumour manipulation during surgical resection increases the load of circulating 
malignant cells (Bosch, Guller et al. 2003). Secondly, volatile anaesthetics and opioids 
depress the function of host cellular defenses, especially NK cells and cytotoxic lymphocytes. 
Thirdly, perioperative factors such as inflammatory response to injury, physiological stress 
response to surgery, hyperglycaemia, and hypothermia may result in a pro-tumour 
environment (Cata, Wang et al. 2013) 
Hence, there are also several confounding factors to consider when examining retrospective 
studies looking at blood loss in cancer surgery. Blood transfusions are administered to 
approximately one third of all patients undergoing liver resections, although this number is 
decreasing (Nagino, Kamiya et al. 2005, Pulitano, Arru et al. 2007, Verma and Schwarz 
2007). Worse outcome in patients requiring blood transfusions or blood products have also 
previously been shown in some studies within the context of liver surgery (Gruttadauria, 
Saint Georges Chaumet et al. 2011, Shiba, Ishida et al. 2013). However, the data is limited 
regarding the impact of red blood cell transfusion (RBCT) on long-term impact in liver 
surgery for CRLM with single centre studies demonstrating conflicting evidence (Younes, 
Rogatko et al. 1991, Gruttadauria, Saint Georges Chaumet et al. 2011, Jiang, Fang et al. 
2013, Hallet, Tsang et al. 2015, Schiergens, Rentsch et al. 2015). The largest of these studies 
was by Kooby et al (Kooby, Stockman et al. 2003) where over 1000 patients underwent liver 
resections between 1986 and 2001, with 55% requiring a blood transfusion. They found 
transfusion to be linked to poorer short term outcomes but on multivariate analysis for long 
term survival, transfusion was not significant whereas a positive resection margin, primary 
tumour histology, the number and size of the liver lesions and the disease free interval were 
significant. Conversely, a more recent study by Hallet et al on regression modelling found 
transfusion, Clinical Risk Score and age to be predictive of poorer long term outcomes. 
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Bennett at al (Bennett, Baker et al. 2017) performed a systematic review looking at the effect 
of RBCT in patients undergoing liver resection for all causes. They found that transfusion 
requirements were decreasing with time and that the majority of papers showed worse 
survival on univariate analyses. However, after multi-variate analyses only 10 out of 18 
studies demonstrated a poorer outcome of RBCT with long-term outcome with only 4 of the 
studies being specific to CRLM.  
The majority of the studies regarding CRLM and transfusion are historical and perhaps not 
relevant today where modern chemotherapy along with biological agents and advancements 
in surgical and anaesthetic techniques have changed the way liver resections are approached.  
It is therefore vital to ascertain the impact of blood transfusions in a UK based population 
undergoing CRLM surgery and to identify strategies to further reduce transfusion 
requirements during liver surgery.   .    
 
1.5 Balancing Bleeding and Ischaemia Reperfusion Injury (IRI) in Liver Surgery 
Although intraoperative bleeding in liver surgery can be prevented by clamping blood vessels 
leading to the liver, this increases the risk of Ischaemia-reperfusion injury (IRI). IRI is 
defined as the tissue damage caused when the vascular supply to the organ is returned after a 
period of ischaemia (Nadarajah, Yaqoob et al. 2017) . The absence of oxygen and nutrients to 
the tissue during the ischaemic period creates a condition in which restoration of the blood 
flow results in inflammatory and oxidative damage via the induction of oxidative stress 
(Fondevila, Busuttil et al. 2003, Teoh and Farrell 2003). IRI can be a serious complication of 
major liver surgery if the procedure involves some form of vascular exclusion (Abu-Amara, 
Gurusamy et al. 2010). It may cause a local and systemic inflammatory response and its 
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clinical manifestations may vary between transient arrhythmias to multi-organ dysfunction 
(Eltzschig and Collard 2004).  
Hence, managing the balance of haemostasis and prevention of IRI is a crucial concept in 
liver surgery in order to optimise both short and long-term outcomes.
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Chapter 2 
Aims and Objectives 
 
2 Aims and Objectives 
2.1 Aim 
Based on the review of the literature, I identified three main areas with minimal or 
incomplete evidence in the current literature: (1) non-invasive/ non-surgical methods to 
reduce intraoperative blood loss, (2) comprehensive analysis of risk factors for bleeding and 
the impact of blood transfusion on survival in patients undergoing hepatectomy for CRLM, 
and (3) randomised controlled trials on isolated vein clamping.  
Based on these findings, the aim and objectives of the research was defined.  The aim of the 
thesis was to study risk factors for bleeding and to perform a feasibility study looking at the 
role of isolated portal vein clamping during CRLM surgery. 
  
2.2 Objectives 
In order to achieve this aim, the objectives were defined as follows: 
a) To review surgical techniques utilised in liver surgery (chapter 3) 
b) To perform a systematic review looking at pharmacological and anaesthetic methods 
which could complement surgical techniques to reduce blood loss (chapter 4)  
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c) To set up a retrospective database of patients undergoing liver surgery from 2005-
2012 and determine the effects of blood transfusion on long term outcomes of patients 
undergoing CRLM resection.  (chapter 5) 
d) To conduct a pilot, randomised control trial looking at the Pringle Manoeuvre versus 
Isolated Portal Vein Clamping (chapter 6) 
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Chapter 3 
Review of Peri- and intra-operative Techniques used to minimise blood loss in liver 
surgery 
 
3 Review of Peri-operative Techniques 
3.1 Introduction 
Minimal intra- and postoperative blood loss is crucial to achieve good results in liver surgery 
and a number of surgical and non-surgical techniques have been developed to reduce 
bleeding. This chapter will describe peri- and intra-operative techniques which are routinely 
used to decrease blood loss during liver surgery. 
3.2 Peri-operative techniques 
Risk factors to predict the likelihood of blood loss can be summarised into patient factors 
(body mass index, recent chemotherapy exposure, underlying liver disorders, co-morbidities 
and cardiovascular fitness, medication history) and tumour factors (number and size, 
distribution and relationship with major vascular structures and tumour vascularity) 
(Gayowski, Iwatsuki et al. 1994, Nordlinger, Guiguet et al. 1996, Robertson, Stukel et al. 
2009, Mathur, Ghaferi et al. 2010). Hence, preoperative considerations include patient 
selection and patient optimisation. Chronic liver failure predisposes to intra- and 
postoperative bleeding due to its associated coagulopathy, volume and electrolyte 
disturbances, hepato-renal and hepato-pulmonary syndromes and low cardiovascular reserve 
capacity (Dagher and Moore 2001, Mazzeo, Lucanto et al. 2004, Tympa, Theodoraki et al. 
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2012). Assessment of severity of liver dysfunction before surgery is important and the risk 
benefit of the procedure needs to be carefully assessed via modified Child-Pugh or MELD 
scores. Liver resections in patients with underlying hepatic cirrhosis and portal hypertension 
still represent a medical challenge with regard to perioperative morbidity, surgical 
management and postoperative outcome although peri-operative advancements have meant 
resections in such patients are still feasible, though the risk-benefit margins need careful 
analysis (Hackl, Schlitt et al. 2016). 
Surgery should be avoided if possible in the setting of acute and alcoholic hepatitis, in a 
patient of cirrhosis who is child class C or has a MELD score more than 15. In this subset of 
patients, the patients should be managed without an operation (Rai, Nagral et al. 2012) . Pre-
operative optimization necessitates correction of electrolyte imbalance and improving renal 
dysfunction, cardiorespiratory assessment, correcting any sepsis and correction of 
coagulation. Intra-operatively, safe anesthetic agents like isoflurane and propofol with 
avoidance of hypotension are advised. In general, nonsteroidal anti-inflammatory drug and 
benzodiazepines should not be used (Rai, Nagral et al. 2012, Hackl, Schlitt et al. 2016). 
General risk factors for bleeding such as anti-thrombotic drugs, a family history of bleeding 
disorders, known clotting abnormalities and evidence of previous excessive post traumatic or 
post-surgical bleeding should also be considered (Chee, Crawford et al. 2008).  
Exercise or pharmacologic stress testing is useful for the preoperative assessment of 
cardiovascular status providing information regarding myocardial contractility and the 
mechanics of blood flow (Redai, Emond et al. 2004). More recently, several centres have 
advocated the use of Cardiopulmonary Exercise testing to evaluate peri-operative risk 
(Junejo, Mason et al. 2012). Recent improvements in radiology have also led to better 
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evaluation of the tumour relation to the major vessels, including three dimensional imaging of 
the liver   (Saini 1997, Israel, Mor et al. 2002, Numminen, Sipila et al. 2005).  
 
3.3 Intra-operative Anaesthetic Techniques 
3.3.1 Anaesthetic agents 
 
Considerate selection of anaesthetic agents is important for hepatic vessel clamping 
techniques. In animal models both isoflurane and sevoflurane decrease portal vein resistance 
(Hoetzel, Geiger et al. 2002), whereas in humans, sevoflurane also increases hepatic arterial 
blood flow (Kanaya, Nakayama et al. 1995).  Theoretically, this may be relevant for isolated 
portal vein clamping as evidence suggests that ischaemic pre- and post-conditioning with 
sevoflurane prior to inflow occlusion may reduce post-operative liver dysfunction (Beck-
Schimmer, Breitenstein et al. 2008, Beck-Schimmer, Breitenstein et al. 2012) 
 
 
3.3.2 Hypothermia 
 
Inadvertent perioperative hypothermia is common and preventable. In the first hour of 
anaesthesia a patient’s core temperature may drop to below 350C due to loss of the 
behavioural response to cold, impairment of thermo-regulatory mechanisms and anaesthesia 
induced peripheral vasodilation and heat loss.  This increases blood loss secondary to 
associated coagulopathy whilst increasing the likelihood of significant cardiac events, wound 
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complications and altering drug metabolism (NICE 2008). During the pre-operative phase, 
clinical staff should ensure patients stay warm by use of additional clothing or blankets and 
forced air warming. A risk assessment should also be performed encompassing American 
Soceity of Anaesthesiologists (ASA) grade, type of surgery being undertaken, pre-operative 
temperature and comorbidities (NICE 2008, Knaepel 2012). Intra-operatively the temperature 
should be measured and documented every 30 minutes. Intravenous fluids and blood products 
used should be warmed to 37
0
C using a warming device prior to use. Internal and external 
warming techniques such as forced air warming should also be used peri-operatively to 
prevent hypothermia-related coagulopathy (Redai, Emond et al. 2004).  
 
3.3.3 Central Venous Pressure 
  
Blood loss reduction by using low central venous pressure anaesthesia (CVP between 2 and 5 
mmHg) is also employed however it use must be weighed against its risks of injury due to 
reduced end organ perfusion (Rees, Plant et al. 1996, Johnson, Mannar et al. 1998, Jones, 
Moulton et al. 1998, Melendez, Arslan et al. 1998). The use of low CVP anaesthesia to 
reduce intra-operative blood loss during liver surgery is now well established  however 
measurement of urine output, pulse, blood pressure and arterial pulse pressure waveforms  to 
assess fluid status and minimise end organ harm are recommended (Smyrniotis, 
Kostopanagiotou et al. 2004) .  
 
3.4 Intra-operative Surgical Techniques 
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3.4.1 Intra-operative Ultrasound (IOUS) 
Localisation of the hepatic lesions that are to be resected and also identification of their 
relation to major vascular structure can also assist in the reduction of blood loss. 
Intra-operative ultrasound (IOUS) has a valuable role as allows identification of lesions for 
resection including additional  lesions not found on pre-operative imaging in a significant 
number of cases (Cervone, Sardi et al. 2000, Zacherl, Scheuba et al. 2002). In addition IOUS 
also accurately assesses proximity and/or invasion to major vascular structures. This allows 
an operative approach to be devised that minimises blood loss. (Cervone, Sardi et al. 2000, 
Ellsmere, Kane et al. 2007, D'Hondt, Vandenbroucke-Menu et al. 2011) 
 
3.4.2 Intra-operative Dissection Techniques  
A number of strategies to transect the liver parenchyma can be employed and appropriate 
selection of these can also minimise blood loss.  
 
 
3.4.2.1 Crushing Technique 
 
Traditionally the liver tissue is fractured between fingers or surgical clamps (“crush-clamp” 
technique) under intermittent inflow occlusion (Pringle manoeuvre) and vessels and hepatic 
ducts are ligated or clamped (Aragon and Solomon 2012) with the  crush clamp technique 
offering superior control to finger fracture when transecting the parenchyma (Poon 2007, 
Kim and Lee 2008, Aragon and Solomon 2012).  Diathermy or argon beam coagulation can 
be applied to the remnant parenchyma during reperfusion, to achieve haemostasis (Postema, 
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Plaisier et al. 1993). This is a simple, quick, efficient and cost-effective technique however a 
number of newer techniques have developed and it is against this crushing technique that 
newer techniques detailed below have been measured (Pamecha, Gurusamy et al. 2009, 
Rahbari, Koch et al. 2009). 
 
3.4.2.2 Ultrasonic Dissection 
 
The Cavitron Ultrasonic Surgical Aspirator (CUSA) combines ultrasonic energy with 
aspiration to divide the liver parenchyma and skeletonise blood vessels and biliary structures 
greater than 2 mm in width (Andrus and Kaminski 1986) which are subsequently ligated. 
CUSA is able to dissect parenchyma but does not directly contribute towards haemostasis 
however accurate identification of blood vessels with minimal damage facilitates vascular 
control and can reduce blood loss. CUSA use is associated with low blood loss and low risk 
of bile leak, though the transaction time is longer than with the crushing technique (Aragon 
and Solomon 2012). A recent RCT showed ultrasonic dissection and the crushing technique 
to be comparable in terms of blood loss and other outcome measures though the crushing 
technique was faster. (Doklestic, Karamarkovic et al. 2012) 
The harmonic scalpel again uses ultrasonic technology like the  CUSA, however the high 
frequency waves generate heat between the jaws of the instrument and achieve a heat based 
sealing of structures and  can contribute towards haemostasis (Gertsch, Pelloni et al. 2000, 
Abbasoglu and Sayek 2003, Arru, Pulitano et al. 2007). It is associated with decreased 
operative time and decreased blood loss and transection times. However, a retrospective 
study showed there was a significant increase in the incidence of post-operative bile leak as 
smaller ducts were likely to remain patent [p=0.01] (Kim, Ahmad et al. 2003).  
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3.4.2.3 Bipolar Sealing Devices  
 
Bipolar vessel-sealing devices such as the Ligasure vessels sealing system are hypothesized 
to seal blood vessels up to 7mm in size, thereby decreasing operative time. Although a small 
single centre study supported the hypothesis of less blood loss and faster operative time 
(Saiura, Yamamoto et al. 2006), a larger RCT comparing this technology with the crush-
clamp technique failed to show differences in both blood loss and operative time (Ikeda, 
Hasegawa et al. 2009). The discrepancy between the two studies may be explained by the fact 
that different techniques may have been utilised between the studies; the number of structures 
ligated per transection was much higher in the study by Ikeda et al, which may be because 
they ligated all structures greater than 2mm in size. Furthermore, different hand pieces were 
used in the two studies.  
 
3.4.2.4 Radiofrequency Assisted Liver Resection   
 
Radiofrequency Ablation (RFA) has been one of the favoured thermal local ablative 
techniques and has demonstrated to achieve good local control of the tumour in cases where 
resection was not feasible (Abitabile, Hartl et al. 2007). RFA probes can also be used to treat 
the parenchyma inducing coagulative necrosis prior to division using a scalpel. However, it 
takes more time and is associated with higher complication rates such as biliary fistula, 
biliary stenosis and abscess formation (Li, Zhang et al. 2012).It is likely that this is due to the 
“heat sink” effect of nearby biliary and vascular structures (Pathak, Jones et al. 2011). 
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Therefore, RFA-assisted liver resection should only be performed for peripherally located 
tumours.  
 
3.4.2.5 Water Jet Dissection 
 
As the liver consists of a three dimensional structure of afferent and efferent duct and vessel 
systems, which are higher in collagen and elastin and therefore differ from the surrounding 
liver parenchyma it is possible to mechanically separate the ducts and vessels from the 
underlying liver parenchyma (Rau, Duessel et al. 2008). A high pressure water jet is utilised 
to dissect the parenchyma and isolate small vascular and biliary structures, which can then be 
ligated and divided (Rau, Duessel et al. 2008). The residual parenchyma is spared from the 
effects of coagulation or charring. However, the technique is time consuming and no 
advantage has been demonstrated in pooled data analyses (Pamecha, Gurusamy et al. 2009, 
Rahbari, Koch et al. 2009).  
 
3.4.2.6 Vascular Staplers 
 
Stapling devices have been introduced for safety and to reduce the overall operative time in 
several types of surgery (Schemmer, Friess et al. 2007). Within liver surgery staplers are 
routinely used to control inflow and outflow vessels. It can also be used to facilitate 
parenchymal transection where a large clamp is used to fracture the liver parenchyma, 
followed by serial firings of the surgical stapler with a vascular load. Reddy et al showed in a 
retrospective series of 112 patients that use of a vascular stapler when compared to crush 
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clamp technique was associated with less operative time, blood loss and transfusion 
requirements (Reddy, Barbas et al. 2008). The CRUNSH trial was a prospective RCT 
comparing crush-clamp to vascular stapler use in elective liver resections. The trial included 
65 patients in each arm, who were comparable in terms of baseline demographics. There was 
no difference in the amount of intra-operative blood loss between the two groups. However, 
when blood loss was normalised to transection area there was an apparent advantage in using 
staplers. These findings do not justify the routine use of staplers but they do suggest further 
studies in high risk groups to ascertain an potential benefits of staplers (eg cirrhotics requiring 
a resection) (Rahbari, Elbers et al. 2014).  A further trial demonstrated staplers to be safe and 
faster than CUSA, with a diminished inflammatory response (Schwarz, Klaus et al. 2015). 
However, there is still not enough evidence to suggest all liver transections should be done 
using stapling devices- cost analyses have not been undertaken in these preliminary trials 
either. 
 
3.4.3 Intra-operative vascular control 
 
In order to reduce blood loss, various methods of hepatic inflow, or simultaneous in- and 
outflow occlusion techniques are applied. The type of occlusive technique employed should 
reflect the reason for resection (for example donor hepatectomy versus oncological surgery), 
tumour location, the presence of underlying liver disease and the cardiovascular status of the 
patient (Abdalla, Noun et al. 2004). Different intra operative vascular control techniques are 
discussed below:  
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3.4.3.1 Continuous Pringle Manoeuvre  
 
The Pringle manoeuvre is a surgical technique where a large haemostat is used to clamp the 
hepatoduodenal ligament and decrease blood flow to the liver, via the portal vein and hepatic 
artery (Gurusamy, Sheth et al. 2009). It can be used in a continuously or in an interrupted 
manner   
Once the lesser omentum is opened a blunt dissector is passed through the foramen of 
Winslow and the hepatoduodenal ligament can be encircled with umbilical tape en masse 
(Chouillard, Gumbs et al. 2010). A tourniquet or vascular clamp is applied until the hepatic 
arterial pulse disappears distally. (Lau, Lai et al. 2010)  
The Pringle manoeuvre results in a 10% increase in mean arterial pressure, a 40% increase in 
systemic vascular resistance, a 5% decrease in pulmonary arterial pressure and a 10% 
decrease in cardiac index (Belghiti, Marty et al. 1998). Pedicle clamping is well tolerated as 
the caval flow is not interrupted. Splanchnic congestion from portal clamping tends to be 
mild, especially with intermittent clamping (Lau, Lai et al. 2010). Persistent bleeding during 
transection is caused by incomplete inflow occlusion or back-bleeding from the hepatic veins. 
Incomplete inflow occlusion can be minimised by application of the pedicle clamp until 
pulsation in the distal hepatic artery has disappeared and ensuring that any accessory hepatic 
arterial systems have also been clamped. Backflow bleeding can be reduced by lowering the 
CVP to less than 5cm H2O, or total or partial clamping of suprahepatic veins or inferior vena 
cava (Lau, Lai et al. 2010).   
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3.4.3.2 Intermittent Pringle Manoeuvre (IPM) 
 
It remains unclear if a single, prolonged period of ischaemia followed by reperfusion is more 
harmful than intermittent clamping results in multiple periods of ischaemia (van Gulik, de 
Graaf et al. 2007). Similar to continuous Pringle manoeuvre, IPM was shown to reduce blood 
loss and operating time when compared with no vascular clamping without increasing 
postoperative complication or mortality rates and was shown to be oncologically equivalent 
(Man, Fan et al. 1997, Capussotti, Muratore et al. 2006, Wong, Hamady et al. 2008, Tralhao, 
Hoti et al. 2009, van den Broek, Bloemen et al. 2011, Lee, Cheung et al. 2012, Park, Joh et al. 
2012). 
Intermittent and continuous hepatic pedicle clamping were compared directly in a few trials 
only. Although a reduced incidence of IRI using IPM was shown in the animal model 
(Isozaki, Adam et al. 1992), this has not been reproduced in patients (Isozaki, Adam et al. 
1992, Isozaki, Okajima et al. 1995, Chiappa, Makuuchi et al. 2001, Capussotti, Nuzzo et al. 
2003, Ozmen, Oruc et al. 2003, van Gulik, de Graaf et al. 2007). Both techniques are 
effective in reducing intra-operative blood loss, whilst proportions of patients requiring blood 
transfusions were comparable in both groups. Complications and mortality were also found to 
be comparable between the two groups. 
There is a paucity of trials comparing IPM with continuous clamping but accounting for the 
animal studies and the theoretical risk of increased Ischaemia Reperfusion Injury (IRI, see 
below) in the continuous clamping group, IPM continues to be preferred by most liver 
surgeons due to the theoretical decrease in the development of IRI.  
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3.4.3.3 Hemi-hepatic Vascular Clamping  
 
Hemi-hepatic vascular occlusion (or half-Pringle manoeuvre) selectively interrupts the 
arterial and venous inflow to the right or left liver lobe. Currently, there is conflicting 
evidence regarding benefits of hemi-hepatic occlusion compared to the Pringle manoeuvre. 
The results of a recent randomised trial suggest hemi-hepatic vascular occlusion to be 
superior in terms of post-operative complication rates and liver function (Ni, Lau et al. 2013).  
However, evidence on reduction of intra-operative blood loss is conflicting, some suggesting 
this technique to be beneficial (Wu, Yeh et al. 2002, Wen, Miao et al. 2009), whilst others 
suggest that there is no difference in blood loss (Figueras, Llado et al. 2005, Liang, Wen et al. 
2009).   
A trial by Fu et al compared hemi-hepatic clamping, the Pringle manoeuvre and isolated 
portal vein clamping. This study showed all three techniques to be safe and comparable in 
terms of post-operative complications (Fu, Lau et al. 2011). However, there was an increased 
incidence of liver dysfunction in the Pringle only group. The study was performed in China 
and the majority of patients had HCC with cirrhosis. These findings led us to investigate the 
feasibility of looking at inflow control during liver surgery in a western cohort of patients 
(see Ch 6). Our trial simply looked at Pringle versus isolated portal vein clamping as hemi-
hepatic clamping is not really feasible in a western cohort where the majority of resections 
are performed for CRLM and hence re-resections are often undertaken.   
 
3.4.3.4 Total Hepatic Vascular Exclusion 
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THVE combines total vascular inflow and outflow occlusion, thereby isolating the liver from 
the systemic circulation. It is suggested to be  useful where backflow bleeding from the 
hepatic veins causes significant blood loss (Abdalla, Noun et al. 2004). 
THVE is indicated for tumours either in close proximity to the major hepatic veins or IVC, or 
tumours that have penetrated these vessels. In instances where thrombus is present within the 
vessel, TVHE may also  prevent thrombus migration, whilst facilitating vessel reconstruction 
(Lau, Lai et al. 2010). 
THVE is associated with major haemodynamic changes. Cessation of the IVC flow causes a 
marked decrease in cardiac output and therefore, an increase of approximately 80% in 
systemic vascular resistance (SVR) and a 50% increase in heart rate. There is also a 10-15% 
decrease in the mean arterial pressure, as well a 40-50% drop in the cardiac index. A decrease 
of more than 50% with regard to cardiac output, or a decrease in SVR of more than 30% in a 
euvolaemic patient, equates to patient intolerance to TVHE. This occurs in approximately 10-
20% of patients due to adrenergic cardiovascular reflexes to increase cardiac output in the 
absence of IVC inflow. Prior to clamp placement, the patient is volume loaded with fluid to a 
CVP of approximately 12-15mmHg to prevent intolerance. A trial exclusion can be 
performed to assess response however the  large fluid volumes loaded may cause post-
operative renal, liver and pulmonary dysfunction (Lau, Lai et al. 2010). 
There have been only a few trials conducted comparing TVHE against other occlusive 
techniques. Belghiti et al (Belghiti, Noun et al. 1996) were the first group to perform an RCT 
comparing TVHE versus Pringle. They found blood loss to be similar between groups, 
though post-operative morbidity was higher in the TVHE. However, Chen et al (Chen, Zhang 
et al. 2006) found significantly more blood loss (p=0.046) and transfusion requirements (p= 
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0.041) in the Pringle only group without any difference in the post-operative morbidity 
between the two groups.  
Given that TVHE is associated with unpredictable haemodynamic changes and increased 
post-operative complications, it is only be used in certain selected cases where there is caval 
and/or hepatic vein involvement of the tumour.  
 
3.4.3.5 Selective Hepatic Vascular Exclusion  
 
SHVE combines inflow occlusion with extra-parenchymal control of the hepatic veins, 
without interruption of caval flow, a strategy that can avoid the haemodynamic instabilities 
caused by TVHE, but retaining the benefit of controlling  backflow bleeding from the hepatic 
veins. This approach is however more technically  challenging than TVHE (Lau, Lai et al. 
2010).  
There have been two retrospective series and one randomised control trial comparing SVHE 
to a Pringle manoeuvre (Smyrniotis, Kostopanagiotou et al. 2003, Zhou, Li et al. 2008, 
Zhang, Lai et al. 2012). The studies each demonstrate blood loss and post-operative 
complications to be higher in the Pringle trial group. However, SVHE takes considerably 
longer and is felt to be most applicable to centrally located tumours with vascular 
involvement. In addition, total anaesthetic time is likely to be longer in patients undergoing 
SVHE and the long term oncological impact of this approach remains unclear. Further larger 
trials are needed to confirm the beneficial effects of SVHE. 
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3.4.3.6 Summary 
 
The Pringle manoeuvre is the established method of inflow control. Particularly in the setting 
of chronic liver disease, it is best to use it intermittently. However, the role of selective 
vascular inflow occlusion still needs to be addressed.  
Total hepatic vascular exclusion and selective hepatic vascular exclusion techniques are 
useful for centrally located tumours and tumours where there is vascular involvement. 
However, they should not be employed routinely.  
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Chapter 4 
 
Systematic Review of Non-Surgical Techniques   used to minimise blood loss in liver 
surgery. 
 
4 Systematic Review of Non-Surgical Techniques 
The role of surgical techniques such as vascular occlusion, parenchymal transection 
technique and use of sealants to decrease blood loss in liver surgery have been extensively 
reviewed previously (Gurusamy, Sheth et al. 2009, Pamecha, Gurusamy et al. 2009, Wang, 
Yang et al. 2011, Ding, Yuan et al. 2013, Sanjay, Ong et al. 2013)and the types of 
intervention have been summarised in Chapter 3.   
In contrast, only a few non-surgical interventions to reduce bleeding during and after liver 
surgery have been have been analysed in the past (Gurusamy, Li et al. 2009, Gurusamy, Li et 
al. 2009). Gurusamy et al have previously summarised cardiopulmonary interventions (low 
CVP, autologous blood transfusions and haemodilution before) and pharmacological 
interventions (Gurusamy, Li et al. 2009, Gurusamy, Li et al. 2012) and hence there is an 
overlap in terms of our included studies and theirs. Some of the techniques are based on 
decreasing hepatic perfusion intra-operatively, potentially resulting in ischaemia-reperfusion 
injury(IRI) which can increase the risk for postoperative liver failure (Lesurtel, Lehmann et 
al. 2009) . A number of recent trials of non-surgical (anaesthetic and pharmacological) 
interventions have emerged and the major difference between this review and the work 
previously done by Gurusamy et al is the inclusion of anaesthetic agents which may confer 
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protection to the liver from Ischaemia-reperfusion injuries . The evidence in this area has not 
been summarised. 
This chapter will describe a systematic review of the available evidence regarding non-
surgical (anaesthetic and pharmacological) interventions used to minimise blood loss during 
liver surgery.  
 
4.1 Methods 
4.1.1 Search Strategy 
 
The review was undertaken  according to the Preferred Reporting Items for Systematic 
Reviews and Meta-analyses (PRISMA) guidance (Liberati, Altman et al. 2009). An electronic 
search of PubMed, Cochrane Library (1995-2013), CINAHL (1990-2013) and Google 
scholar was conducted by two independent researchers (SP and AH
1
). This was undertaken 
using a sensitive search strategy incorporating the following MeSH search terms: 
 [(“Blood Loss” OR “Bleeding” OR “Hemmorhage”, “Haemorrhage” OR “Haemostasis” OR 
“Hemostasis” OR “Blood Transfusion”) AND (“Liver” OR “Hepatic” OR “Hepato” OR 
“Resection” OR “Segmentectomy” OR “Hepatectomy”) AND (“Randomised Control Trial” 
OR “Randomized Control Trial” OR “Controlled Clinical Trial”)].  
Bibliographies of relevant studies supplemented by the “related articles” link in PubMed 
were used to identify additional studies. Studies published in abstract form only or 
unpublished reports were excluded from the analysis. Each citation and associated abstracts 
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were screened independently by the two researchers (SP/AH
1
). The searches were completed 
and review closed on the 18
th
 October 2013. 
                                                 
1
 SP denotes myself and AH is a research fellow within the HpB department  
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4.1.2 Inclusion Criteria 
 
Included studies analysed the effect of anaesthetic or pharmacological methods to decrease 
blood loss in liver surgery. Only randomised control trials (RCT) were considered for 
inclusion. The studies were carefully evaluated for duplication or overlapping of data. Only 
studies in English language after 1990 were considered, as hepatic surgery developed as a 
sub-speciality during the 1990s.  
 
4.1.3 Exclusion Criteria 
 
Animal studies, case reports, letters and editorials were excluded. Studies looking at vascular 
clamping techniques, parenchymal transection technique, liver transplantation, use of low 
central venous pressure (CVP) anaesthesia versus vascular clamping techniques, fibrin 
sealants and paediatric populations were also excluded. 
 
4.1.4 Outcome Measures 
 
The primary outcomes of interest were overall blood loss (measured in mL) and transfusion 
requirements (measured in mL or units). Secondary outcome of interest was the risk of 
ischaemia-reperfusion injury (measured by peak ALT levels). Other clinical outcomes such 
   
34 
 
as length of ITU/hospital stay, long term survival outcomes and complications were not 
included as the majority of studies did not report these.   
 
4.1.5 Study Selection 
 
Two authors (SP and AH) independently performed the search strategy. Both the authors 
reviewed the abstracts identified by the search to exclude those that did not meet our 
inclusion criteria. When no abstract was available or the abstract details were inadequate, the 
full article was reviewed. Differences between the two authors (SP and AH) in selection of 
the studies were resolved by consensus with the senior author (DM 
2
). If the selection of the 
study was still not resolved by consensus between the three authors, the lead author’s (DM) 
decision was considered as final.
2
 denotes Danilo Miskovic. 
 
4.1.6 Data Extraction 
 
Extraction of data was done by the two authors (SP and AH) independently using a 
standardised proforma and any disagreement resolved by consensus with the senior author 
(DM). The following demographic and clinical parameters were recorded: study 
characteristics (first author, year of publication), population characteristics and outcomes of 
interest.  
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4.1.7 Quality Assessment 
 
Randomised control trials were assessed using the Cochrane risk of bias tool by two authors 
(SP and AH)  (Turner, Shamseer et al. 2012) 
4.2 Results 
A total of 17 studies met the inclusion criteria. There were 8 studies on pharmacological 
approaches constituting 894 patients, and another 9 studies on anaesthetic techniques, 
including 679 patients. The study quality was variable (Table 1). 8 studies (Lentschener, 
Benhamou et al. 1997, Hasegawa, Takayama et al. 2002, Matot, Scheinin et al. 2002, Wong, 
Irwin et al. 2003, Lodge, Jonas et al. 2005, Wu, Ho et al. 2006, Hashimoto, Kokudo et al. 
2007, Ryu, Nahm et al. 2010)   were judged to be of low risk of bias with 5 studies 
((Jarnagin, Gonen et al. 2002, Wang, Liang et al. 2006, Pulitano, Aldrighetti et al. 2007, 
Beck-Schimmer, Breitenstein et al. 2012, Toprak, Sahin et al. 2012) ) at low risk of 
randomisation bias without explicit details of allocation concealment or blinding of outcomes 
assessment. Randomisation details were unclear in 4 studies ((Shimada, Matsumata et al. 
1994, Inagaki, Nonami et al. 1999, Shao, Yang et al. 2006, Guo, Jin et al. 2013)) 
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Database – PubMed, the Cochrane library (since 1995), CINAHL (since 1990) 
and Google Scholar  
 
Number of articles identified by electronic search = 1417 
 
Last search performed on 18
th
 October 2013 
 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 : PRISMA Flowchart depicting the search strategy and selection of articles for the 
review 
 
 
Excluded following title screen= 
1389 
Inappropriate publication type n= 
1255 
Vascular clamping=45 
Review article n=5 
Transection techniques n=24 
Liver transplant n=43 
Fibrin/collagen n=15 
Paediatric studies n=1 
Non-English articles n=1 
 
 
 
Number of abstracts reviewed n=28 
 
Studies included in the systematic 
review n=17 
 
Full text reviewed n=21 
 
 
 
Excluded following abstract review 
n=7 
 
Liver transplant n=1 
Not reporting primary outcome n=3 
Non-randomised studies n=2 
Fibrin/collagen n=1 
 
Excluded following full text review  
n=4 
 
Not reporting primary outcome n=3 
Retrospective study n=1 
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Study Jadad criteria Total Score 
 Described as 
randomised 
(+1) 
Method of 
randomisation 
appropriate 
(+1) 
Inappropriate 
randomisation 
method (-1) 
Described as 
double blind 
(+1) 
Method of 
blinding 
appropriate 
(+1) 
Inappropriate 
blinding 
method (-1) 
Description of 
withdrawals/ 
dropouts 
described (+1) 
 
PHARMACOLOGICAL         
Wu et al  1 1 0 1 1 0 1 5 
Pulitano et al  1 1 0 0 0 0 1 3 
Lodge et al  1 1 0 0 0 0 1 3 
Wong et al  1 1 0 1 1 0 1 5 
Inagaki et al  1 0 0 0 0 0 1 2 
Lentschener et al  1 1 0 1 1 0 1 5 
Shimada et al  1 0 0 0 0 0 1 2 
Shao et al  1 0 0 0 0 0 1 2 
ANAESTHETIC         
Beck-Schimmer  et al 1 1 0 0 0 0 1 3 
Toprak et al  1 1 0 0 0 0 1 3 
Ryu et al  1 1 0 1 1 0 1 5 
Matot et al  1 0 0 0 0 0 1 2 
Jarnagin et al  1 0 0 0 0 0 1 2 
Guo et al  1 0 0 0 0 0 0 1 
Hashimoto et al  1 1 0 1 1 0 1 5 
Hasegawa et al  1 1 0 0 0 0 1 3 
Wang et al  1 1 0 0 0 0 1 3 
Table 1: Assessment of study quality using JADAD score 
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4.2.1 Pharmacological Approaches to minimise blood loss after liver surgery 
 
Of the eight studies, five studies, describing pharmacological methods did not show an effect 
on blood loss (see Table 2). In three studies, an effect was found. In two trials (Lodge, Jonas 
et al. 2005, Shao, Yang et al. 2006) the authors investigated potential benefits of the 
recombinant coagulation factor (RCF) VIIa and concluded that there was no effect to 
decrease blood loss during  liver surgery. Pulitano et al (Pulitano, Aldrighetti et al. 2007) 
concluded that use of methylprednisolone did not decrease blood loss intra-operatively. 
Similarly, there was no beneficial effect of anti-thrombin III concentrates (Shimada, 
Matsumata et al. 1994) or desmopressin (Wong, Irwin et al. 2003). 
Potentially beneficial effects were identified for the following three agents: 
- Tranexamic Acid (TA):  
Wu et al (Wu, Ho et al. 2006) performed a double-blinded, placebo-controlled randomised 
trial comparing use of TA versus placebo recruiting 212 patients undergoing liver surgery for 
benign and malignant indications. Patients in the intervention group received 500mg of TA 
immediately prior to the operation and then 250 mg QDS for 3 days; patients in the control 
group had a similar volume of normal saline administered. The two groups were comparable, 
as expected, in terms of parenchymal transection method, use of intermittent in-flow 
occlusion, background quality of the liver and extent of resection. Patients in the intervention 
group had significantly less blood loss (overall blood loss 300 [30-2100] ml versus 600 [40-
3410] ml, p= 0.0001), a lower blood transfusion rate (p<0.0001), shorter operative time 
(p=0.003) and hospital stay. It should also be noted that a relatively high proportion (51.8%) 
of patients in this sample had evidence of cirrhosis or chronic hepatitis.   
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- Nafamostat Mesilate:  
10 patients received the serine-protease inhibitor Nafamostat Mesilate (NM) and were 
compared to a similar sized control group in a randomised controlled trial (Inagaki, Nonami 
et al. 1999). The 10 patients in the intervention group were given a continuous intravenous 
administration of 2mg/kg/day of NM for 7 days starting from the day of the operation. Details 
of randomisation and placebo administration were not provided. The intra-operative blood 
loss was lower in the intervention group though this did not reach statistical significance 
(1610 ± 1756 ml versus 957 ± 458 ml). Further statistical details were not provided. As 
secondary outcomes, Natural Killer cell activity and helper/suppressor ratios of T 
lymphocytes were found to be significantly increased compared to the control group. This 
may be of oncological importance, particularly when coupled with less intra-operative blood 
loss.  
- Aprotinin:  
Lentschener et al (Lentschener, Benhamou et al. 1997) performed a double-blind RCT 
looking at the use of aprotinin (protease inhibitor) versus placebo in 97 patients undergoing 
elective liver resection. The intervention group received a loading dose of 2x 10
6  
kallikrein 
inactivator units (KIU) of aprotinin, followed by a continuous infusion of 5x 10
5  
KIU per 
hour administered until skin closure. An additional bolus of 5x10
5 
KIU was administered for 
every 3 transfused red blood cell units. Patients in the control group received a similar 
volume of 0.9% Normal Saline placebo. The two groups, as anticipated, were comparable in 
terms of parenchymal transection method, use of intermittent inflow occlusion, background 
quality of the liver and extent of resection. The mean blood loss and transfusion requirements 
were significantly lower (1217 ± 966 versus 1653 ± 1221 ml, p=0.048) in the aprotinin group.
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Author Year Population Intervention No. 
patients 
Blood Loss 
(mL) 
Statistical 
significance 
Transfusion 
requirements 
[units or mL] 
(intra-/post op) 
No. of 
patients 
transfused 
Statistical 
significance 
Wu et al  2006 Liver 
resection-All 
Tranexamic Acid 108 300  
(30-2100) 
P=0.0001 - 0 P<0.0001 
   Placebo 106 600  
(40-3410) 
 - 17  
          
Pulitano et al  2007 Liver 
Resection-All 
Methylprednisolone 36 621  
(350-720) 
P=0.382 0.54 +/- 0.6 - P= 0.089 
   Placebo 37 662  
(300-800) 
 1.32 +/-0.5 -  
          
Shao et al  2006 Liver 
Resection-All 
Recombinant Factor 
VIIa (RCF) 50uL/kg 
71 800 (50-7000) P=0.77 - - - 
   RCF VIIa 100ul/kg 74 500 (70-6500)  - - - 
   Placebo 76 500 (40-4700)  - - - 
          
Lodge et al  2005 Liver 
Resection-All 
RCF VIIa 20ul/kg 63 1372+/-1301  P=0.07 1354 +/- 989   P=0.78 
   RCF VIIa 80ul/kg 59 1073+/- 997  1036 +/- 904   
   Placebo 63 1422 +/- 1271  1024 +/- 1001   
          
Wong et al  2002 Liver 
Resection-All 
Desmopressin 30 832.5  
(350-2955) 
P=0.93  3 P=0.45 
   Placebo 30 800 (250-7128)   5  
          
Inagaki et al  1999 Liver 
Resection 
(HCC/mets) 
Nafamostat Mesilate 10 957+/-458 NS - -  
   Control 10 1610 +/- 1756  - -  
          
Lenthschener 
et al  
1997 Liver 
Resection-All 
Aprotinin 48 1217 +/- 966 P=0.048 30  P=0.015 
   Placebo 49 1653 +/- 1221  77   
          
Shimada et al  1993 HCC Antithrombin III 
concentrate 
13 1393 +/- 181 NS 4.8 +/-1.6  NS 
   Placebo 11 1856 +/-360  4.4 +/- 1.4   
Table 2: A summary of RCTs investigating pharmacological interventions to reduce blood loss in liver surgery. (Underline indicates p<0.05) 
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4.2.2 Anaesthetic Techniques 
Nine trials (Table 3) were included in the analysis that recruited 679 patients. There was a 
range in the quality of the studies as assessed by the Jadad score (Table 1). The studies 
described interventions into three main groups: (a) anaesthetic agents, (b) manipulation of 
physiological parameters and (c) haematological control. 
 
4.2.2.1 a) Anaesthetic Agents 
 
- Pharmacological Post-conditioning (Sevoflurane):  
Beck-Schimmer et al (Beck-Schimmer, Breitenstein et al. 2012) performed a 3-group RCT 
comparing patients undergoing pharmacological post-conditioning with sevoflurane (n=48), 
intermittent Pringle manoeuvre (n=50) and continuous Pringle manoeuvre [control](n=17) in 
patients undergoing liver resection. In the control and intermittent clamping group, propofol 
was applied continuously until the end of surgery. In the post-conditioning group, propofol 
infusion was stopped after reperfusion and replaced by sevoflurane 3.2% end-tidal 
concentration for 5 minutes, followed by the post conditioning phase for 10 minutes and 
subsequent washout for 15 minutes. Propofol anaesthesia was re-started after this. Blood loss 
was similar between all three groups. However, post-conditioning (p=0.044) and intermittent 
clamping (p=0.015) reduced the transaminase levels significantly compared to the control 
group. Furthermore both groups also had a lower risk of complications and shorter hospital 
stay when compared with the control group.   
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- Desflurane versus Isoflurane during Donor Hepatectomy:  
Toprak et al (Toprak, Sahin et al. 2012) compared two inhalation anaesthetic agents, 
Desflurane (n=40) and isoflurane (n=40) in patients who were all ASA I or II undergoing 
liver donor hepatectomy in a randomised controlled trial. All patients underwent a standard 
anaesthetic technique. Anaesthesia was maintained using either desflurane or isoflurane. The 
two groups were comparable demographically. The blood loss was smaller in the isoflurane 
group though no statistical analysis was undertaken. However, transaminases and INR were 
higher in the isoflurane group when compared to the desflurane group.   
 
4.2.2.2  Manipulation of Physiological Parameters 
 
- Hypoventilation:  
Hasegawa et al (Hasegawa, Takayama et al. 2002) assessed whether reducing the tidal 
volume during surgery would be effective in reducing intra-operative blood loss, via a 
randomised controlled trial where patients were allocated to either normoventilation or 
hypoventilation. During liver transection, the tidal volume was 10mL/kg and the respiratory 
rate was 10/minute. In the hypoventilation group, the tidal volume was reduced to 4mL/kg 
and the respiratory rate was 15/minute. They found that hypoventilation did not decrease 
blood loss or peri-operative transfusion requirements.  
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- Low Central Venous Pressure:  
Low CVP anaesthesia is an established technique employed to reduce blood loss during liver 
resection. Wang et al (Wang, Liang et al. 2006) randomised 50 patients with hepatocellular 
carcinoma to either low CVP or control groups. The low CVP group had a markedly lower 
volume of intra-operative blood loss than the control group (903.9 ml ± 180.8mL versus 
2329.4 ± 2538.4 mL, p<0.01). Furthermore, operative time, hospital stay and post-operative 
liver function tests were significantly improved via lowering the CVP intra-operatively.  
In another study, Ryu et al (Ryu, Nahm et al. 2010) randomised adult liver donors to 
milrinone induced low CVP (n=19) or low CVP via fluid restriction (n=19). Milrinone is a 
phosphodiesterase 3 inhibitor which works to increase the contractility of the heart (Rieg, 
Suleiman et al. 2014). During low CVP hepatic surgery, the preload is reduced which carries 
potential risks such as end organ ischaemia and haemodynamic instability. There was 
significantly less bleeding in the milrinone only group (p<0.001). Interestingly the milrinone 
only group also had better post-operative aminotransferases on days 1-3. No patients had any 
significant side effects from milrinone use.  
 
 
4.2.2.3  Haematological Control 
 
- Acute Normovolaemic Haemodilution versus Control:  
There were a total of 238 patients undergoing liver resection that were randomised across 3 
trials to haemodilution (n=117) or control (n=121). The number of participants in each trial 
was 78 (Matot et al), 130 (Jarnagin et al) and 30 (Guo et al). In each of the  studies the 
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volume of blood to be removed was calculated pre-operatively. The haemodilution process 
began after intubation with blood being removed and stored in standard citrate-phosphate-
dextrose storage bags. The volume of blood removed was replaced by either 6% medium-
molecular weight hydroxyethyl starch or a combination of crystalloid and colloid.    The 
majority of the patients underwent major (> 3 segment resection) liver resections. The 
proportions of cirrhotic/steatotic livers were not described. The number of patients requiring 
blood transfusion was significantly lower in the haemodilution group. However, the operative 
blood loss did not differ between groups. 
-Intra-operative Blood Salvage:  
Hashimoto et al (Hashimoto, Kokudo et al. 2007) randomised living donors intra-operatively 
to a blood salvage group [BS] (n=40) or control group (n=39). In the BS group a blood 
volume equivalent to 0.7% of the patient‘s blood volume was withdrawn prior to the start of 
parenchymal transection. Blood loss during hepatic parenchymal transection was 
significantly lower (p=0.034) in the BS group compared to control. However, overall blood 
loss and transfusion requirements between the two groups were similar. It should be noted 
that the CVP was lower in the BS group and hence the slightly lower overall blood loss may 
in fact be attributed to the lower CVP rather than BS.
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Table 3: A summary of RCTs investigating anaesthetic interventions to reduce blood loss in liver surgery. (Underline indicates p<0.05 ) 
Author Year Population Intervention No 
Patients 
Blood Loss (ml) Statistical 
Significance 
Transfusion 
requirements [units or 
ml] (intra-/post op) 
No. of 
patients 
transfused 
Statistical 
significance 
Peak AST (IRI) Statistical 
Significance 
Beck-
Schimmer et 
al  
2012 Liver 
Resection- All 
Pharmacological post-
conditioning 
48 200 (100-325) - 0 0 - 443 P=0.015 
   Intermittent Clamping 50 225 (150-350) - 0 0 - 438  
   Control 17 200 (100-500) - 0 0 - 631  
            
Toprak et al  2012 Living Donor 
Hepatectomy 
Isoflurane 40 503 +/- 203 - 0 0 - 235  
   Desflurane 40 542 +/- 227 - 0 0 - 136 P< 0.05 
            
Ryu et al  2009 Living Donor 
Hepatectomy 
Milrinone 18 142 +/- 129 P< 0.05 - - - - - 
   Control 19 378 +/- 167  - - - - - 
            
Jarnagin et al ( 2008 Liver 
Resection- All 
Acute Normovolaemic 
Haemodilution (ANH) 
63 800 (100-3200) P= 0.42 28 8 P=0.067   
   Control 67 700 (100-4000)  47 17    
            
Hashimoto et 
al  
2007 Living Donor 
Hepatectomy 
Blood Salvage 40 403 (120-1240) P= 0.257  3 P= 0.115   
   Control 39 440 (130-1230)   9    
            
Wang et al  2006 HCC Low CVP 25 903.9 +/- 190.8 P<0.01 525.00 +/- 237.57 8 P<0.05 561 P>0.05 
   Control 25 2329.4 +/- 
2538.4 
 1285.71 +/- 1162.13 14  700  
            
Guo et al  2004 HCC ANH 15 710.9 +/- 75.9 NS 350.5 +/- 70.7  P< 0.01   
   Control 15 734.7 +/- 83.1  457.8 +/-181.3     
            
Matot  2002 Liver 
Resection- All 
ANH 39 750 (100-7000) NS  4 P= 0.014   
   Control 39 890 (100-7500)   14    
            
Hasegawa et 
al  
2002 Liver 
Resection- 
Tumours 
Hypoventilation 40 630 (72-3600) NS  4 NS   
   Control 40 630 (120-3520)   3    
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4.3 Discussion 
Hepatic surgery has become significantly safer with advancements in surgical, radiological and 
anaesthetic techniques (Jarnagin, Gonen et al. 2002, Chan, Chiang et al. 2011). It has been well 
documented that both short and long-term outcomes are dependent on the avoidance of blood 
transfusions (Parrott, Lennard et al. 1986, Little, Wu et al. 1990, Tartter 1992). The purpose of 
this systematic review was to summarise the evidence of the effects of non-surgical interventions 
on the intra-operative blood loss during liver resections.  
In this review, three categories of anaesthetic support to decrease blood loss were identified. 
Lowering the CVP state, whilst maintaining adequate organ perfusion is a key anaesthetic 
concept. As shown, there are also pharmacological agents to achieve this such as the use of 
Milrinone (Ryu, Nahm et al. 2010). However, most patients undergoing a hepatectomy receive 
an epidural catheter which decreases analgesic requirements, reduces the stress response and also 
gives rise to a sympathetic autonomic blockade. This decreases the systemic vascular resistance 
and lowers the CVP (Feltracco, Brezzi et al. 2008). Intravenous fluid administration or restriction 
is also guided by various methods of invasive and non-invasive methods of goal-directed fluid 
therapy (Bundgaard-Nielsen, Holte et al. 2007). Therefore milrinone is seldom required and has 
not been widely adopted. Nevertheless, it has been shown in animal experiments that Milrinone, 
injected intravenously immediately after reperfusion, may reduce the ischaemia-reperfusion 
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injury (Toyoda, Tosaka et al. 2013). The use of milrinone is liver surgery should be investigated 
further to assess effectiveness in decreasing the ischaemia-reperfusion injury. 
Pharmacokinetic knowledge of anaesthetic agents may also play a role in reducing the extent of 
IRI seen in hepatic surgery. All volatile inhalational drugs are partly metabolised by the liver and 
may affect hepatic blood flow, as well as having other cardiovascular side-effects (Wissing, 
Kuhn et al. 2000). Sevoflurane and desflurane appear to reduce the degree of IRI which may be 
clinically relevant if the functional liver remnant is small. However, only two randomised trials 
have been performed examining the role of anaesthetic agents in reducing blood loss and the 
degree of IRI in liver surgery and hence further trials are needed before recommendations can be 
provided.   
Blood preservation techniques such as intra-operative blood salvage and acute normovolaemic 
haemodilution demonstrate a tendency towards lower blood loss and transfusion requirements. 
Autologous blood transfusion techniques such as blood salvage avoids the risk of homologous 
blood transfusion and has been shown to be cost effective in major spinal surgery (Kumar, Chen 
et al. 2012). Concerns have been raised regarding use of autologous blood donation in 
oncological surgery due to a perceived risk of recurrent cancer, however, evidence suggests that 
it is safe to employ (Fujimoto, Okamoto et al. 1993, Bower, Ellis et al. 2011, Kumar, Chen et al. 
2014). Other issues with autologous blood donation include a high discard rate and a higher risk 
of ischaemic events  (Goodnough 2004, Ubee, Kumar et al. 2011).  
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The health economic aspects of routinely using such strategies in liver surgery need to be 
defined.  In the interim period till such analyses occur, acute normovolaemic haemodilution and 
intra-operative blood salvage should be considered for major liver resections or in cases where 
blood loss is expected to be greater than normal. 
Considering pharmacological approaches, Tranexamic Acid and aprotinin both decrease 
intraoperative blood loss (table 2). Aprotinin was withdrawn from the market due to concerns 
about increased rates of thrombosis, renal dysfunction and death (McMullan and Alston 2013) 
which  may explain why there has been only one RCT. Both TA and aprotinin have been shown 
to successfully decrease blood loss and transfusion requirements in patients undergoing a 
hepatectomy. Further trials, within liver surgery however, are required to validate these findings 
and justify routine use of tranexamic acid, though some advocates may feel these agents be used 
routinely in high risk cases such as re-resections which are being undertaken increasingly 
nowadays with the trend towards parenchyma-sparing surgery. Nafamostat Mesilate (NM) was 
shown to decrease blood loss and heighten the immune response in one trial which may be of 
particular importance in oncology. However, the trial numbers were low and insufficient to draw 
any firm conclusions.  
 
 Most studies included in this review had methodological weaknesses. As demonstrated in Table 
1, study quality was variable. Although all included studies were randomised control trials, 
randomisation details were not provided in all cases. There is also significant heterogeneity in 
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the populations studied. Though 17 RCTs were included, most of them examined different 
strategies to reduce intra-operative blood loss and transfusion requirements and most were also 
underpowered, without a formal sample size calculation. Therefore, pooling of results and meta-
analyses was not possible. 
Furthermore, it is accepted that blood transfusion requirements do not necessarily directly 
correlate to blood loss as different centres will have varying trigger points for transfusion and 
that blood loss is dependent on several patient and physician-based factors. Additionally, the 
methodology of estimating blood loss was not given in most papers and this would be subject to 
inter-observer variability. Additionally, most papers used ALT to measure ischaemia-reperfusion 
injury although the effect of post-operative ALT on short- or long-term outcome has not been 
previously been published.  
 Patients are currently assessed  and counselled with regard to fitness to surgery via pre-operative 
assessment and cardiopulmonary exercise testing (Lentschener and Ozier 2002). However, the 
risk of bleeding is not formerly assessed despite the availability of pre-operative radiological 
images and knowledge of patient factors which may predispose to bleeding. It may be 
appropriate to formerly assess the risk of intra-operative blood loss prior to surgery and then 
ensure certain pathways are followed once a certain trigger figure is reached (e.g. 500ml blood 
loss). A parallel may be drawn to obstetric medicine where WOMAN- an international, 
randomised doubled blinded placebo controlled trial is examining the role of TA use in post-
partum haemorrhage once a certain amount of blood loss has occurred. Similarly we propose a 
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multi-faceted approach to pre-operative bleeding risk assessment in liver surgery and initiation of 
management strategies once a certain amount of blood loss has occurred.  
Future trials should examine optimal use of anaesthetic agents, both for anaesthesia maintenance 
and pharmacological post-conditioning. Although, anaesthetic agents may not significantly 
reduce blood loss there is evidence to suggest reduced IRI. Milrinone may also facilitate 
maintenance of a low CVP intra-operatively whilst simultaneously reducing the IRI and blood 
loss during liver surgery. There is a paucity of trials examining the use of TA in Liver surgery 
given the positive findings of the two RCTs. Nafamostat Mesilate also reduced blood loss whilst 
increasing NK cell activity. Well-designed studies could help optimise usage of these drugs in 
the future.  Future efforts should also be directed towards producing guidelines for assessing the 
risk of intra-operative blood loss and subsequent strategies to deal with bleeding once a threshold 
has been passed. 
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Chapter 5 
 
The effect of peri-operative blood loss and blood transfusion on long term survival 
following liver surgery for CRLM  
 
5  The effect of peri-operative blood loss and blood transfusion on long term survival 
following liver surgery for CRLM  
 
5.1 Introduction 
Recent developments in surgical technique, anaesthesia and peri-operative care have resulted in 
lower morbidity and mortality rates after liver resections for the treatment of CRLM (Jarnagin, 
Gonen et al. 2002, Chan, Chiang et al. 2011). Furthermore, Neoadjuvant and adjuvant 
chemotherapy protocols have led to an increase in the proportion of patients eligible for curative 
resections (Adam, Delvart et al. 2004, Falcone, Ricci et al. 2007, Folprecht, Gruenberger et al. 
2010, Lam, Spiro et al. 2012). However, intra-operative blood loss remains a significant concern 
as blood transfusions are known to predispose to poorer short- and long-term outcomes (Parrott, 
Lennard et al. 1986, Little, Wu et al. 1990, Tartter 1992, Panagopoulos, Karakantza et al. 2008). 
Increasing evidence from other surgical subspecialties (including breast and oesophago-gastric 
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surgery) indicates that cancer patients who received blood transfusions had poorer long-term 
survival rates (Parrott, Lennard et al. 1986, Little, Wu et al. 1990, Tartter 1992, Herman and 
Kolodziejski 1993, Amato and Pescatori 2006, Panagopoulos, Karakantza et al. 2008, Sun, Wang 
et al. 2015). In resected primary colorectal cancer a link between transfusions, earlier recurrence 
and decreased survival has been established (Burrows and Tartter 1982, Foster, Costanza et al. 
1985, Miki, Hiro et al. 2006). There is limited data regarding the impact of red blood cell 
transfusion (RBCT) on long-term impact in resectional surgery for CRLM. The majority of 
published studies on this topic for CRLM resections are analyses of single centre experiences 
using uni- and multivariate analyses, with conflicting evidence regarding the effect of RBCT and 
long term outcome (Younes, Rogatko et al. 1991, Gruttadauria, Saint Georges Chaumet et al. 
2011, Jiang, Fang et al. 2013, Hallet, Tsang et al. 2015, Schiergens, Rentsch et al. 2015). There 
remains debate about whether there is a real causal relationship between blood transfusion and 
long-term outcome, or whether the poorer long-term outcome is due to the more complicated 
surgery (larger tumour volume/number) and associated risks.  Previous studies looking at long 
term outcomes are largely historical and therefore, given the changes in chemotherapy and 
reduced transfusion requirements over time, it would be useful to re-evaluate this relationship, 
especially in the context of expanding indications for more complex and recurrent resections.  
5.2 Aim 
The primary aim of this chapter is to examine the cause and effects of blood loss and blood 
transfusions on long-term outcomes after hepatectomy for colorectal liver metastases, in a 
contemporary series.  
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5.3 Methods 
A retrospective cohort study was performed, using the prospectively maintained database of all 
patients undergoing liver resections at The Leeds Teaching Hospitals, between 2005-2012 
5.3.1 Inclusion Criteria 
 
Patients were included in the final analysis if they underwent surgery for CRLM. Patients 
undergoing simultaneous resections, two-stage procedures, re-resections and concurrent ablative 
techniques were excluded, as these patients represent a very different risk group profile.  
5.3.2 Outcome Measures 
 
The primary outcomes were defined as (1) overall survival (OS) with ‘death’ as the end point in 
relation to blood transfusion and (2) relapse–free survival (RFS) with ‘recurrence’ as the end 
point in relation to blood loss and blood transfusion. Secondary outcome measures were factors 
associated with RBCT and OS. The relationship between OS and complications was also 
examined, via the Clavien-Dindo Score. 
 
5.3.3 Definitions 
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The hospital blood transfusion database was cross-checked. A major hepatectomy was defined as 
resection of 3 or more contiguous or non-contiguous hepatic segments according to the Couinaud 
classification (Mullen, Ribero et al. 2007). Recurrence was defined as a radiological diagnosis on 
cross-sectional imaging. For death as an end-point, OS computed from date of surgery to date of 
death and for recurrence as an end point, RFS is computed from date of surgery to date of 
recurrence   End of follow up for OS was defined as date of death or 4
th
 June 2014.  End of 
follow up for RFS was defined as date of recurrence, date of death or 4
th
 June 2014.  
Perioperative transfusion was defined as transfusion of one or more units of allogenic RBC 
within 7 days of surgery. As actual Intra-operative blood loss (IBL) was not routinely collected 
in the retrospective data an estimated IBL was computed using the following formula (Gross 
1983): 
𝑰𝑩𝑳 = 𝑬𝑩𝑽 𝒙 
(𝑯𝒐 − 𝑯𝒇)
𝟏
𝟐 (𝑯𝒐 + 𝑯𝒇)
 
EBV: estimated Blood volume (10 units x 500ml), Ho: preoperative Hb, Hf:  postoperative Hb.  
IBL was then estimated  using another formula (Bourke and Smith 1974) which applied the 
natural Logarithm function: 
𝑰𝑩𝑳 = 𝑬𝑩𝑽 𝒙 𝑰𝒏
𝑯𝒐
𝑯𝒇
 
The estimates corresponded well (Kappa= 0.8) Maximum discrepancy between the estimates was 
< 5%, mainly when estimating very high IBL. 
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 Adjuvant or neoadjuvant therapy was used in patients who had not had any chemotherapy 
within 12 months of hepatic surgery, or in those who had a positive resection margin.  
The Clavien-Dindo score is widely used throughout surgery for grading adverse events which 
occur as a result of surgery (Dindo, Demartines et al. 2004) 
Fong et al published the Clinical Risk Score which used various prognostic criteria to identify 
patients most likely to benefit from surgery (Fong, Fortner et al. 1999). Clinical Risk Score ( 
CRS) was computed for each patient based on ; CEA > 200 dg/L,  number of liver lesions, size 
of largest liver lesion,  nodal status of the primary tumour and  disease free interval < 12 months  
(Fong, Fortner et al. 1999, Hallet, Tsang et al. 2015) . In this study, CRS variable was used as a 
binary variable; CRS  =0 (and CRS > 0) . 
  
5.3.4 Data Extraction 
 
Data extraction was undertaken by three researchers (SP, AAD, FK) using a pre-designed data 
extraction form. Data was extracted on baseline patients  demographics, pre-operative clinical 
characteristics (use of neoadjuvant chemotherapy, co-morbidities, size and number of tumours, 
presence of extra-hepatic disease, tumour markers and routine pre-operative bloods), intra-
operative characteristics (use of hepatic inflow occlusion, type and extent of resection) and post-
operative features (pathology, post-operative complications, post-operative chemotherapy, 
recurrence, date of death).  Post operatively patients were followed up clinically and 
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radiologically with computed tomography of the chest, abdomen and pelvis every 3-6 months for 
the first two years and then yearly until 10 years postoperatively.   
 
5.3.5 Statistical Analysis 
 
Data were analysed using SPSS statistical software (IBM SPSS Statistics USA, Version 21, 
2012) for uni- and multivariate analysis and STATA (StataCorp Texas USA, Version 11.1, 2009) 
for survival analysis. 
 
5.3.5.1 Univariate Analysis 
 
Descriptive analysis described characteristics of patients who required transfusion and compared 
them to those who did not.  For categorical data, analysis included the use of cross tabulation, 
Odds ratios & Chi square to test the difference/ association between study groups. Fisher Exact 
test was used when indicated   The Pearson chi-square test of association was used to examine 
the relationship between each variable and outcome. Statistical assumptions required for a valid 
application of the chi-square test were examined and found to be justified. The magnitude of the 
effect was quantified using the odds ratio (OR) with 95% Confidence interval.  Both parameteric 
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as well as non parametric tests and GLM ANOVA were used to assess the difference in means 
for continuous and numerical variables between the transfused and non-transfused. 
 
5.3.5.2 Multivariate Analysis 
 
Joint and conditional multivariate association between variables and outcome was assessed using 
binary logistic regression. All variables that were shown to be significant in the univariate 
analysis at p < 0.05 were included in a multivariate analysis. Logistic regression was used to 
adjust simultaneously for study variables seen as potential confounders and examined possible 
interaction terms:     
 Log Probability Intra-operative bleeding   (Log OR) = Constant+ B1X1 + B2X2+........BnXn 
whereby X is the variable to be explored and B is its regression coefficient. Odds ratio for individual 
variables is computed from the regression equation as OR = e
B
, adjusted for all other variables in 
the model. Variables not included in the final model are those variables which did not provide a 
statistically significant multivariate contribution to the prediction of intra-operative bleeding.  
The appropriateness of the logistic link and model specification was assessed, the data was 
screened for potentially influential observations, and the extent of multicollinearity amongst 
predictor variables was examined using variance inflation factors (VIF).  These model 
diagnostics (VIF < 2, tolerance .02) indicated that a logistic specification was appropriate and the 
predictors in the model did not suffer from problems associated with information overlap. The 
   
58 
 
sample size is sufficiently large to ensure stable logistic regression parameter estimates were 
obtained which are not suspect on accuracy or precision 
 
5.3.5.3 Prediction Analysis 
 
A prediction score was calculated from all predicting factors in the multivariate analysis and the 
linear function for the binary logistic regression model:      
B1x1+b2x2.....+ Constant = predictive score 
The prediction validity was assessed using ROC curves 
 
5.3.5.4 Survival Analysis 
 
  Survival analysis was performed using STATA version 8. The Kaplan -Meier method with 
Log-rank test was applied to compare survival curves in the compared groups.  Cox proportional 
hazard regression assessed the effect transfusion on the probability of survival during the follow 
up period.  Variables identified as significantly associated with transfusion on univariate analysis 
(p<.05) were included in the regression model.   Hazard ratios HR was calculated with 95% 
confidence intervals. Hazard Ratios were interpreted as the instantaneous relative risk of death 
any time between 2005 and 2014 for patients who underwent hepatectomy at St James 
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University Hospital, Leeds between 2005 and 2012.  Patients were followed up until June 2014. 
Kaplan -Meier curve was used to estimate the survival outcomes 
 
5.4 Results  
5.4.1 Patient Characteristics 
 
Six Hundred and Ninety patients who underwent hepatectomy between 2005 and 2012 were 
included and follow up was undertaken until June 2014 (Table 4). Of these, 461 (66.8%) patients 
were males and 229 (33.2%) females with a mean age of 67.2 years [standard deviation (SD) 
=10] range 25 to 82 years [median 66, interquartile range (IQR) 13 years].   
Two hundred and fifty patients (36%) had preoperative anaemia with a haemoglobin of less than 
130 g/L (NICE 2013). Three hundred and twenty seven patients (47%) had multiple liver 
metastases with a maximal tumour number of 21 (median 3, IQR 2) and a mean tumour size of 
41 mm [range: 9-120, standard deviation (SD) =21].  There were 337 of the 690 patients (49%) 
underwent a major liver resection (i.e. resection of 3 or more segments), and in 238 cases (35%) 
an anatomical hepatectomy was performed.  
Sixty-four (9.3%) patients required peri-operative RBCT. Recurrences were reported in 436 
(63%) patients (of which 237 were intra hepatic) during the follow up period. The median follow 
   
60 
 
up was 33 months (IQR 28.5). At final follow-up, 352 (51%) patients were alive and 338 (49%) 
died.  
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Table 4: Characteristics of patients undergoing hepatectomy for CRLM  
 Transfused patients 
N=64 
Not transfused patients 
N =626 
P   value 
Male gender 38 (59%) 422 (67%) 0.124 
Pre-operative anaemia  <130g/L 48 (75%) 202 (32%) <.001 
Cardiac disease 15(26%) 91(16%) 0.047 
Vascular disease 9(16%) 49 (9%) 0.081 
Diabetes mellitus 9 (16%) 61 (11%) 0.198 
Hypertension 18 (31%) 165 (30%) 0.458 
Primary tumour location (colon) 42(71%) 312 (54%) 0.009 
Pre-operative Chemotherapy 17(29%) 154(27%) 0.412 
Extra hepatic spread 6 (9%) 82(13%) 0.264 
Major liver resection 40(63%) 297(47%) 0.015 
Type of hepatectomy  (anatomical 
resection) 
29(45%) 209(33%) 0.021 
Resection Margin status: 
R0 
R1 
R2 
 
34(53%) 
30(47%) 
1(2%) 
 
352(57%) 
265(43%) 
4 (1%) 
 
0.323 
0.314 
0.390 
Post-operative complications 23(36%) 138(22%) 0.012 
Clinical Risk Score  CRS >0 3 (5%) 65 (10%) 0.12 
Age (years)             Mean (sd) 68.6 (12) 65.6 (10) 0.034 
Size of large tumours in mm Median 35 IQR 60 Median 35 IQR 33 0.83 
Pre-operative CEA Median 6     IQR 30 Median 8.50       IQR 30 0.93 
Pre-operative CRP Median 6.40  IQR 30 Median 5  IQR   6 0.64 
Number of tumours Median 3    IQR 4 Median  2       IQR 3 0.97 
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5.4.2 Long Term Outcomes 
 
5.4.2.1 Overall Survival and RBCT 
 
The median follow up was 33 months (IQR 28.5).   The median overall survival was 46 months 
(95% CI 39-53).  For those who received RBCT median survival was significantly lower at 41 
months (95% CI 41-57) compared to 49 months (95% CI 36-46) in those who did not receive 
RBCT (p=0.036) (Figure 2).  After 1, 3 and 5 years, overall survival rates were 83%, 54% and 
30% respectively for patients who were transfused compared to 91%, 62% and 43% for non-
transfused patients. RBCT was associated with poorer OS. 
Figure 2 : OS and Transfusion status 
 
Log rank test p=.036 
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5.4.2.2 Relapse Free Survival and RBCT 
 
The median RFS survival was 16 months (95% CI 13.8-18.2).  For those who received RBCT 
median survival was 15 months (95% CI 9.7- 20.2) compared to 17 months (95% CI 14.4- 19.6) 
for those who did not receive RBCT but this difference was not significant (p=0.28).  At 1 year, 
3 years and 5 years RFS rates were 58%, 35% and 30% for those who had RBCT and 55%, 35% 
and 29% for non-transfused patients respectively (Figure 3). 
Figure 3 : RFS and transfusion status 
 
Log rank test p= 0.28 
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5.4.2.3 Overall Survival (OS), Relapse Free Survival (RFS) and Blood Loss 
 
IBL was not significantly related with either OS or RFS (Figures 4 and 5).   For high IBL median 
overall survival was 3.8 years (95% CI 3.1-4.8) compared to 4 years (95% CI 3.4-4.1) for those 
had a lower IBL (Log rank test p=0.28).  Median RFS for high volume IBL was 1.33 years (95% 
CI 1.1-1.7) compared to 1.4 years (95% CI 1.2-1.7) for those with less IBL (p=.82) 
   
Figure 4: OS and Estimated Blood Loss 
 
Log rank test p= 0.28 
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Figure 5: RFS and Intraoperative Blood Loss 
 
Log rank test p= 0.82 
 
5.4.2.4 Overall Survival (OS) and Postoperative Complications.   
 
The median survival for patients with minor post operative complications based on Clavien-
Dindo scores 1 and 2 was  4.2 years  (95% CI  3.5-4.8)  versus 2.4 years (95% CI 1.6-3.2) for 
patients with scores >2  (Log Rank test   X
2 
19 df 1   p=0.0001) [Figure 6] 
Patients who had Clavien-Dindo scores >2 and received RBCT had a median survival of 1.2 
years (95% CI 0-4.9) compared to median survival of 2.4 years (95% CI  0.6 -3.2) for those with 
the same CD score who did not have RBCT (Figure 7).  The median survival for those who had 
CD Score 1 and  2 and who received RBCT  was 3.8 years (95% CI  2.8-4.6) compared to 4.4 
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median survival years (95% CI 3.7-5.1)  for those with same CD score but who did not receive 
RBCT (p=0.001) ( Figure 7) 
Figure 6 : Overall Survival by Clavien Dindo Scores 
 
Log rank test p= 0.0001 
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Figure 7: Comparison of OS for patients with high and low Clavien-Dindo Scores by transfusion 
status 
 
 
Log rank test p= 0.01 
 
 
5.4.3 Factors Associated with OS and RFS 
 
Factors associated with OS and RFS in Cox regression analysis are presented in Table 5. In 
addition to RBCT, age at surgery, sex, pre-operative chemotherapy, post-operative complications 
and CRS (derived from size and number of liver lesions, CEA level >200 dg/L and nodal status 
of primary lesion) were included in the model. Pre-operative chemotherapy, post-operative 
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complications and CRS were independently associated with reduced overall survival, though 
RBCT was not. RBCT was not associated with RFS 
 
Table 5: Cox regression Analysis of factors predisposing to OS and RFS 
 Overall 
Survival 
    Relapse free 
survival 
  
                                            
Hazard ratio 
 
95.0% CI for 
HR 
 
P value 
                                           
Hazard ratio 
 
95.0% CI for 
HR 
 
P value 
Age 1.008 0.996-1.019 0.187 1.001 0.99  - 1.01 0.798 
Male gender  1.001 0.782-1.283 0.991 1.043 0.84  - 1.29 0.696 
Pre operative 
chemotherapy 
1.780 1.383-2.291 0.000 1.709 1.37 – 2.13 0.000 
Clinical Risk 
Score >0 
2.362 1.875-2.974 0.000 2.541 2.07 - 3.12 0.000 
Clavien-Dindo 
Score 
1.566 1.153-2.126 0.004 1.026 0.762-1.38 0.865 
RBCT 1.360 0.962-1.924 0.082 1.271 0.904 – 1.78 0.168 
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5.4.4 Factors Associated with RBCT 
 
5.4.4.1 Univariate Analysis 
 
Table 4 summarises the univariate analysis of variables associated with the need for RBCT.  
Significant factors included major liver resections [OR 1.8 (95% CI 1.1-3,1), p=0.015)], 
anatomical resections [OR 2.1 (95% CI 1.3-3.8), p=0.02], size of largest tumour [OR 1.8 (85% 
CI 1.1-3,1), p=0.04), age [OR 1.03 (95% CI 1.02-1.16), p= 0.034], post-operative complications 
[ OR 1.97 (95% CI 1.14-3.33), p= 0.012], Charlson scores of 1 and 2 (X
2  
12.3, p=0.015), 
preoperative anaemia ( OR of 6.3 (95% CI 3.5-11.3,  p <0.001) and colonic primary tumours 
[OR  1.9 (95% CI 1.13 - 3.32), p=0.009] . Patients who received RBCT were older than those 
who did not (p=0.034) 
 
5.4.4.2 Multivariate Analysis 
 
Three co-variates (Table 6) were shown to be significant in predicting the need for RBCT: (1) 
pre-operative anaemia [OR 7.97 (95% CI  4.1- 15.6, p<.001), (2) the size of the largest tumour 
[OR 1.01 (95%CI  1.00-1.02, p=.001) and the primary tumour location [OR 2.4 (95%CI  1.3 - 
4.7, p=0.008).  A drop of postoperative Hb did not achieve significance as a predictor (OR 1, 
p=0.25). 
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Table 6: Logistic regression Analysis of factors predisposing to RBCT 
 RBCT   
                                            
Hazard ratio 
 
95.0% CI for HR 
 
P value 
Pre operative anaemia 7.968 4.063-15.626 0.01 
Primary tumour Location in 
the colon 
2.424 1.262-4.653 0.008 
Size of largest tumours  1.011 1.003-1.020 0.011 
 
5.4.4.3 Prediction Modelling for RBCT 
 
A prediction score was calculated from all predicting factors in the multivariate analysis is:    
  0.012 Size of largest tumour  +   2.07x pre operative anaemia + 0.885x primary tumour 
location - 4.278= score 
The model has good predictive properties with an area under the ROC curve (AUC) of 0.845 
(Figure 8). 
In the above formula the variables take the values of 0 or 1 depending on whether there was pre 
operative anaemia (1 = Yes, 0 = No) and  primary tumour location (1 =Colon and 0=Rectum). If 
the value obtained from calculating the formula is negative (or zero) the model predicts that there 
no transfusions will be required. If the formula is positive then the need for transfusions can be 
predicted.  
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Figure 8: ROC curve assessing predictive accuracy of the logistic model predicting RBCT        
 
Area Under Curve (AUC) for predicting RBCT  p=0.845     
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5.4.5 Factors Associated with Blood Loss 
 
The median IBL was 833ml (IQR 590 ml, range 0-2605 ml), the median Hb drop was 2.3 g/dL 
(IQR 1.7 g/dL, range 0-8.9 g/dL) and 64 (9.3%) patients received a transfusion.   An IBL volume 
of 650 ml (Hb drop of 1.4 g /dL) corresponded to the maximum joint sensitivity on the ROC plot 
AUC 0.81 (95% CI  0.76-88).    Univariate analysis identified the following variables to have 
significant associations with a drop in pre-operative Hb (IBL) ≥1.4 g/dL (based on ROC curve):    
1. Pre-operative chemotherapy and Hb drop [OR 0.7 (95% CI .44-.98, p=.028)]       
 2. RBCT and Hb drop [OR 3.5 (95% CI 2.2-5.9, p> 0.001)]    
3. Size of the largest tumour (mean diameter 44.2 mm in higher IBL versus 38.5mm in lower 
level IBL [OR 1.01 (95% CI 1-1.14, p =.034)]  
4. Closest resection (5mm in high IBL versus 3.8mm in lower IBL [OR .97 (95% CI  .95- .99, 
p=0.036)]  
However, multivariate analysis confirmed that only the size of the largest tumour > 3.5 cm 
(p>0.001) as the main predictor of high IBL.  
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5.5 Discussion 
To date, this is the largest and most contemporary study on the effects of blood transfusions on 
survival after hepatectomy for colorectal liver metastases. In the current study, 690 patients 
underwent liver resection, of whom 64 (9.3%) needed a blood transfusion. Our transfusion rate 
was lower than most published series- this is likely to be secondary to improved surgical and 
anaesthetic advancements recently, in comparison to older series. Transfusion was associated 
with a decreased overall survival. However, there was no association between blood transfusion 
and earlier disease recurrence. Furthermore, on multivariate regression RBCT was not 
independently associated with OS, although post-operative complications, pre-operative 
chemotherapy and CRS were. Multi-variate analysis found pre-operative anaemia, location of 
primary tumour and size of liver metastases to be predictive of the likelihood of RBCT. A 
predictive score was developed, although this will need to be validated on other cohorts.  
Our findings suggest that the poorer OS seen in patients who underwent RBCT was likely to be 
multifactorial and due to peri-operative complications, rather than due to earlier disease 
recurrence per se. Patients who had a major complication had a significantly reduced overall 
survival and this impact was exaggerated if the patient also had a blood transfusion. It is feasible 
that peri-operative transfusion is a surrogate marker for larger volume disease (major liver 
resection, anatomical resection and size of largest tumour all associated with RBCT on univariate 
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analysis) and hence the poorer OS was multifactorial, linked to more extensive surgery and the 
associated complications.  
Previous studies of patients undergoing colectomies for primary colorectal cancer have 
demonstrated a link between blood transfusion and earlier disease recurrence (Burrows and 
Tartter 1982, Foster, Costanza et al. 1985, Miki, Hiro et al. 2006). Although mechanisms for this 
observation are not fully understood, it is believed that micrometastatic cells evade immune 
surveillance due to decreased tumour surveillance as the transfusion modifies the immune 
response by a decrease in the natural killer cell activity, phagocytic activity and an increase in 
suppressor T-cell activity with inhibition on interleukin 2 (Amato and Pescatori 2006, Kneuertz, 
Patel et al. 2011, Schiergens, Rentsch et al. 2015). This leads to transfusion-related host 
immunosuppression causing decreased tumour surveillance and early recurrence (Kooby, 
Stockman et al. 2003).  
Our study did not find an independent association between liver resection, blood transfusion and 
earlier disease recurrence, although there was a negative association between transfusion and 
overall survival.  It may be feasible that stage IV disease represents a different disease entity and 
hence the immune response to RBCT is different. It is also plausible that better systemic and 
multi-modal therapies keep micro-metastatic disease well controlled.   
A small number of previous studies have also examined the effect of RBCT on patients 
undergoing a hepatectomy for CRLM (Jiang, Fang et al. 2013, Hallet, Tsang et al. 2015, 
Schiergens, Rentsch et al. 2015). However, the majority of these studies are limited by the 
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relatively low patient numbers. A few studies have found an association between RBCT and 
decreased overall and disease free survival (Stephenson, Steinberg et al. 1988, Rosen, Nagorney 
et al. 1992, Hallet, Tsang et al. 2015). However, other investigators have found transfusion to be 
associated with poorer short term outcomes but not necessarily long-term outcomes (Kooby, 
Stockman et al. 2003, Cannon, Brown et al. 2013). Recently Postlewait et al (Postlewait, Squires 
et al. 2016) also found that RBCT was associated with increased complications but not disease-
specific survival. In their study, only patients who underwent a major hepatectomy were 
included. Our study includes all liver resections as significant blood loss may also be 
encountered when performing non-anatomical resections for large liver metastases. The 
relatively high R1 rates in our series are due to the fact that large non-anatomical resections were 
often undertaken.  
Currently there is considerable variation in use of blood products and more restrictive transfusion 
strategies should be used (Carson, Terrin et al. 2011).  However, this study would support 
judicious use of blood transfusion during the peri-operative period, ideally within the context of 
a guideline. 
A recent review identified that strategies to inform risk of perioperative bleeding were not 
routinely performed (Pathak, Hakeem et al. 2015). Certain pharmacological agents such as 
tranexamic acid and aprotinin were also shown to decrease blood loss during liver surgery but 
are yet to be widely adopted due to a paucity of evidence (Pathak, Hakeem et al. 2015). Although 
transfusion rates in this study were low, patients with large tumours and pre-operative anaemia 
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were more likely to receive a transfusion. Identifying risk factors predisposing to transfusion 
may further reduce transfusion requirements.  
This study is limited by its retrospective design and inherent biases due to the long study period. 
It is also likely that the finding suggesting that location of primary tumour as a prognostic 
indicator of transfusion requirements is a retrospective bias although previous research has found 
it to be an independent predictor of long-term survival (Younes, Rogatko et al. 1991, Adam, de 
Haas et al. 2011). There is emerging evidence suggesting that the prognosis between left sided 
and right sided colon cancers may vary, which may also influence outcome in hepatic surgery 
(von Einem, Heinemann et al. 2014, Brule, Jonker et al. 2015).  
Our findings suggest that transfusion is not associated with poorer long term outcomes and that it 
should be used judiciously in the peri-operative period, ideally within the context of a guideline. 
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Chapter 6 
Pilot Randomised Controlled Trial: A study to compare the impact or  The Pringle 
Manoeuvre or  Isolated Portal Vein Clamping on blood loss during liver surgery 
 
6 Randomised Controlled Trial: The Pringle Manoeuvre versus Isolated Portal Vein 
Clamping (RfPB Funded Trial) 
6.1 Background  
The portal vein and the hepatic artery supply 75% and 25% of the liver’s blood supply 
respectively, with each vessel contributing 50% of the liver’s oxygen requirement (Rahbari, 
Wente et al. 2008).  The Pringle manoeuvre is commonly used to prevent blood loss at the time 
of liver resection by clamping the vascular pedicle containing the hepatic artery and the portal 
vein together during liver resection surgery (Figure 9). During clamping a deprivation of 
oxygenation at the cellular level occurs. Cellular damage occurs when the ‘starved’ cells are 
reperfused, resulting in ischaemia reperfusion injury (IRI) (see chapter 1.4) (Montalvo-Jave, 
Escalante-Tattersfield et al. 2008). It has been suggested that undertaking isolated control of the 
hepatic portal vein and  not clamping the hepatic artery allows a continued supply of energy 
substrates and oxygen to the hepatic cells, which could potentially reduce the damage caused by 
IRI whilst ensuring adequate vascular control intra-operatively. An RCT in China compared 
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these two techniques along with a different technique and found that portal vein clamping in 
isolation resulted in faster recovery of liver functions (Fu, Lau et al. 2011). Choice of anaesthetic 
agents may also play a role here as animal studies have shown hepatic arterial inflow to be 
increased using sevoflurane (Ko, Gwak et al. 2010) .  
 
 
Figure 9: A Diagram of the Pringle Manoeuvre (http://www.surgicalcore.org/popup/43202) 
 
6.2 Aims and Objectives of RCT 
6.2.1 Aims 
The primary aim of this pilot RCT was to test whether the components of a larger multi-centre 
trial can work together. Specifically: 
1) The ability to recruit and randomise patients into the study 
2) The ability to conduct portal vein clamping surgical procedure 
3) The appropriateness of the follow-up assessments  
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6.2.2 Secondary Objectives 
  
The secondary objectives were to collect information with regard to the following: 
1. Incidence of septic complications in portal vein clamping versus Pringle manoeuvre 
2. Procedural outcomes including intra-operative blood loss, length of clamping  
     time, length of time transecting the liver and duration of the operation  
4. Post-operative events including bleeding, post- operative transfusion requirements, 
non- infective cardio- respiratory complications and 30- day mortality rate  
 
6.3  Methods 
6.3.1 Ethical Approval 
 
Ethical approval was sought from the Leeds East NRES committee and approval 13/YH/0195 
;(30.7.2013 ; see Appendix 8.2) was granted. Leeds Teaching Hospitals NHS trust was the 
sponsor.  
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6.3.2 Study Design 
 
This was a prospective, parallel group, single blind, randomised controlled pilot study. A total of 
80 patients were recruited. The first 20 patients were part of a learning curve development (non-
randomised) for portal vein clamping. The subsequent 60 patients randomised and enrolled into 
the study. This was a pilot study and therefore the sample size was deemed suitable to inform 
feasibility of performing a larger, multi-centre trial investigating Pringle manoeuvre versus 
isolated portal vein clamping in liver surgery.  
 
6.3.3 Inclusion Criteria 
 
The inclusion criteria were as below: 
(a) At least 18 years of age 
(b) Undergoing open liver resection surgery for CRLM 
(c) Portal venous clamping is considered appropriate 
(d) Participating patients should understand the study objectives and be able and 
     willing to provide written informed consent 
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(e) Able to complete study questionnaire  
 
6.3.4 Exclusion Criteria  
 
The exclusion criteria were as below: 
           (a) Patients having simultaneous bowel and hepatic surgery 
           (b) Patients participating in other trials that could impact the outcomes measures  
                being recorded 
           (c) Pregnancy at the time of surgery 
           (d) Patients taking immunosuppressive medication within 3 months of surgery 
           (e) Patients undergoing laparoscopic surgery 
           (f) Patients who have previously undergone portal vein embolisation  
 
6.3.5 Blinding 
 
Patients were blinded to the surgical procedure allocated to minimise the reporting bias. 
However, blinding of surgeons performing the surgical procedure was not possible.  
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6.3.6 Recruitment 
 
Patients who were diagnosed with resectable CRLM and who met the inclusion criteria were 
deemed eligible for the trial.  
Patients who met the eligibility criteria were invited to take part by the consultant surgeon during 
the clinic appointment. Patients were given information about the study, involving both verbal 
information and Patient Information Leaflets (PIL) which included detailed information about 
the rationale, design and personal implications of the study. After receiving PIL, patients had at 
least 24 hours to consider participation. The patient was given the opportunity to discuss the 
study with their family and healthcare professionals before they were asked whether they would 
be willing to take part in the study.  
Three QoL questionnaires (EORTC QLQC30, QLQ-LM21 and EQ-5D-3L) were posted to the 
patients and information was provided on how to fill them in. Patients were asked to fill the 
questionnaires within the last week before the operation and handover to the surgical team on the 
day of procedure. Patients also received a phone call in the week prior to surgery to remind them 
to complete the questionnaires. Participating research staff members were required to complete a 
log of all patients screened for eligibility. Anonymous information was collected including: 
 Age 
 Gender 
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 Ethnicity 
 
Screened patients who were not randomised either because they are ineligible or because they 
decline participation will also have the following information recorded: 
 The reason(s) for ineligibility for study participation OR 
 The reason declined (if the patient was eligible for study participation). 
 
The screening data (baseline demographic data, as outlined above) was obtained via a Case 
Report Form (CRFs) and collated via a secure database. 
 
6.3.7 Randomisation 
Patients were randomised centrally using a secure automated system provided by the Leeds 
Clinical Trials Research Unit (CTRU). The CTRU were telephoned on the morning of surgery to 
provide treatment allocation and the surgeon informed regarding the chosen procedure pre-
operatively.  
The following information was required at randomisation: 
 Participant details, including initials, gender and date of birth 
 Site code for research site  
 Name of person making the randomisation 
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 Name of treating surgeon 
 Confirmation of eligibility 
 Confirmation and date of written informed consent 
 Stratification factors (see below) 
 
Participants were randomised on a 1:1 basis to have either the Pringle manoeuvre (‘Pringle’ 
group) or portal vein clamping (‘PVC only’ group) used as the method of clamping during their 
operation. Each participant was allocated a unique study number.  The randomisation was 
stratified using stratified random permuted blocks to ensure that treatment groups are well 
balanced for the following stratification factors, details of which will be required at 
randomisation: 
 Body Mass Index (BMI) 
o Less than 30 
o Greater than or equal to 30 
 Previous chemotherapy exposure within the last 3 months 
 
6.3.8 Surgical Procedure 
 
At the time of surgery, the standard procedure for operative dissection planned for that patient 
was undertaken. Surgery was performed through a reverse L shaped incision. During surgery, a 
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careful search of the abdominal cavity was performed to determine the extent of the local 
disease, extra hepatic metastasis and seeding within the peritoneal cavity. After mobilisation of 
the liver, intra operative ultrasound scan was performed to assess the number, size of the lesions 
and the relation of the tumour to major blood vessels. When ready to proceed with liver resection 
the surgeon achieved portal inflow control using the method allocated by the randomisation 
process.  
 
Details of intervention by group 
Intervention Group: 
 In the main portal vein occlusion group, the portal vein was isolated and occluded with a clamp. 
 
Control Group: In the Pringle manoeuvre group, the entire hepato-duodenal ligament containing 
both hepatic artery and portal vein, was occluded using standard vascular clamp. 
In both the groups, intermittent vascular occlusion was performed with cycles of 15 minute 
inflow occlusion followed by 5 minutes of reperfusion. 
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6.3.9 Postoperative Care:  
The postoperative management will be identical in both the groups and will involve Intensive 
Care Unit (ITU) or High Dependency Unit (HDU) stay for the first 24-48 hours, or longer if 
required. Stable patients will be transferred to the ward with routine care involving daily ward 
rounds and monitoring with bloods. Any untoward complication will be managed appropriately 
by the clinical team managing the patient and the details will be recorded in the clinical notes. 
The Clavien-Dindo score was used to grade adverse events occurring post-operatively and is the 
standard classification system used for all surgical specialities.  
 
6.4 Results  
6.4.1  Patient Characteristics 
 
The sample included 80 patients (20 in the learning phase and 60 in the trial phase, see Figure 
10). Patients were stratified based on their BMI and whether they had received pre-operative 
chemotherapy within the last 3 months or not (see Table 7 and 8).  
In the learning phase (see Table 9) there were 9 male patients and 11 females. The mean age was 
58.4 years (standard deviation [SD]= 10.4) ranging from 27 years of age to 74 years.  The mean 
BMI was 28.2 (SD=7.6), ranging from 17.8 to 51.7. Patient co-morbidities can be seen in Table 
9. Nine patients underwent neoadjuvant chemotherapy.  
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Seven patients underwent major resection, whilst 12 had minor resections in the learning phase 
group. Unfortunately, one patient was not resectable due to advanced disease. Six patients had an 
anatomical resection, whereas 11 had a non-anatomical resection (see Table 11). Two patients 
had both an anatomical and a non-anatomical resection.   
There were no eligibility violations or withdrawals in the learning phase group. 
 
Table 7: Recruitment Stratification Factors for Learning Phase 
 
 
PVC (n=15) 
 
No Inflow Occlusion 
(n=5) 
 
Total (n=20) 
 
BMI     
< 30 11 (55%) 3 (15%) 14 (70%) 
      >=30 4 ( 20%) 2 (10%) 6 (30%) 
Previous chemotherapy in last 3 months     
      Yes 4 ( 20%) 2 (10%) 6 (30%) 
No 11 (55%) 3 (15%) 14 (70%) 
 
Table 8: Recruitment Stratification for Trial Phase 
 
 
PVC (n=30) 
 
Pringle (n=30) 
 
Total (n=60) 
 
BMI     
< 30 19 (63%) 17 (57%)                    36 (60%) 
      >=30 11 (27%) 13 (43%)            24 (40%) 
Previous chemotherapy in last 3 months               
      Yes 4 (13%) 5 (17%)               9 (15%) 
No 26 (87%) 25 (83%)                     51 (85%) 
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Figure 10: A Consort Flow Diagram of patient participation in trial 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessed for eligibility (n=267) 
Excluded (n=187) 
 Declined to participate (n=11) 
 Declined surgery (n=6) 
 Pre-op portal vein embolization (n=23) 
 Primary inoperable (n=2) 
 Disease measurability (n=32) 
 Palliative chemotherapy (n=19) 
 Synchronous surgery (n=8) 
 Laparoscopic surgery (n=41) 
 Participation in surgical trials (n=8) 
 Radio frequency ablation (n=6) 
 SIRT (n=4) 
 Performance status (n=3) 
 Resources (n=16) 
 Clinician’s decision (re-do) (n=1) 
 Concomitant medication (n=2)  
 Language barrier (n=1) 
 Learning difficulties (n=1) 
 Not definitive colorectal metastases 
(n=3) 
 
Analysed (n=24) 
 Excluded from analysis  (n=6  ) 
- FU data only 
Lost to follow-up (n=6) 
Local hospital follow-up (n=5) 
Unable to contact (n=1) 
 
 
Allocated to intervention (n=30 Pringle Manoeuvre) 
 
 Received allocated intervention (n=27) 
 Did not receive allocated intervention (n=3) 
- No inflow occlusion required  
Lost to follow-up (n=2) 
Local hospital follow-up (n=1) 
Unable to contact (n=1) 
Analysed (n=29) 
 Excluded from analysis (give reasons) (n=3  ) 
- FU data only 
 
Allocation 
Analysis 
Follow-Up 
Randomized (n=60) 
Enrolment 
Allocated to learning curve intervention (n=20 
Portal Vein Clamping) 
 
 Received portal vein clamping (n=15) 
 Did not receive portal vein clamping (n=5)  
- no inflow occlusion required 
 
30-day follow-up completed (n=30) 
 
3-month follow-up completed (n=27) 
 Patient declined follow-up (n=1) 
 Unable to contact (n=1) 
 Patient died (n=1) 
Allocated to intervention (n=30 Portal vein clamping) 
 
 Received allocated intervention (n=26) 
 Did not receive allocated intervention (n=4)) 
- PRINGLE performed  
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Table 9: Patient Demographics for Learning Phase 
 
PVC (n=15) 
 
No Inflow Occlusion 
(n=5) 
 
Total (n=20) 
 
Age at referral      
Mean (SD) 
Median (IQR) 
Range 
57.5 (11.6) 
61.0 (52,65) 
(27,74) 
61.0 (5.4) 
60.0 ( 56.5, 66) 
(55,69) 
58.4 (10.4) 
61.0 (54.3, 64.8) 
(27,74) 
Gender     
      Male 8 (40%) 1 (5%) 9 (45%) 
      Female 7 (35 %) 4 (20%) 11 (55%) 
BMI  (kg/m
2
)    
Mean (SD) 
Median (IQR) 
Range 
28.7 (8.4) 
26.2 (23.9, 33.3) 
(17.8,51.7) 
26.7 (4.4) 
29.1 (21.9, 30.3) 
(17.8, 51.7) 
28.2 (7.6) 
26.6 (22.7, 30.4) 
(17.8, 51.7) 
Co-morbidities (presence)    
      Smoker  3 (15%) 0 (0%) 3 (15%) 
      Cardiovascular Disease 2 (10%) 0 (0%) 2 (10%) 
      PVD 2 (10%) 0 (0%) 2 (10%) 
      Respiratory Disease 3 (15%) 0 (0%) 3 (15%) 
      Diabetes 1 (5%) 0 (0%) 1 (5%) 
      Hypertension 2 (10%) 0 (0%) 2 (10%) 
      Chemotherapy 7 (35%) 2 (10%) 9 (45%) 
Pathological classification of primary tumour 
(pT) 
   
      N missing 1 1 2 
      pT1 0 (0%) 0 (0%) 0 (0%) 
      pT2 1 (5%) 0 (0%) 1 (5%) 
      pT3 8 (40%) 4 (20%) 12 (60%) 
      pT4 5 (25%) 0 (0%) 5 (25%) 
Pathological classification of primary tumour 
(pN) 
   
      N missing 2 1 3 
      pN0 2 (10%) 0 (0%) 2 (10%) 
      pN1 7 (35%) 2 (10%) 9 (45%) 
      pN2 4 ( 20%) 2 (10%) 6 (30%) 
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In the main trial group there were 31 male patients and 29 female patients (see Table 10). The 
mean age was 62.3 years (SD= 12.5 years), ranging from 31 to 82 years of age. The mean BMI 
was 28.3 (SD=5.4), ranging from 20.0 to 42.2. Eleven out of 30 patients underwent some form of 
neoadjuvant chemotherapy.  
           Thirty one patients underwent a major resection, whilst 27 had a minor resection. Two 
patients were not resectable. Twenty-nine patients had an anatomical resection, whereas 22 had a 
non-anatomical resection. Seven patients had a combination of anatomical and non-anatomical 
resections (see Table 12).  
There were no eligibility violations or withdrawals in the trial phase group either.   
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Table 10: Patient Demographics for Trial Phase 
 
 
PVC (n=30) 
 
Pringle (n=30) 
 
Total (n=60) 
 
Age at referral      
N missing 0 0 0 
Mean (SD) 
Median (IQR) 
Range 
61.4 (13.5) 
63.0 (53,72) 
(31,82) 
63.1 (11.6) 
65.0 (55,75) 
(37,81) 
 
62.3 (12.5) 
64.0 (53.5, 73.0) 
(31,82) 
Gender     
      Male 18 (60%) 13 (43%) 31 (52%) 
      Female 12 (40%) 17 (57%) 29 (48%) 
BMI  (kg/m
2
)    
N missing 0 0 0 
Mean (SD) 
Median (IQR) 
Range 
28.4 (4.8) 
28.7 (25.0,30.7) 
(20.0-38.2) 
28.2 (6.1) 
26.6 (24.0, 32.0) 
(20.0,42.2) 
28.3 (5.4) 
28.0 (24.3,31.2) 
(20.0,42.2) 
 
Co-morbidities (presence)    
      Smoker  2 (7%) 4 (13%) 6 (10%) 
      Cardiovascular Disease 12 (40%) 17 (57%) 28 (47%) 
      PVD 4 (13%) 2 (7%) 6 (10%) 
      Respiratory Disease 7 (23%) 9 (33%) 16 (27%) 
      Diabetes 5 (17%) 5 (17%) 10 (16%) 
      Hypertension 11 (37%) 9 (30%) 20 (33%) 
      Chemotherapy 6 (20%) 5 (17%) 11 (18%) 
Pathological classification of primary tumour 
(pT) 
   
      N missing 3 1 4 
      pT1 3 (10%) 0 (0%) 3 (5%) 
      pT2 1 (3%) 2 (7%) 3 (5%) 
      pT3 16 (53%) 15 (50%) 31 (52%) 
      pT4 7 (23%) 12 (40%) 19 (32%) 
Pathological classification of primary tumour 
(pN) 
   
      N missing 4 1 5 (8%) 
      pN0 9 (30%) 7 (23%) 16 (27%) 
      pN1 7 (23%) 10 (33%) 17 (28%) 
      pN2 10 (33%) 12 (40%) 22 (37%) 
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6.4.2 Procedural Outcomes 
 
In the learning phase group, five patients were deemed to be not suitable for any form of inflow 
occlusion. Generally the operating time was shorter for those patients requiring no occlusion 
(mean 145.5 minutes (SD=37.5) versus 84.0 (SD=54.5), though blood loss slightly greater (mean 
790 ml (SD=1238.1) versus mean 410 (SD=224.6). The mean total clamping time in the PVC 
only group was 29.4 minutes (SD=10.7). The mean total time transecting the liver was 53.0 
minutes (SD= 21.9 minutes) in the PVC group and 47.5 minutes (SD=31.8 minutes) in the no 
clamping group. The mean total operating time was 145.5 minutes (SD=37.5 minutes) versus 
84.0 minutes (SD=54.5 minutes) in the no clamping group (see Table 11  ). No patients in the 
learning phase required a blood transfusion.  
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Table 11: Learning Phase Procedural Outcomes 
 
PVC (n=15) 
 
No Inflow Occlusion 
(n=5) 
 
Total (n=20) 
 
Total operative time (mins)    
Mean (SD) 145.5 (37.5) 84.0 (54.5) 133.9 (46.2) 
Median (IQR) 142.0 (115,176) 83.0 (56.5,111.0) 137.5(92.5, 165.8) 
Range (88, 198) (30,139) (30,198) 
Total clamping time (mins)    
Mean (SD) 29.4 (10.7) NA 29.4 (10.7) 
Median (IQR) 30.0 (25,35) NA 30.0 (25,35) 
Range (10.0,48.0) NA (10.0,48.0) 
Total time transecting the liver (mins)    
Mean (SD) 53.0 (21.9) 47.5 (31.8) 52.3 (22.1) 
Median (IQR) 46.0 (35.5,60.5) 47.5 (25.0,70.0) 46.0(35.0,61.0) 
Range (29.0,98.0) (25.0, 70.0) (25.0,98.0) 
Estimated blood loss (ml)    
Mean (SD) 410 (224.6) 790 (1238.1) 505 (623.2) 
Median (IQR) 500(225,550) 300 (-,-) 400 (212.5, 500.0) 
Range (50,800) (100,NA) (50,800) 
Number of transfusion units    
      0 15 (100%) 5 (100%) 20 (100%) 
ASA grade    
      1 2 (13%) 2 (40%) 4 (20%) 
      2 11 (73%) 1 (20%) 12 (60%) 
      3 1 (7%) 1 (20%) 2 (10%) 
Number of metastases    
      N missing 9 2 11 
      0 0 ( 0%) 0 (0%) 0 (0%) 
      1 3 ( 20%) 2 (40%) 5 (25%) 
      2 1 ( 7%) 0 (0%) 1 (5%) 
      3 1 (7%) 1 (20%) 2 (10%) 
      6 1 (7%) 0 (0%) 1 (5%) 
      …    
Size of largest metastases (cm)    
N 1  1 2 
N missing 14  4 18 
Mean (SD) 7.4 (-) 0.5 (-) 4.0 (4.9) 
Median (IQR) 7.4 (-) 0.5 (-) 4.0 (0.5,7.4) 
Range (7.4) (0.5) (0.5,7.4) 
Was intra-operative ultrasound performed?    
      N missing 0 0 0 
      Yes 7 (47%) 2 (40%) 9 (45%) 
      No 8 (53%) 3 (60%) 11 (55%) 
Was the resection:    
      Major 7 (47%) 0 (0%) 7 (35%) 
      Minor 8 ( 53%) 4 (80%) 12 (60%) 
      Not applicable 0 (0%) 1 (20%) 1 (5%) 
      Anatomical  6(40%) 0 (0%) 6 (30%) 
      Non-anatomical 7(47%) 4 (20%) 11 (55%) 
      Both 2(13%) 0 (0%) 2 (10%) 
      Not applicable                                                                  0 (0%) 1 (20%) 1 (5%) 
      N/A                                                                                     0 (0%) 1 (5%) 1 (5%) 
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In the trial phase group (by treatment received), twenty-six patients underwent PVC only, 31 
patients underwent the Pringle manoeuvre for inflow control whilst three patients were deemed 
to be not suitable for any form of inflow occlusion by the operating surgeon. Generally the 
operating time was shorter for those patients requiring no occlusion (mean 101.5 minutes 
[SD=82.7] versus 132.8  [SD=34.3] for the Pringle group and 128.4 [SD=51.9] for the PVC only 
group) .  The intra-operative blood loss was slightly greater in the PVC only group (mean 436.5 
ml (SD=289.7) versus mean 311.6 (SD=199.6). The mean total clamping time in the PVC only 
group was 36.3 minutes (SD=14.0) compared with a mean total clamping time of 34.9 minutes 
(SD=17.4) in the Pringle group. The mean total time transecting the liver was 53.6 minutes (SD= 
34.6 minutes) in the PVC group versus 49.6 minutes (SD=24.6) in the Pringle group. The mean 
total operating time in the PVC only group was 128.4 minutes (SD=51.9 minutes) versus 132.8 
minutes (SD=34.3 minutes) and 101.5 minutes (SD=82.7) in the no clamping group (see table 
12).  
No patients in the trial phase required an intra-operative blood transfusion.  
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Table 12: Procedural Characteristics Trial Phase 
 PVC (n=26) Pringle (n=31) No Inflow Occlusion 
(n=3) 
Total (n=60) 
Total operative time 
(mins) 
    
N 25 29 2 56 
N missing 1 2 1 4 
Mean (SD) 128.4 (51.9) 132.8 (34.3) 101.5 (82.7) 129.5 (44.0) 
Median (IQR) 120.0 (94.0, 149.0) 125.0 (107.0, 159.0) 101.5 (43.0, 160.0) 123.5 (96.5, 156.5) 
Range (66,268) (76,194) (43, 160) (43,268) 
Total clamping time (mins)     
N 26 31 NA 57 
Mean (SD) 36.3 (14.0) 34.9 (17.4) NA 35.5 (15.8) 
Median (IQR) 34.5 (29.5, 42.5) 32.0 ( 25.0, 43.0) NA 33.0 (28.0, 44.0) 
Range (8.0, 73.0) (11.0, 97.0) NA (8.0,89.0) 
Total time transecting the 
liver (mins) 
    
N 25 30 0 55 
N missing 1 1 3 5 
Mean (SD) 53.6 (34.6) 49.6 (24.6) - 51.4 (29.4) 
Median (IQR) 49.0 (33.5, 64.0) 45.5 ( 32.8, 71.2) - 47.0 (34.0, 65.5) 
Range (7.0, 182.0) (11.0, 103.0) - (7.0, 182.0) 
Estimated blood loss (ml)     
N 26 31 1 58 
N missing 0 0 2 2 
Mean (SD) 436.5 (289.7) 311.6 (199.6) - 363.1 (251.8) 
Median (IQR) 400.0 (200.0, 500.0) 300.0 ( 180.0, 400.0) - 300.0 (200.0, 500.0) 
Range (50.0, 1500.0) (30.0, 800.0) - (30.0, 1500.0) 
      …     
ASA grade     
      1 8 (31%) 10 (32%) 1 (33%) 19 (32%) 
      2 17 (65%) 20 (65%) 2 (67%) 39 (65%) 
      3 0 (0%) 1 (3%) 0 (0%) 1 (2%) 
Number of metastases     
      N missing 6 12 1 19 
      0 0 (0%) 1 (3%) 0 (0%) 1 (2%) 
      1 8 (31%) 5 (16%) 1 (33%) 14 (23%) 
      2 3 (12%) 5 (16%) 1 (33%) 9 (15%) 
      3 4 (15%) 2 (65%) 0 (0%) 6 (10%) 
      4 2 (77%) 3 (10%) 0 (0%) 5 (8%) 
      5 
      6 
      7 
      11 
1 (4%) 
1 (4%) 
1 (4%) 
0 (0%) 
1 (3%) 
1 (3%) 
0 (0%) 
1 (3%) 
0 (0%) 
0 (0%) 
0 (0%) 
0 (0%) 
2 (3%) 
2 (3%) 
1 (2%) 
1 (2%) 
Size of largest metastases 
(cm) 
    
N 5 5 0 10 
N missing 21 26 3 50 
Mean (SD) 2.6 (1.5) 3.7 (2.6) - 3.2 (2.1) 
Median (IQR) 2.5 (1.5,2.6) 3.4 (2.5, 4.8) - 2.6 (1.5,4.8) 
Range (1,5) (1,8) - (1,8) 
Was the resection:     
      Major 14 (54%) 17 (55%) 0 (0%) 31 (52%) 
      Minor 12 (46%) 14 (45%) 1 (33%) 27 (45%) 
      Not applicable 0 (0%) 0 (0%) 2 (67%) 2 (3%) 
      Anatomical  13 (50%) 16 (52%) 0 (0%) 29 (48%) 
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      Non-anatomical 9 (35%) 12 (39%) 1 (33%) 22 (37%) 
      Both 4 (15%) 3 (10%) 0 (0%) 7 (12%) 
      Not applicable                                                                  0 (0%) 0 (0%) 2 (67%) 2 (3%) 
 
6.4.3 Post-operative Outcomes- Liver Function Tests 
 
In the learning phase the mean peak bilirubin for patients who underwent PVC clamping was 
21.2 µmol/L (SD=12.5) versus 17.2 µmol/L (SD=9.9) in the no clamping group (see supplement 
8.8). There was a trend towards a higher mean peak ALT in the PVC group (312.5 IU/L 
[SD=138.0] versus 207.6 IU/L [SD=194.0] in the no clamping group, see Table 13).  
Table 13: Peak Post-operative Bilirubin and ALT: Learning Phase  
 
PVC (n=15) 
No Inflow Occlusion 
(n=5) 
 
Total (n=20) 
 
Post surgery liver function test A: mean (SD) 
      N missing 
 
1 
 
0 
 
1 
      Peak Bilirubin  21.2 (12.5)  17.2 (9.9) 20.2 (11.7) 
Post surgery liver function test B: mean (SD)    
      N missing 
      Peak ALT 
1 
312.5 (138.0) 
0 
207.6 (194.0) 
1 
284.9 (156.2) 
 
In the trial phase (treatment received), the mean peak bilirubin for patients who underwent PVC 
clamping was 28.8 µmol/L   (SD=20.5) versus 26.7 µmol/L (SD=21.2) for those who underwent 
Pringle and 14.3 µmol/L (SD=6.7) for those who had no clamping. The mean peak ALT in the 
PVC only group was 327.0 IU/L (SD=201.2) compared to 336.3 IU/L (SD=426.0) in the Pringle 
group and 591.7 IU/L (SD=825.2) in the no clamping group (see table 14 ).  
Table 14: Peak Post-operative Bilirubin and ALT: Trial Phase 
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 PVC (n=26) Pringle (n=31) No Inflow 
Occlusion (n=3) 
Total (n=60) 
Post surgery Peak 
Bilirubin: mean 
(SD) 
    
      N Missing 2 0 0 2 
      Peak Bilirubin 28.8 (20.5) 26.7 (21.2) 14.3 (6.7) 27.0 (20.4) 
Post surgery Peak 
ALT: mean (SD) 
    
      N Missing 2 0 0 2 
      Peak ALT 327.0 (201.2) 336.3 (426.0) 591.7 (825.2) 345.6 (373.0) 
 
 
6.4.4 Post operative Follow Up 
 
In the learning group all the 30 day follow ups were completed during outpatient clinic 
appointments. The mean time to be seen was 32.4 days (SD=6.7) with a range from 23 to 45 
days. At 3 months 12 patients were followed up in the outpatient clinic and five by telephone. 
Three patients were lost to follow up. 
In the trial phase, 51 patients were seen in clinic for the 30 day follow ups. Nine patients were 
lost to follow up. Thirty nine patients were seen in clinic and 21 were followed up by telephone 
 
6.4.5 Post operative Complications and Blood Transfusion Requirements 
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In the learning phase five patients in the PVC only group suffered minor complications. Four 
patients had wound infections, whilst one patient had pneumonia (all Clavien Dindo II). No 
patients required any subsequent surgery and no patients required a post-operative blood 
transfusion.  
In the trial phase (by treatment received), six patients had one complication in the PVC only 
group compared to four patients who had one complication and three that had two complications 
in the Pringle group (see Table 11) 
One patient in the Pringle group had to return to theatre due to wound dehiscence and one patient 
also required a transfusion between surgery and 30 days post-operatively.  
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Table 15: Complications in Trial Phase 
 
Number of 
complications 
PVC (n=26) Pringle (n=31) No Inflow 
Occlusion (n=3) 
Total (n=60) 
      0 20 (77%) 24 (77%) 2 (67%) 46 (76%) 
      1 6 (23%) 4 (13%) 0 (0%) 10 (17%) 
      2 0 (0%) 3 (10%) 1 (33%) 4 (7%) 
      …     
Type of 
complication (not 
mutually exclusive) 
    
      Wound 
infection  
1 (4%) 4 (13%) 0 (0%) 5 (8%) 
      Intra-abdominal 
infection 
1 (4%) 1 (3%) 1 (33%) 3 (5%) 
      Need for re-
operation (open 
surgery within one 
month) 
0 (0%) 1 (3%) 0 (0%) 1 (2%) 
      Urinary 
infection 
1 (4%) 1 (3%) 0 (0%) 2 (3%) 
      Pulmonary 
embolism 
0 (0%) 0 (0%) 1 (33%) 1 (2%) 
Viral Infection 1 (4%) 0 (0%) 0 (0%) 1 (2%) 
Increased pain post 
op 
0 (0%) 1 (3%) 0 (0%) 1 (2%) 
      Pneumonia 1 (4%) 1 (3%) 0 (0%) 2 (3%) 
      Ileus 1 (4%) 1 (3%) 0 (0%) 0 (0%) 
Number of septic 
complications 
    
      0 21 (81%) 26 (84%) 2 (67%) 49 (82%) 
      1 5 (19%) 3 (10%) 1 (33%) 9 (15%) 
      2 0 (0%) 2 (6%) 0 (0%) 2 (3%) 
      …     
      …     
Clavien-Dindo 
classification of 
complications 
    
      II 5 8 3 16 
      IIIa 1 1 0 2 
      IIIb 0 1 0 1 
      IVa 0 0 0 0 
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6.4.6 Safety Outcomes 
 
There was one post-operative death in the learning phase group immediately prior to the three 
month Follow Up period. This was not related to the surgery. There were no other serious 
complications in either the learning phase or trial phase groups.  
 
6.5 Discussion 
Peri-operative blood transfusions may lead to poorer short and long-term outcomes. In order to 
mitigate intra-operative blood loss the Pringle manoeuvre is often used during partial 
hepatectomy. However, the Pringle manoeuvre has some adverse effects as well such as 
ischaemia-reperfusion injury and splanchnic congestion.  
A systematic review of 30 studies on liver resection for CRLM using Pringle manoeuvre 
conducted in 2006, showed septic complications to be as high as 19% (Simmonds, Primrose et 
al. 2006). The Leeds group have used selective intermittent Pringle manoeuvre (clamping for 15 
minutes and releasing for 5 minutes) and demonstrated a septic complication rate of 12%. It has 
also previously been demonstrated that a post-operative infective complication is an independent 
predictor of recurrence of cancer in the long term (Farid, Aldouri et al. 2010). Therefore, by 
reducing liver tissue injury, isolated portal vein clamping has the potential to reduce the post-
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operative septic complications thereby improving both short and long-term outcomes. A recent 
RCT compared these two techniques along with hemi-hepatic vascular occlusion and found that 
selective inflow control resulted in faster recovery of liver functions (Fu, Lau et al. 2011). 
Therefore, the primary aim of our pilot study was to assess the feasibility of performing a larger 
multi-centre trial comparing the Pringle Manoeuvre and isolated portal vein clamping.  
 Our main findings were that it was technically feasible to perform isolated portal vein clamping 
in patients. Furthermore, it was possible to recruit patients into the trial and perform short term 
follow-up on them.. The operating times between the two groups were similar though there was a 
trend towards more blood loss in the PVC only group. There were no peri-operative transfusion 
requirements, although one patient in the Pringle group did require a blood transfusion post-
operatively.  
The limitations of the study included some design faults which could be incorporated when 
designing the main trial.  Post-operative inflammatory markers (such as White Cell Count and 
CRP) were not measured which may have been useful. Furthermore, pre-operative selection of 
patients regarding the need for intra-operative inflow occlusion could be more rigorous as almost 
10% of patients in the trial underwent no inflow occlusion at all. It may be prudent to only 
include patients requiring a major hepatectomy in the main trial and/or to randomise once the 
initial laparotomy and intra-operative ultrasound have been performed   
Future work will include completing the quality of life outcomes.   
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The objectives of the trial have been met; namely to recruit and randomise, to perform PVC 
clamping and to collect peri-operative data. However, a UK wide consensus would be useful 
prior to proceeding to a multi-centre trial. Some UK centres do not even routinely use any form 
of inflow occlusion and the method of determining the benefit of PVC only clamping has not 
been firmly established. Post-operative liver function tests have been used previously, however it 
is not known how these affect long term survival and hence their relevance here. 
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7 Conclusions  
 The research as outlined in this thesis was aimed towards understanding the role of surgical and 
non-surgical techniques to decrease peri-operative blood loss in liver surgery and therefore 
improve patient related outcomes.  
The systematic review of non-surgical techniques identified that certain anaesthetic agents 
(sevoflurane and desflurane) reduced the degree of IRI. Furthermore, pharmacological agents 
such as tranexamic acid were proven to decrease intra-operative blood loss though there was a 
paucity of randomised controlled trials in these areas.  
The retrospective study demonstrated that patients who underwent a blood transfusion had a 
poorer long term outcome. However, the poorer OS seen in patients who underwent RBCT was 
likely to be multifactorial and due to peri-operative complications, rather than due to earlier 
disease recurrence per se. Nonetheless, factors such as pre-operative anaemia, larger burden of 
disease and pre-operative chemotherapy predisposed to a greater likelihood of transfusion.  
The main findings of the RCT were that it was technically feasible to perform isolated portal 
vein clamping in patients and to recruit patients into the trial. However, a larger RCT will be 
needed to obtain definitive evidence on the role of PVC in hepatic resections in the future.  
It was not possible to identify specific strategies to decrease the degree of IRI. Although certain 
anaesthetic agents were seen to decrease the IRI further studies are needed in this area. The role 
of isolated portal vein clamping in decreasing IRI also remains uncertain. Part of the difficulty in 
driving this forward is that there is no universally agreed biochemical definition (liver function 
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tests and inflammatory markers) of ischaemia reperfusion injury and it is not feasible to take 
liver biopsies in a post-operative patient.  
Due to logistical difficulties, the Quality of Life data is still incomplete but should be finished 
within the next 3 months. Specifically, the change in patient quality of life (QOL) outcomes at 3 
months post-surgery will be examined as below: 
1. The aim of the health economic component (via analysis of the three quality of life 
questionnaires - EORTC QLQC30, QLQ-LM21 and EQ-5D-3L) was to collect data for a 
full economic evaluation. Specifically,  
a) To test the acceptability and feasibility of health care resource use questionnaires 
developed in accordance with the existing literature on liver surgery and with the 
team of clinical experts who will help identify the participants’ pathway of care.  
b) To assess whether the health-related quality of life questionnaire, EQ-5D-3L, used for 
obtaining utility weights for constructing quality-adjusted life years (QALYs), is 
acceptable based on completion rates. 
 
Further research should involve a consensus study to ascertain what constitutes a liver 
ischaemia-reperfusion injury post-operatively. The systematic review and RCT demonstrated 
that many investigators use post-operative ALT to measure IRI, without any evidence to suggest 
its utilisation as a marker for IRI.  
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A multi-centre RCT looking at isolated portal vein clamping versus Pringle will also help place 
portal vein clamping in the management algorithm for patients undergoing CRLM surgery, 
although it may be prudent to get consensus from UK HPB surgeons as to whether they feel this 
is a research priority. Further trials should also look at the role of tranexamic acid in cases where 
blood loss risk is high.  
Future research areas should include:  
- Using a database to retrospectively evaluate the short- and long term effects of peak post-
operative ALT. This could be done prospectively as well, via collaboration between HPV 
units  
- An RCT between volatile (desflurane/isoflurane)  and non-volatile inhalational 
anaesthetic agents in patients undergoing liver surgery to ascertain if volatile anaesthetic 
agents are protective for the liver 
- A further RCT in patients at high risk of blood loss utilising tranexamic acid. A 
consensus will need to be reached as to what defines “high risk of blood loss during liver 
resection” but it is likely to include patients undergoing major resections, patients who 
have had recent chemotherapy and those with increased BMI.  
- A consensus between UK liver surgeons needs to be reached regarding whether further 
trials around isolated portal vein clamping are warranted, prior to proceeding to a multi-
centre RCT. Many surgeons do not routinely employ any form of inflow control during 
resections. It is therefore, not currently possible due to the evidence base and 
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practicalities to recommend stratification of inflow modulation, on the basis of the pilot 
RCT and evidence review in this thesis.   
 In summary, it is likely that a combination of approaches will be required in the future to further 
improve outcomes. For example, use of PVC for inflow control may be appropriate in a patient 
with BMI >30 who has recently undergone chemotherapy and who needs an extended resection. 
It may also be prudent to employ other strategies to decrease blood loss in such a patient. 
However, a patient who requires only a metastectomy in a peripherally located tumour may not 
require even inflow control. The type of approach should be individually tailored to the patient. 
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Liver Resection for Colorectal Liver Metastasis - A Pilot 
Study 
REC reference: 13/YH/0195 
IRAS project ID: 123555 
 
Thank  you  for  your  letter  of  18th   July,  responding  to  the  Committee’s  request  for  further 
information on the above research and submitting revised documentation. 
 
The further information has been considered on behalf of the Committee by the Chair. 
 
We plan to publish your research summary wording for the above study on the NRES website, 
together  with  your  contact  details,  unless  you  expressly  withhold  permission  to  do  so. 
Publication will be no earlier than three months from the date of this favourable opinion letter. 
Should you wish to provide a substitute contact point, require further information, or wish to 
withhold permission to publish, please contact the Co-ordinator Hayley Jeffries, 
hayley.jeffries@nhs.net 
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Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above 
research on the basis described in the application form, protocol and supporting documentation 
as revised, subject to the conditions specified below
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Ethical review of research sites 
 
NHS sites 
 
The favourable opinion applies to all NHS sites taking part in the study, subject to management 
permission being obtained from the NHS/HSC R&D office prior to the start of the study (see 
"Conditions of the favourable opinion" below). 
 
Conditions of the favourable opinion 
 
The favourable opinion is subject to the following conditions being met prior to the start of the 
study. 
 
Management permission or approval must be obtained from each host organisation prior to the  
start of the study at the site concerned. 
 
Management permission ("R&D approval") should be sought from all NHS 
organisations involved in the study in accordance with NHS research governance 
arrangements. 
 
Guidance on applying for NHS permission for research is available in the Integrated Research 
Application System or at  http://www.rdforum.nhs.uk 
 
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites ("participant identification centre"), guidance should be 
sought from the R&D office on the information it requires to give permission for this 
activity. 
 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation. 
 
Sponsors are not required to notify the Committee of approvals from host organisations 
 
It is the responsibility of the sponsor to ensure that all the conditions are complied with 
before the start of the study or its initiation at a particular site (as applicable). 
 
Approved documents 
 
The final list of documents reviewed and approved by the Committee is as follows: 
 
Document Version Date 
Covering Letter 1.0 28 May 2013 
Covering Letter  18 July 2013 
GP/Consultant Information Sheets 1.0 28 May 2013 
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Investigator CV Raj Prasad  
Letter of invitation to participant 1.0 28 May 2013 
Other: CV - Abdul Hakeem   
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Other: CV - Giles Toogood   
Other: CV - Samir Pathak   
Other: CV - Rajesh Dey   
Other: CV - Gillian Ivey   
Other: CV - Sarah Brown   
Other: CV - Mark Glen Vero   
Other: Letter from funder  14 November 2012 
Participant Consent Form 2.0 18 July 2013 
Participant Information Sheet: Randomisation 
(Tracked changes) 
2.0 18 July 2013 
Participant Information Sheet: Learning Curve 
(Tracked Changes) 
2.0 18 July 2013 
Protocol 1.0  
REC application 1.0  
Response to Request for Further Information   
Summary/Synopsis part of protocol 12 May 2013 
 
Statement of compliance 
The Committee is constituted in accordance with the Governance Arrangements for Research 
Ethics Committees and complies fully with the Standard Operating Procedures for Research 
Ethics Committees in the UK. 
 
After ethical review 
Reporting requirements 
 
The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
    Notifying substantial amendments 
    Adding new sites and investigators 
    Notification of serious breaches of the protocol 
    Progress and safety reports 
    Notifying the end of the study 
 
The NRES website also provides guidance on these topics, which is updated in the light of 
changes in reporting requirements or procedures. 
 
Feedback 
 
You are invited to give your view of the service that you have received from the National 
Research Ethics Service and the application procedure.  If you wish to make your views known 
please use the feedback form available on the website. 
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Further information is available at National Research Ethics Service website > After Review
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13/YH/0195                                         Please quote this number on all correspondence 
 
We are pleased to welcome researchers and R & D staff at our NRES committee members’ 
training days – see details at  http://www.hra.nhs.uk/hra-training 
 
With the Committee’s best wishes for the success of this 
project. Yours sincerely 
pp  
 
 
Dr C E Chu 
Chair 
 
Email:hayley.jeffries@nhs.net. 
 
Enclosures:               “After ethical review – guidance for researchers” [SL-AR2] 
 
Copy to:                     Mr Derek Norfolk, R&D, Leeds 
 
Ms Anne Gowing, Leeds Teaching Hospitals NHS Trus
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9.3 Research Protocol 
Department of Hepatobiliary and Transplant Surgery 
St James’s University Hospital NHS Trust 
 
 
Research Protocol 
 
 
Version 2.0 
 
 
Date 18.07.2013 
 
 
 
Study Short Title: Pringle Manoeuvre versus Portal Vein Clamping for Liver Resection 
 
Study Full Title: Randomised Control Trial of Pringle Manoeuvre versus Portal Vein  
                            Clamping in patients undergoing Liver Resection for Colorectal Liver  
                            Metastasis – A Pilot Study 
 
Sponsor Name: Leeds Teaching Hospitals NHS Trust 
 
Funder Name: National Institute for Health Research:  Research for Patient Benefit (RfPB) 
 
Funder Reference: PB-PG-0711-25080 
 
 
 
 
Chief Investigator: 
 
  Name: K Raj Prasad 
 
  Title: Mr 
    
  Clinical Address: Department of Hepatobiliary and Transplant Surgery 
                                                    St. James’s University Hospital NHS Trust 
                                                    Bexley Wing Level 3 
                                                    Beckett Terrace 
                                                    Leeds 
                                                    LS9 7TF 
 
  Contact telephone number: 0777 1866619 
 
  Contact email address: raj.prasad@leedsth.nhs.uk 
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Signatures Page 
 
 
Pringle Manoeuvre versus Portal Vein Clamping for Liver Resection [1.0, 22.04.2013] 
 
 
 
Written and approved by the following: 
 
 
 
___________________________ ________________________ 
            Mr K Raj Prasad                      Date    
          [Chief Investigator] 
 
 
 
 
___________________________ ________________________ 
           Mr Giles J Toogood       Date 
[Co-investigator]
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Key contacts 
 
 
Chief Investigator:  
 
                      Name: Mr K Raj Prasad 
 
  Clinical Address: Department of Hepatobiliary and Transplant Surgery 
                                                    St. James’s University Hospital NHS Trust 
                                                    Bexley Wing Level 3 
                                                    Beckett Terrace 
                                                    Leeds 
                                                    LS9 7TF 
 
  Contact telephone number: 0777 1866619 
 
  Contact email address: raj.prasad@leedsth.nhs.uk 
 
 
 
 
Co-investigator 
 
                      Name: Mr Giles Toogood 
 
  Clinical Address: Department of Hepatobiliary and Transplant Surgery 
                                                    St. James’s University Hospital NHS Trust 
                                                    Bexley Wing Level 3 
                                                    Beckett Terrace 
                                                    Leeds 
                                                    LS9 7TF 
 
  Contact telephone number: 07887830729 
 
  Contact email address: giles.toogood@leedsth.nhs.uk 
 
 
 
Research Fellow:  
 
                      Name: Mr Samir Pathak 
 
  Clinical Address: Department of Hepatobiliary and Transplant Surgery 
                                                    St. James’s University Hospital NHS Trust 
                                                    Bexley Wing Level 3 
                                                    Beckett Terrace 
                                                    Leeds 
                                                    LS9 7TF 
 
  Contact telephone number: 07779 607659 
 
  Contact email address: samirpathak@doctors.net.uk 
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Research Fellow:  
 
                      Name: Mr Abdul R Hakeem 
 
  Clinical Address: Department of Hepatobiliary and Transplant Surgery 
                                                    St. James’s University Hospital NHS Trust 
                                                    Bexley Wing Level 3 
                                                    Beckett Terrace 
                                                    Leeds 
                                                    LS9 7TF 
 
  Contact telephone number: 0788 5736860 
 
  Contact email address: umah@leeds.ac.uk 
 
 
 
 
Research Fellow:  
 
                      Name: Mr Rajesh Dey 
 
  Clinical Address: Department of Hepatobiliary and Transplant Surgery 
                                                    St. James’s University Hospital NHS Trust 
                                                    Bexley Wing Level 3 
                                                    Beckett Terrace 
                                                    Leeds 
                                                    LS9 7TF 
 
  Contact telephone number: 0744 2153021 
 
  Contact email address: dr_rdey@yahoo.com 
 
 
 
 
 
Statisticians at Clinical Trials Research Unit (CTRU): 
 
                      Name: Ms Sarah Brown 
   Principal Statistician 
 
                      Address: Clinical Trials Research Unit 
                                       University of Leeds 
                                       Leeds 
                                       LS2 9JT 
 
                      Contact Telephone number: 0113 3431475 
 
                      Contact email address: medsbro@leeds.ac.uk 
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                      Name: Mr Neil Corrigan 
   Medical Statistician 
 
                      Address: Clinical Trials Research Unit 
                                       University of Leeds 
                                       Leeds 
                                       LS2 9JT 
 
                      Contact Telephone number: 0113 343 1493 
 
                      Contact email address: N.Corrigan@leeds.ac.uk 
 
 
 
Health Economist: 
 
                      Name: Dr Roberta Longo 
                               Health Economist 
                       
Address: Research Fellow 
      Academic Unit of Health Economics 
      Leeds Institute of Health Sciences 
      Charles Thackrah Building 
      University of Leeds 
      Leeds  
      LS2 9LJ 
 
 
                      Contact Telephone number: 0113 343 0324 
 
                      Contact email address: r.longo@leeds.ac.uk 
 
 
 
 
Lead R&D Contact: 
 
                      Name: Dr Derek Norfolk 
    Associate R&D Director 
 
                      Address:  Research and Development Department  
            34 Hyde Terrace 
                                               Leeds 
                                        LS2 9LN 
                      Contact Telephone number: 0113 392 2878 
                           Contact email address: Derek.norfolk@leedsth.nhs.uk 
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Abbreviations 
 
Abbreviation Description 
CRLM Colorectal liver metastasis  
HDU High Dependency Unit 
HPB Hepatopancreatobiliary  
ICU Intensive Care Unit 
IRI Ischaemia Reperfusion Injury 
LTHT Leeds Teaching Hospitals NHS Trust 
NIHR National Institute for Health Research 
PPI Patient Public Involvement  
QoL Quality of Life 
RCT Randomised Controlled Trial 
REC Research Ethics Committee 
RfPB Research for Patient Benefit 
SJUH St James’s University Hospital NHS Trust 
TMG Trial Management Group 
TSC Trial Steering Committee 
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1.0  Protocol Summary 
 
 
GENERAL  INFORMATION 
Short Title Pringle Manoeuvre versus Portal Vein Clamping for Liver 
Resection 
Full Title Randomised Controlled Trial of Pringle Manoeuvre versus Portal 
Vein Clamping in patients undergoing Liver Resection for 
Colorectal Liver Metastasis – A Pilot Study 
Sponsor Leeds Teaching Hospital NHS Trust 
Sponsor ID  
EudraCT No. Not applicable 
MREC No. Not applicable  
Chief Investigator Mr K Raj Prasad 
Co-ordinating Centre Department of Hepatobiliary and Transplant Surgery 
St. James’s University Hospital NHS Trust, Leeds 
National / International National 
STUDY  INFORMATION 
Phase Pilot Study 
Indication Colorectal liver metastasis (CRLM). 
Design Prospective, parallel group, single blind, randomised controlled 
pilot study. 
Primary Objectives 
 
 
 
 
 
 
 
 
 
Secondary Objectives 
The primary objective of the pilot randomised controlled trial 
(RCT) is to test whether the components of a larger multi- centre 
trial can work together. 
Specifically, 
1. The ability to recruit and randomise patients into the study 
2. The ability to conduct portal vein clamping surgical procedure 
3. The appropriateness of the follow-up assessments 
 
 
To collect information on the following outcome measures to 
further inform the main trial 
1. Incidence of  septic complications in portal vein 
clamping versus Pringle manoeuvre 
2. Incidence of ischaemia-reperfusion injury in the two 
arms 
3.  To measure the regeneration of the remnant liver in the 
two arms 
4.  Procedural outcomes including intra-operative blood 
loss, length of clamping  
     time, length of time transecting the liver and duration of 
the operation will be  
     recorded  
5. Post-operative events including bleeding, post- 
operative transfusion requirements, non- infective 
cardio- respiratory complications and 30- day mortality 
rate will be recorded 
6.   Change in patient quality of life (QOL) outcomes at 3 
months post surgery 
7.  A 10x10mm biopsy of normal liver will also be taken 
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2.0 Introduction 
during surgery to assess for  
      immunohistochemical evidence of ischaemia-
reperfusion injury 
 
The aim of the health economic component is to test the 
feasibility of collecting data for a full economic evaluation on 
the main study. 
Specifically,  
8. To test the acceptability and feasibility of health care 
resource use questionnaires developed in accordance 
with the existing literature on liver surgery and with the 
team clinical experts who will help identify the 
participants’ pathway of care.  
9. To assess whether the health-related quality of life 
questionnaire, EQ-5D, used for obtaining utility weights 
for constructing quality-adjusted life years (QALYs), is 
acceptable based on completion rates. 
 
 
 
Expected start date 01.06.2013 
Subject enrolment phase 16 months 
Follow-up duration 3 months 
End of Trial Definition The 3
 
month clinical visit of the last patient recruited to the trial. 
Expected completion date 31.12.2015 
TRIAL  SUBJECT  INFORMATION 
Number of trial subjects 80 
Age group of trial subjects 18 and above 
Inclusion criteria 1. At least 18 years of age 
2. Undergoing liver resection surgery for CRLM 
3. Portal venous clamping is considered appropriate 
4. Willing to provide informed consent 
5. Patients able to complete questionnaires 
Exclusion criteria 1. Patients having simultaneous bowel and hepatic surgery 
2. Patients participating in other trials that could impact the 
outcomes measures being recorded 
3. Patients who are pregnant  
4. Patients taking immunosuppressive drugs  
INVESTIGATIONAL  MEDICINAL  PRODUCT 
IMP name(s) Not applicable 
Duration of IMP Treatment Not applicable 
IMP Supplier(s) Not applicable 
Non IMP name(s) Not applicable 
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2.1 Background 
 
The portal vein and the hepatic artery supply 75% and 25% of the liver’s blood            
supply respectively, with each vessel contributing 50% of the liver’s oxygen           
requirement 
1
. The Pringle manoeuvre is commonly used to prevent blood loss at the time 
of liver resection. It involves clamping the vascular pedicle containing the            hepatic 
artery and the portal vein together during liver resection surgery. During            clamping a 
deprivation of oxygenation at the cellular level occurs, which is            worsened by the fact 
that surgery will remove some of the functioning volume of the liver. Research has shown 
that the true damage occurs when the ‘starved’ cells are reperfused, resulting in ischaemia 
reperfusion injury (IRI) 
2
. Not clamping the hepatic artery allows a continued supply of 
energy substrates to the cells, potentially reducing the damage caused by IRI. A recent 
randomised controlled trial (RCT) compared these two techniques along with a different 
technique and found that portal vein clamping resulted in faster recovery of liver functions 
3
. The proposed pilot study will overcome some of the methodological weaknesses in the 
reference study whilst piloting the approach in the UK. 
 
2.2 Rationale for the Proposed Study 
 
Colorectal cancer is the third most common cancer in the UK with around 110 new cases 
diagnosed each day 
4
. More than half of these patients present with cancer spread to the liver 
and those with early tumours can potentially be cured by resecting these deposits. Unlike 
most organs, which have a single blood supply, the liver receives blood from two sources, 
namely portal vein and hepatic artery supplying 75% and 25% of its blood respectively. 
Both contribute 50% of the liver’s oxygen requirement, with the hepatic artery supplying 
predominantly oxygen rich blood and portal vein circulating deoxygenated blood from the 
gut to be cleansed by the liver. 
 
During liver resection surgery, it is standard practice to clamp both these vessels (‘Pringle 
manoeuvre’), so as to avoid bleeding. Though the Pringle manoeuvre is an established 
technique, it is not without risk. Clamping both the blood vessels leads to ischaemic damage 
to the liver, which is worsened further by reperfusion of toxic substances when the clamp is 
released (ischaemia reperfusion injury). This leads to dead non-functioning cells, which can 
become infestated by microorganisms leading to septic complications. 
 
A systematic review of 30 studies on liver resection for CRLM using Pringle manoeuvre 
conducted in 2006, showed septic complications to be as high as 19% 
5
. Our group have 
used selective intermittent Pringle manoeuvre (clamping for 15 minutes and releasing for 5 
minutes) showing a septic complication rate of 12%. We have also demonstrated that a post-
operative infective complication is an independent predictor of recurrence of cancer in the 
long term 
6
. Therefore, by reducing liver tissue injury, isolated portal vein clamping has the 
potential to reduce the post-operative septic complications thereby improving both short and 
long-term outcomes. A recent RCT compared these two techniques along with a different 
technique and found that isolated portal vein clamping resulted in faster recovery of liver 
functions 
3
. Further research is now required to obtain definitive evidence on the benefits of 
portal vein clamping technique in other clinical outcomes. 
 
 
3.0 Study Objectives 
                 
           Primary objectives 
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           Pilot Study 
 
The primary objective of the pilot RCT is to test whether the components of a larger              
multi-centre trial can work together. 
           Specifically, 
           1. The ability to recruit and randomise patients into the study 
           2. The ability to conduct portal vein clamping surgical procedure 
           3. The appropriateness of the follow-up assessments 
            
       
           Secondary objectives 
            
            To collect information on the following outcome measures to further inform the  
            main trial 
3. Incidence of  septic complications in portal vein clamping versus Pringle manoeuvre 
4. Incidence of ischaemia-reperfusion injury in the two arms 
3.  To measure the regeneration of the remnant liver in the two arms 
4.  Procedural outcomes including intra-operative blood loss, length of clamping  
     time, length of time transecting the liver and duration of the operation will be  
     recorded  
5. Post-operative events including bleeding, post- operative transfusion requirements, non- 
infective cardio- respiratory complications and 30- day mortality rate will be recorded 
6.   Change in patient quality of life (QOL) outcomes at 3 months post surgery 
7.  A 10x10mm biopsy of normal liver will also be taken during surgery to assess for  
      immunohistochemical evidence of ischaemia-reperfusion injury 
 
The aim of the health economic component is to test the feasibility of collecting data for a full 
economic evaluation on the main study. 
Specifically,  
c) To test the acceptability and feasibility of health care resource use questionnaires 
developed in accordance with the existing literature on liver surgery and with the team 
clinical experts who will help identify the participants’ pathway of care.  
d) To assess whether the health-related quality of life questionnaire, EQ-5D, used for 
obtaining utility weights for constructing quality-adjusted life years (QALYs), is 
acceptable based on completion rates. 
 
            
 
 
 
 
4.0 Study Design 
 
This is a prospective, parallel group, single blind, randomised controlled pilot study. A total 
of 80 patients will be recruited. The first 20 patients are part of a learning curve 
development for portal vein clamping 
 
Setting: The project will be carried out at St James's University Hospital NHS Trust        
(SJUH) which is part of The Leeds Teaching Hospitals NHS Trust (LTHT). Patients  
attending the Hepatobiliary (HPB) clinic at SJUH who meet the inclusion criteria will be 
invited to take part during the clinic appointment.  
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4.1      Blinding 
 
 Patients will be blinded to the surgical procedure allocated to minimise the bias in patient 
reported outcome measures. However, blinding of surgeons performing the surgical 
procedure is not possible. As the outcome measures are objective there is little risk of 
assessment bias in the study. 
 
 4.2    Endpoints 
 
4.2.1  Primary Endpoint 
 
Pilot Study: The pilot study will be considered as successful, if the following domains run as 
specified in the protocol. 
 
1. Recruitment of patients into the study in line with the planned recruitment target    (5 
patients per month on average, with a total of 80 over the 16 month recruitment period) 
2. Complete data capture. Should data capture be incomplete, we will further analyse 
reasons for failure to recruit and/or reasons for conversion from isolated portal vein 
clamping to standard Pringle manoeuvre  
 
 
 
4.2.2    Secondary endpoint(s) 
 
  Pilot Study: The following secondary outcome measures will be recorded. 
 
Intra-operative outcomes:  
 
The following parameters will be recorded by the operating surgeon, his assistant or the 
research fellow (if present in theatre) via a case report from (CRF).  
 
1. Intra- operative blood loss (mls): This is the amount of blood lost intra- operatively 
during the full length of operation. This will be recorded at the end of the procedure from 
the suction drains. 
 2. Length of clamping time (mins): The total duration of clamping time will be recorded 
 3. Length of time spent on "transecting the liver" (mins) (from start of cutting the liver to 
liver bed haemostasis) 
 4. Total length of operation (mins): The length of operation from skin incision to skin 
closure will be recorded. This will provide information about the difficulty of the  
 procedure and will include the time taken for the initial clamp application. 
 
 
 Immediate postoperative outcomes (within 30 days): 
The following parameters will be recorded by the research fellow at 30 days post operative 
intervention, via a CRF. 
 
 5. Postoperative bleeding: This outcome indicates if the patient had any postoperative 
bleeding causing haemodynamic instability, need for transfusion or need for further 
laparotomy. 
 6. Transfusion requirements (number of RBC units transfused). 
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 7. Recovery of liver functions: Liver function tests will routinely be performed  
 immediately following surgery (Day 0/in theatre recovery) and then every morning  
 from Day 1 to Day 7.  
 8. Non infective cardio respiratory complications: Cardio-respiratory complications 
including atrial fibrillation, myocardial infarction and pulmonary oedema. 
 9. 30 day overall mortality rate 
 10. The development of septic complications by 30 days post procedure. These will be 
graded using the Clavien-Dindo classification as Grade III– V 7. This data will be recorded 
via telephone follow up if the patient has been discharged, or via case note review if the 
patient is still admitted.  
 
 Health Economic endpoints: 
 The following outcome measures will be recorded by the research fellow at the point of 
discharge, via a CRF. 
 
11. Length of HDU/ICU stay (days): Number of postoperative days in HDU/ICU will be 
recorded. 
 12. Length of hospital stay (defined as day of operation to day of discharge) 
 
The following health economic outcome measures will be recorded by the research fellow at 
the 3 month out-patient appointment, via a CRF 
Secondary, primary, community and social care services that participants may have used 
after discharge  
 
 
 
 Delayed Postoperative outcomes (3 months): 
The following parameters will be recorded by the research fellow at the 3 month out-
patient appointment, via a CRF 
 13. Liver regeneration: The growth of remnant liver will be assessed by performing 
Computerised Tomography (CT) scan pre-operatively and at 3 months post surgery. This is 
routine for any patient undergoing CRLM resection and will enable quantification of the 
extent of liver regeneration following cancer resection. This will be measured using 3-
Dimensional volumetry tools on the pre and post resection CT images 
8
. 
 
The following parameters will be collected by the Research fellow 
14. Quality of life assessment in cancer trials provides a more accurate evaluation of the 
wellbeing of the patients and of the benefits and side effects that may result from the 
surgery. The patient’s quality of life will be assessed using three standard  
 questionnaires. These questionnaires will be completed both pre- operatively and at 3 
months post surgery. 
 A. European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire Core30 (EORTC QLQC30,version 3.0): This is a 30point questionnaire and 
has five functional scales assessing physical, social, emotional, cognitive and overall daily 
activities. This questionnaire also takes account of the financial burden of cancer accrued 
to the patients 
9
. 
B. Liver Metastasis Colorectal (QLQLMC21): This is a 21point questionnaire, which is 
specific for colorectal liver metastasis patients. This questionnaire assesses patients 
symptoms pertaining to the cancer and the influence of the disease on their day to day 
activities 
10
. 
C. EuroQol5Dimensional Questionnaire (EQ5D): This questionnaire looks into general 
health outcome. It questions on 5 dimensions namely: mobility, self care, usual activities, 
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pain/discomfort and anxiety/depression. The questionnaire is supplemented by a visual 
analogue scale (VAS) for recording a respondent’s     current self assessed health on a 
scale from 0 (worst imaginable health state) to 100 (best imaginable health state) 
11
. 
 
 
5.0 Patient Selection 
 
5.1      Eligibility Criteria 
 
           Patients will be assessed for eligibility at the surgical out-patient clinic, in the Bexley 
           Wing, of St James’s University Hospital.  
 
5.1 Inclusion Criteria 
 
(a) At least 18 years of age 
(b) Undergoing liver resection surgery for CRLM 
(c) Portal venous clamping is considered appropriate 
(d) Participating patients should understand the study objectives and be able and 
     willing to provide written informed consent 
(e) Able to complete study questionnaire  
 
5.1.2 Exclusion Criteria 
            
           (a) Patients having simultaneous bowel and hepatic surgery 
           (b) Patients participating in other trials that could impact the outcomes measures  
                being recorded 
           (c) Patients who are pregnant  
           (d) Patients taking immunosuppressive medication  
            
           Eligibility waivers to inclusion/exclusion criteria are not permitted. 
 
5.2 Recruitment, Consent and Randomisation Processes 
  
          The research site will be required to have obtained local ethical and management 
          approvals prior to the start of recruitment onto the study. The recruitment target 
          requires 80 participants over a 16 month period. 
 
 
5.2.1  Recruitment  
 
Patients who have been diagnosed with resectable colorectal liver metastases and who fit the 
inclusion/exclusion criteria will be deemed eligible for this study by the Consultant Liver 
surgeon in charge of their care. To confirm eligibility, radiology images will be reviewed by 
the consultant surgeon in the clinic to ensure that there are no contraindications to portal vein 
clamping.  
 
Patients who meet the eligibility criteria will be invited to take part by the consultant surgeon 
during the clinic appointment. Patients will be given information about the study, which will 
involve both verbal information and Patient Information Leaflets (PIL). The PIL will include 
detailed information about the rationale, design and personal implications of the study. After 
receiving PIL, patients will have at least 24 hours to consider participation. The patient will 
be given the opportunity to discuss the study with their family and healthcare professionals 
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before they are asked whether they would be willing to take part in the study. This process 
will be clearly documented into the patient’s medical notes.  
 
 
Three Quality of Life (QoL) questionnaires will be posted to the patients and information 
will be provided how to fill them. Patients will be asked to fill the questionnaires within the 
last week before the operation and handover to the surgical team on the day of procedure. 
Patients will receive a phone call in the week prior to surgery to remind them to complete the 
questionnaires. Those who are undecided about participating in the study will be asked to fill 
the questionnaires on the morning of the procedure.  
 
Participating research staff will be required to complete a log of all patients screened for 
eligibility. Anonymous information will be collected including: 
 
 Age 
 Gender 
 Ethnicity 
 
Screened patients who are not randomised either because they are ineligible or because they 
decline participation will also have the following information recorded: 
 
 The reason(s) for ineligibility for study participation OR 
 The reason declined (if the patient was eligible for study participation). 
 
The screening data (baseline demographic data, as outlined above) will be obtained and 
collated via a secure database. 
 
5.2.2 Consent 
 
           Patients will be formally assessed for eligibility and invited to provide informed,  
           written consent. During further clinical appointment or on the morning of surgery,  
           informed written consent will be obtained by either the Consultant Surgeon or the       
           Research Fellow all of whom have undertaken GCP training. Informed, written   
           consent must be obtained prior to being recruited into the study. 
The right of the patient to refuse consent without giving reasons will be respected. Further, 
the patient will remain free to withdraw from the study at any time without giving reasons 
and without prejudicing any further treatment. A copy of the consent form will be given to 
the patient, one filed in the Study Master File (the original), one filed in the hospital notes 
and a fourth copy sent to the Sponsor.  The written consent will be taken by a clinician, who 
has signed / dated the staff authorisation / delegation log.  The process of obtaining written 
consent will be clearly documented in the patient’s medical notes.  
 
 
5.2.3 Randomisation 
 
 After the process of informed consent and completion of the baseline questionnaires, 
patients will be randomised centrally using a secure automated system provided by the 
Leeds Clinical Trials Research Unit (CTRU).  
 
Randomisation will be performed centrally using the CTRU office hours telephone 
randomisation service (open 9.00 to 17.00 Monday to Friday excluding public/band 
   
148 
 
holidays, the period between Christmas and New Year, Thursday afternoon before Good 
Friday and all Tuesdays following a bank holiday except for Mayday and New Year’s Day). 
 
The following information will be required at randomisation: 
 
 Participant details, including initials, gender and date of birth 
 Site code for research site  
 Name of person making the randomisation 
 Name of treating surgeon 
 Confirmation of eligibility 
 Confirmation and date of written informed consent 
 Stratification factors (see below) 
 
Participants will be randomised on a 1:1 basis to have either the Pringle manoeuvre or portal 
vein clamping used as the method of clamping during their operation. Each participant will 
be allocated a unique study number.  The randomisation will be stratified using stratified 
random permuted blocks to ensure that treatment groups are well balanced for the following 
stratification factors, details of which will be required at randomisation: 
 
 Body Mass Index (BMI) 
o Less than 30 
o Greater than or equal to 30 
 Previous chemotherapy exposure within the last 3 months 
 
  
 
5.2.4   Surgical Procedure 
 
 Surgical procedure: At the time of surgery, the standard procedure for operative dissection 
will take place. Surgery will be performed through a reverse L shaped incision. The surgeon 
will clamp using the allocated method. During surgery, a careful search of the abdominal 
cavity will be performed to determine the extent of the local disease, extra hepatic metastasis 
and seeding within the peritoneal cavity. After mobilisation of the liver, intra operative 
ultrasound scan will be performed to assess the number, size of the lesions and the relation 
of the tumour to major blood vessels. A wedge liver biopsy (10x10mm) is taken from the 
unaffected liver (the part of the liver without clamped blood supply) before closure to study 
the extent of reperfusion injury. This will not be adding additional risk to the patient.  
 
Intervention group: In the main portal vein occlusion group, the portal vein will be isolated 
and occluded with a clamp. 
 
Control group: In the Pringle manoeuvre group, the entire hepatico-duodenal ligament 
containing both hepatic artery and portal vein, will be occluded using standard vascular 
clamp. 
 
In both the groups, intermittent vascular occlusion will be performed with cycles of 15 
minute inflow occlusion followed by 5 minutes of reperfusion. 
 
Postoperative care: The postoperative management will be identical in both the groups and 
will involve Intensive Care Unit (ITU) or High Dependency Unit (HDU) stay for the first 
24-48 hours, or longer if required. Stable patients will be transferred to the ward with routine 
care involving daily ward rounds and monitoring with bloods. Any untoward complication 
   
149 
 
will be managed appropriately by the clinical team managing the patient and the details will 
be recorded in the clinical notes. 
 
 
5.2.5 Patients who Withdraw Consent 
 
If a patient wishes to withdraw, information collected to the point of withdrawal will be 
included in the analyses. Withdrawal will be documented on the corresponding CRF. The 
patient will remain free to withdraw from the study at any time without giving reasons and 
without prejudicing any further treatment. The patient will continue to receive treatment as 
per standard practice for patients undergoing liver resection for CRLM that is followed in 
the Liver Unit at SJUH. 
 
5.2.6 Managing / replacing patient who withdraw from the study early 
 
           The patients, who withdraw from the study following recruitment or randomization or 
           after the surgical procedure, will continue to receive treatment as per standard                    
           practice for patients undergoing liver resection for CRLM that is followed in the Liver   
           unit of SJUH.  
           The patients will not be replaced in the study and the data from the patient will be  
           used in final analysis on an intention to treat basis. Those who leave  
           the study at any point will have their anonymity maintained and their further  
           treatment/care will not be affected.  
 
 
5.2.7 Definition for the End of Study 
 
           The end of the study is the last clinical visit, corresponding to the third month out- 
           patient visit for the last subject recruited to the study.  
 
 
6.0 Study Schedule 
 
6.1  Assessments and Procedures  
 
First out-patient appointment: 
 Assessment of eligibility for the study by Consultant Surgeon 
 Verbal study information and Patient Information Leaflets (PIL) given to eligible 
patients 
 
Second out-patient appointment or day of surgery: 
 Informed consent will be obtained 
 Baseline demographic data obtained for eligible patients (sex, date of birth, age, 
study number, Body mass index (assessed using height and weight), alcohol and 
smoking history, other comorbidities, primary tumour characteristics, chemotherapy 
history, medication history, pre-operative bloods and ASA grade) 
 QoL questionnaires (EORTC QLQ-C30, EORTC QLQ – LMC21, EQ-5D-3L) will 
be given to the patients to complete 
 Treatment allocation will occur (randomised) 
 Surgical procedure carried out as per treatment arm 
 Intra-operative parameters will be obtained (Type of incision, adhesions to 
abdominal wall/liver, surgical procedure received, conversion, reason for conversion, 
   
150 
 
time of clamping, blood loss, time of operation, time for transection, major or minor 
resection, anatomical/non-anatomical resection, intra-op blood transfusion, use of 
platelets/Fresh Frozen Plasma, use of fibrin sealant or pro-thrombotic) 
 
Day 1-7 post-procedure: 
 Routine blood tests including full blood count, renal function tests, liver function 
tests and clotting profile will be measured from day 1 till day 7 post-operatively  
 
Day 30 post-procedure: 
 If patient still an in-patient at 30 days post surgery, an assessment of incidence of 
septic complications will be made 
 If the patient has been discharged at 30 days post surgery, a telephone call will be 
made to assess for incidence of any septic complications 
 Data on histology, post-op blood transfusion, ITU and/or HDU stay, use of 
tranexamic acid, other post-op complications, 30-day mortality 
 
3 months follow-up assessment: 
 3 month volumetric analysis using CT scan  
 Recurrence 
 Loss to follow-up 
 Post-op QOL questionnaires (EORTC QLQ-C30, EORTC QLQ – LMC21, EQ-5D-
3L) 
 Health care resource use questionnaire 
 
 
 
 
7.0  Safety Reports 
 
            For the purpose of this trial the safety reporting term “adverse events” will be  
            referred to as “complications”. 
 
7.1      Defining Complications 
            
           A complication is any unfavourable and unintended sign, symptom,  
           syndrome or illness that develops or worsens during the period of observation in the   
           study, and has a causal relationship to the trial. The trial includes the surgical  
           intervention and any trial specific interventions e.g. the consent process and the  
           completion of questionnaires. A complication does include a/an: 
a) exacerbation of a pre-existing illness 
b) increase in frequency or intensity of a pre-existing episodic event or condition 
c) condition detected or diagnosed after the surgical procedure, even though it may have 
been present prior to the start of the study 
 
           A complication does not include a:  
a) medical or surgical procedure (eg tooth extraction) but the condition that lead to the 
procedure may be a complication 
b) pre-existing diseases or conditions present or detected at the start of the study that did 
not worsen 
c) situation where an untoward medical occurrence has not occurred (hospitalisation for 
cosmetic procedure, social and/or convenience admissions) 
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d) disease or disorder being studies or sign or sympom associated with the disease or 
disorder unless more severe than expected for the participants condition.  
 
7.2      Defining Serious Complications 
            
           A Serious complication is defined as a complication which satisfies at least one of  
           the following:  
a) results in death 
b) is life-threatening 
c) requires or prolongs hospitalisation 
d) results in persistent or significant disability or incapacity 
e) may jeopardise the participant and may require medical or surgical intervention to 
prevent one of the outcomes listed above 
f) any other significant clinical event, not falling into any of the criteria above, but 
which in the opinion of the investigator requires reporting 
 
           For the purposes of the trial, pre-planned elective hospital admissions will not be  
           classed as a serious complication 
 
7.3      Defining Unexpected Serious Complications (USCs)  
            
           All serious complications assigned by investigators as both related to the   
           procedure and unexpected are subject to expedited reporting. A complication is    
           related if it resulted from administration of any research procedures; note that all  
           complications are related to the research procedures by definition (since untoward  
           medical events which are unrelated to the research procedures are not being  
           classed as complications or reported in this trial).A complication is unexpected  
           when information is not consistent with the expected risk  
           profile of the procedure. 
  
 
7.4       Reporting Complications 
             
            Information about complications, whether volunteered by the patient or discovered   
            by the investigators via history, physical examination, laboratory testing or  
            radiological investigation will be collected and recorded on the CRF.  
            
            Complications will be collected for all participants from time of surgery until the final   
            trial visit of the final trial patient  
  
            A summary of all captured complications will be sent to the sponsor if requested 
 
 
7.5     Reporting Serious Complications      
           
          Serious complications will be collected for all participants from time of surgery until  
          the final trial visit.  
           
          Serious complications must be reported on a sponsor-approved form and faxed  
          through to the trial manager within 24 hours of any member of the research team  
          becoming aware of a potential serious complication.  
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7.6      Reporting USCs            
           
           All serious complications assigned by investigators (or another suitably qualified  
           delegated clinician)  
           as both related to trial treatment and unexpected, will be discussed  
           with the Principal Investigator (PI) before reporting. If the consensus is that this is  
           unexpected then such serious complications will be reclassified as USCs and will  
           undergo expedited reporting to the Research Ethics Committee (REC).  
 
           All USCs occurring whilst on Trial until the final trial out-patient visit, must be  
           reported on a sponsor approved form and faxed through to the trial manager,  
            within 24 hours of any member of the research team becoming aware of a  USC.          
           The Research team will inform the REC
(a)
 and the sponsor
(b)
 within the following      
           timescales:  
(a) USCs resulting in Death or are deemed to be life-threatening must be reported to the 
REC within 7 calendar days of the PI being aware of the event. Follow-up information 
must be reported within a further 8 calendar days. 
(a) Any USCs not resulting in Death or deemed to be life-threatening must be reported to 
the REC within 15 calendar days of the PI being informed of the event. Follow-up 
information must be reported within a further 8 calendar days 
 
(b) All USCs must be reported to the sponsor QA office within 24 hours of the event being 
reported to the PI. 
       
 
7.7 End of Trial Report 
 
Upon completing the trial, as defined in 5.2.7 above, an end of trial report will be submitted 
to the REC, sponsor and other regulatory authorities with 90 days. A copy of this end of trial 
report should also be submitted to the Sponsor’s office 
 
 
8.0 Data Collection, Source Data and Confidentiality 
 
8.1 General 
 
All information collected during the course of the trial will be kept strictly confidential.   
Information will be held securely on paper and electronically at the Department of HPB and 
Transplant Surgery, SJUH campus.  
The data storage will comply with all aspects of the Data Protection Act 1998. Operationally 
this will include:  
 consent from patients to record personal details including name, date of birth and 
hospital ID 
 appropriate storage, restricted access and disposal arrangements for patient personal and 
clinical details 
 consent from patients for access to their medical records by responsible individuals from 
the research staff, the sponsor or from regulatory authorities, where it is relevant to trial 
participation 
 consent from patients for the data collected for the trial to be used to evaluate safety and 
develop new research. 
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8.2  Archiving 
 
In line with the principles of GCP / UK Clinical trial Regulations guidelines, at the end of 
the trial, data will be securely archived at LTHT for a minimum of 15 years.  Arrangements 
for confidential destruction will then be made.Data to the point of withdrawal will still be 
used. No records will be destroyed without first obtaining written permission from the 
Sponsor. 
 
 
9.0 Statistical Considerations 
 
9.1  Sample Size  
 A total of 80 patients will be recruited into the pilot study. Twenty patients (corresponding 
to the first 5 patients for each of the 4 surgeons) will undergo portal vein clamping surgical 
procedure in order to address any learning curve associated with this procedure. In clinical 
opinion, a sample of five patients is sufficient to address any learning curve. 
Sixty patients (30 per group) will be randomised to the surgical procedure. The sample size 
is based on the recommended number for a pilot study 
12
. 
 
 
 
 
 
 
9.2  Statistical Analysis 
 
 The number of patients recruited per month will be presented. Baseline data will be 
summarized to comparability between groups. The intention-to-treat patient population will 
be used.  Analysis will focus on descriptive statistics and confidence interval estimation 
rather than formal hypothesis testing. Outcome measures will be summarised and 95% 
confidence intervals presented by treatment group and overall. The difference in outcomes 
between the intervention and control groups will also be summarized and 95% confidence 
intervals presented.  Data will be reported in line with the CONSORT statement.  
 
 
10.0 Data Monitoring and Quality Assurance 
 
10.1 Data Monitoring 
 
All data obtained in this study as well as related health records will remain strictly 
confidential at all times. The information will be held securely on paper and electronically in 
the Department of Hepato-pancreatico-biliary (HpB) and Transplant Surgery, St James’s 
Hospital under the provisions of the 1998 Data Protection Act. Anonymity of data will be 
ensured. The spreadsheets will be password protected and will only be accessible to 
members of the research team. 
The sponsor will permit monitoring audits and will review data collected, including consent 
forms. Data will be monitored for quality and completeness by the research  
fellow. Entries on CRFs will be verified by inspection against source data. A sample of 
CRFs will be checked on a regular basis for verification of all entries made. In addition the 
subsequent capture of data on the Trial database will be checked. Where corrections are 
required these will carry a full audit trail and justification.  
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10.2 Quality Assurance 
 
The Sponsor has systems in place to ensure that there is reporting and appropriate action 
taken in respect of: 
(a) serious breaches of GCP, the trial protocol and the Clinical Trial Authorisation. 
(b) Urgent safety Measures 
(c) Protocol violations 
 
A “serious breach” is a breach which is likely to effect to a significant degree: 
(a) The safety or physical or mental integrity of the trial participants; or 
(b) The scientific value of the trial 
 
            Investigators will promptly notify the Sponsor Office of the following within the required 
time frame, once they become aware of : 
(a) Serious breached of GCP, the trial protocol and the clinical Trial Authorisation 
(b) Urgent Safety measures 
(c) Protocol violations 
(d) Any amendments to the trial 
(e) Any other issues as stated in the Research Sponsorship Agreement 
 
            The study will be conducted in accordance with the principles of GCP and the NHS  
           Research Governance. There will be thorough adherence to departmental  
           standard operating protocols (SOPS). 
 
10.3 Good Clinical Practice (GCP) and Regulatory Compliance 
    
    This clinical trial, which does not involve the use of an investigational medicinal  
    product has been designed and will be run in accordance with the Principles of   
    GCP and the current regulatory requirements, as detailed in the Medicines for  
    Human Use (Clinical Trials) Regulations 2004 (UK S.I. 2004 / 1031) and any  
    subsequent amendments of the clinical trial regulations 
 
10.4      Trial conduct 
 
Approval will be obtained from the Research Ethics Committee (REC) prior to starting the 
trial. The Chief Investigator will be responsible for the ethical and governance issues. Two 
committees will be established to govern the conduct of the study – Trial Management 
Group (TMG) and TSC. The Trial Management Group will comprise the full research team 
and will have responsibility for project management, monitoring timescales, recruitment, 
analysis, ethical issues and safety. The TSC will include the research team and members 
with trial methodology and clinical expertise who are independent of the research team, 
including an           independent chairperson. The PPI co- applicants will be full members of 
the TSG and TMG and will contribute to the management of the study. 
 
KRP will be responsible for the ethical and governance issues.  Clinical and research 
governance will be monitored by the R&D at SJUH. 
 
 
 
11.0 Ethical Considerations 
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The trial will be performed in accordance with the recommendations guiding ethical 
research involving human subjects adopted by the 18th World Medical Assembly, Helsinki, 
Finland, 1964, amended at the 52
nd
 World Medical Association General Assembly, 
Edinburgh, Scotland, October 2000. Informed written consent will be obtained from the 
patients prior to recruitment into the study.  The right of a patient to refuse participation 
without giving reasons will be respected.  The patient will remain free to withdraw at any 
time from the study without giving reasons and without prejudicing his/her further 
treatment.  
The study will be submitted to approval by a main REC, prior to entering patients into the 
study. A copy of the final protocol, patient information leaflets, consent form and all other 
relevant study documentation will be provided to the main REC. 
 
 
12.0 Statement of Indemnity 
 
Clinical negligence indemnification will rest with The Leeds Teaching Hospitals NHS Trust 
under standard NHS arrangements. The sponsor, Leeds Teaching Hospitals NHS trust, will 
provide insurance and/or indemnity to meet the potential legal liability for harm to patients 
arising from the management and design of the research.  
 
 
 
 
13.0 Publication Policy 
 
The trial will be registered with an authorised registry, according to the International 
Committee of Medical Journal Editors (ICMJE) guidelines, prior to the start of recruitment. 
 
The success of the trial depends upon the collaboration of all participants. For this  reason, 
credit for the main results will be given to all those who have collaborated in the trial, 
through authorship and contributorship. Uniform requirements for authorship for 
manuscripts submitted to medical journals will guide authorship decisions. These state that 
authorship credit should be based only on substantial contribution to: 
 
 Conception and design, or acquisition of data, or analysis and interpretation of data 
 Drafting the article or revising it critically for important intellectual content 
 Final approval of the version to be published 
 
and that all of these conditions must be met (www.icmje.org).  
 
To maintain the scientific integrity of the trial, data will not be released prior to the first 
publication of the analysis of the primary endpoint, either for trial publication of oral 
presentation purposes, without the permission of the Trial Steering Committee (TSC).  
 
The results of this trial will be presented at national and international meetings. They will 
also be submitted for publication in peer-reviewed journals. The investigators will follow 
International Committee of Medical Journal Editors (ICMJE) guidelines.  
Participants who wish to receive information about the results from the Trial can ask their 
SSP/RN. They will be made aware that this will be some time after their participation in the 
Trial has finished. 
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15.0  Appendices 
         
A. Flow diagram of patient pathway  
B. Main study objectives and endpoints            
 
 
A. Flow diagram of patient pathway with schematic representation of when 
data will be collected 
 
 
DATA TO BE COLLECTED                                           PATIENT PATHWAY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Initial investigations  
(CT and/or MRI) 
First clinic appointment: 
Assessment of eligibility, 
patient information leaflet (PIL) 
provided 
30 day follow up (phone call if 
patient discharged) 
3 month out-patient follow-up 
Baseline parameters obtained  
Randomisation details 
Day 1 to day 7 blood test 
results recorded  
Post-op complications and 
completion of 30-day mortality 
Volumetric analysis, resource 
use QOL questionnaires  
QoL questionnaires returned  
Hospital stay 
               Admission 
      Written informed consent 
                  Operation 
 Randomisation into group (first 
20 into portal vein only group 
for learning curve and next 60 
to be randomised 1:1 into portal 
vein arm or Pringle arm 
Intra-operative data 
QoL questionnaires sent 
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B. Main study (for information only): 
 
           Objectives: 
 
           Primary objective: 
The primary objective of the main study is to demonstrate that portal vein clamping is 
superior to the Pringle manoeuvre technique in terms of the proportion of            patients 
with septic complications by 30 days post hepatic resection. 
 
           Secondary objectives:            
1. To demonstrate that portal vein clamping results in reduced ischaemia reperfusion injury 
to the liver 
           2. To demonstrate that portal clamping results in better regeneration of the remnant  
           liver 
3. To compare the two clamping methods in terms of procedural outcomes including intra-
operative blood loss, length of camping time, length of time transecting the liver and 
duration of the operation 
4. To compare the two clamping methods in terms of post-operative events            including 
bleeding, post- operative transfusion requirements, non- infective cardio-            respiratory 
complications and 30- day mortality rate 
5. To test the feasibility of collecting data for a full economic evaluation on the main study 
6. To compare patient quality of life (QoL) outcomes at 3 months post surgery 
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9.4 Patient Information Leaflet  
 
John Goligher Colorectal Unit 
Colorectal & HPB Research Office 
Ground Floor Lincoln Wing 
St James’ University Hospital 
Beckett Street 
Leeds 
LS9 7TF 
                                                Tel: 0113 2064672 / 0113 2069215 
                                                       Catherine Moriarty / Louise Clarke       
 
 
PATIENT INFORMATION SHEET v3.0 
(for patients undergoing learning curve part of the study) 
 
 
Randomised Controlled Trial of Pringle Manoeuvre versus Portal Vein 
Clamping in Patients undergoing Liver Resection for Colorectal Liver 
Metastasis - A Pilot Study 
 
PART 1 
 
1. Invitation 
You are being invited to take part in a research study. Before you to take part, it is important 
for you to understand why the research is being done and what it will involve. Please take 
time to read the following information carefully, and discuss it with others if you wish.  
 
PART 1 tells you the purpose of this study and what will happen if you take part. 
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PART 2 gives more detailed information about the study methodology. 
Your liver surgeon and the study doctor would like to ensure that you completely understand 
the study and the study requirements. Please contact us if anything is unclear, or if you would 
like more information. 
2. What is the purpose of the study? 
As you are aware, you have been diagnosed with liver metastasis (deposits of cancer in the 
liver) from colorectal (bowel) cancer. Your liver surgeon thinks that the colorectal liver 
metastasis (CRLM) is operable by resecting the part of the liver with tumour (liver resection). 
It has been conclusively proven that surgery is the best form of treatment for such CRLM.  
The liver has 8 segments and up to 70% of the liver can be safely removed surgically. The 
remaining liver grows back over a period of 4-6 weeks. St James’s University Hospital is one 
of the leading centres for liver resections in the UK and has an international reputation. The 
centre currently performs around 270 liver resections per year for CLRM.  
The liver is supplied by two blood vessels - the hepatic artery and the portal vein, each 
carrying about 25% and 75% respectively of the total blood flow to the liver, and 50% each 
of the total oxygen supply to the liver. During liver resection, it is standard practice to clamp 
the hepatic artery and the portal vein for short periods during the operation. This is done with 
the objective of reducing blood loss during surgery. This part of the procedure is called the 
Pringle manoeuvre.  
However, clamping both of the blood vessels to the liver means that the liver will be starved 
of oxygen and nutrients (ischaemia) for the length of time the clamp is on. Recent studies 
have shown that the damage occurs when the blood flow to the liver is restored (reperfusion), 
which leads to flow of accumulated toxic substances into the liver. This has been termed as 
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ischaemia-reperfusion injury (IRI) and leads to liver damage and thereby increases risk of 
post-operative infections within the liver.  
There has been some recent research suggesting that clamping of the portal vein only during 
liver resection (instead of Pringle manoeuvre in which the hepatic artery is also clamped) 
achieves the same effect as the Pringle manoeuvre in terms of reducing blood loss, with 
possible advantages, as the liver continues to receive blood supply through the hepatic artery. 
This potentially reduces the degree of injury to the liver cells, and may translate into 
decreased incidence of infections after the operation with overall improvement in patient 
outcome but may increase the risks of bleeding 
 However, as stated, the evidence for this is limited and the initial positive findings still need 
to be confirmed. Hence, we are performing this study which will randomly allocate patients 
to either undergo isolated portal vein clamping or the traditional Pringle manoeuvre during 
the operation. .   
The main purpose of the study at this stage is to assess the ability to recruit and randomise 
patients into the study, assess the appropriateness of follow-up and collect data. .  
We shall also look at the occurrence of septic (infectious) complications at 30 days after your 
surgery as well as: 
- Blood loss during surgery 
- Duration of surgery and portal vein clamping or Pringle manoeuvre  
- Blood transfusion if required and the number of units transfused 
- Recovery of liver function which will be assessed by daily liver function tests 
- Non-infective complications affecting the heart and/or lungs 
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Three months after your surgery we will be looking at delayed outcomes such as the rate and 
extent of liver regeneration via a CT or MRI scan and quality of life after surgery. . The CT 
scan at 3 months will mean exposure to ionising radiation which carries a minimal risk to 
you. However, all patients undergoing liver surgery are subjected to this as part of standard 
care. 
During the procedure, we will be taking a small piece (10x10 mm) of your healthy liver, so as 
to assess ischaemia reperfusion injury. This does not add any further risk to the surgery as the 
biopsy will be taken from the part of the liver that has already been removed. The rest of the 
procedure and the post-operative follow up will be performed as similar to those patients who 
are not part of the study.  
3. Why have I been chosen? 
Your liver surgeon has advised the research team to approach you for the study. All patients 
who need liver surgery for CRLM are invited to take part. A total of 80 patients will be 
recruited as part of this study at St James’s University Hospital. The first 20 patients will be 
enrolled into the learning curve part of the study and next 60 patients randomly allocated to 
either of the two different clamping techniques (explained in later sections). You are one of 
the first 20 patients and hence will undergo isolated portal vein clamping. 
4. Do I have to take part? 
No. Participation is entirely voluntary. If you decide to take part you will be given this 
information sheet to keep and asked to sign a consent form to confirm that you understand 
what is involved when taking part in this trial. You are free to leave this trial at any time 
without giving a reason. This will not affect the quality of care that you receive. 
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5.         What will happen to me if I take part? 
The research team will post 3 questionnaires to your home address, which would need to be 
filled in during the last week before your operation. If you agree to participate you will 
undergo liver resection surgery for CRLM using the portal vein clamping technique.  
The risks and benefits of this technique will be explained to you as per usual hospital 
practice. The consultant will give additional time to explain the procedure to you during the 
outpatient visit. You shall have adequate time to think about it before giving consent (either 
during next outpatient visit or on the day of surgery). The procedure will be is performed 
according to the well-established standard of practice already being followed in the hospital. 
In the case of any difficulty faced by the surgeon while performing isolated portal vein 
clamping, the procedure will be converted to a traditional Pringle manoeuvre. 
You shall receive standard post-operative care and follow up as received by all patients 
undergoing liver surgery for CRLM.  
The only additional requirement will be to receive 2 phone calls from a member of the 
research team just before your admission to remind you of the questionnaire that needs 
completing and at 30 days after your surgery to assess your recovery. It is most likely that 
you will have been discharged from hospital at this point and so a telephone follow up will 
occur. However, if you are still an in-patient, a member of the research team may come and 
speak to you instead.  
A summary of the events, study tests and procedures is provided below: 
Before the operation  Information sheet and verbal study 
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related information provided 
 Consent obtained in the clinics or on 
the day of surgical procedure 
 Three questionnaires will be posted to 
you so as to get information on quality of life 
prior to surgery. You will receive a phone 
call in the week before your operation to 
remind you to complete the forms 
During the operation  Portal vein clamping performed 
during the surgical procedure 
After the operation and at 3 month follow-
up in clinic 
 Clinical assessment, daily blood tests 
including liver function tests and CT scan at 
3 months after operation (all these 
tests/investigations are routine as performed 
for someone not part of the study)  A CT 
scan involves minimal exposure to ionising 
radiation 
 Telephone call for follow up at 30 
days post surgery (if you have been 
discharged home) 
 A further 3 questionnaires will be 
provided at 3 months period, so as to assess 
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your quality of life following surgical 
procedure. 
 
It is important for you to understand that participation in the study is entirely voluntary. In 
addition if you agree to participate initially and reconsider at a later date you may decline to 
continue with the study follow up. 
6.  What do I have to do?  
When you have had the opportunity to read this patient information sheet a member of the 
research team will contact you to see if you would like to participate. If you do then your 
consent will be obtained at either a clinic visit or on the morning of surgery. There will be no 
additional clinic appointments or investigations if you decide to take part. The only additional 
requirement will be a telephone follow-up call 30 days following surgery by a member of the 
research team providing you have been discharged.  
If you decide not to take part you shall receive the standard of care available to all patients 
undergoing similar surgery in the Liver Unit at St James’ University Hospital.   
7.  What is the procedure that is being tested? 
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The research compares two techniques employed during liver surgery to control blood loss – 
The Pringle manoeuvre and isolated portal vein clamping. The Pringle manoeuvre (currently 
standard practice) clamps both the portal vein and the hepatic artery. Isolated portal vein 
clamping allows oxygenated blood to still be delivered to the liver via the hepatic artery 
while the portal vein is clamped.  
At the time of surgery, the standard procedure for operative dissection will take place. 
Surgery will be performed through a reverse L-shaped incision made on the abdomen. The 
surgeon will clamp using the allocated method and then proceed to removing the affected part 
of the liver. A wedge liver biopsy (10x10mm) is taken from the affected liver (the part of the 
liver with clamped blood supply) to study the extent of reperfusion injury. This will not be 
adding additional risk to the patient as the biopsy will be taken from the liver that is being 
resected. The liver biopsy specimen will be sent to the pathology laboratory along with the 
resected liver specimen for standard histo-pathological examination as is routinely performed 
in Pathology department. The tumour tissue will be stored in the pathology department as per 
normal clinical practice but the biopsy taken from the sample will be destroyed after 18 
months. 
8.     What are the alternatives for diagnosis or treatment? 
The alternative is to not clamp the blood vessels at all during surgery. However, this is 
infrequently performed worldwide because of the risk of increased bleeding. If you do not 
wish to participate in the study, it is likely that a Pringle manoeuvre would still be performed 
during your operation and you will receive standard post operative care and follow up as per 
routine for patients undergoing CRLM resection. 
9. What are the side effects of any treatment received when taking part? 
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This study compares two different methods of clamping blood vessels during liver resection 
surgery. It does not involve any drug treatment, so side effects following the procedure are 
unlikely. 
Portal vein clamping alone is not commonly performed during liver resection surgery. 
However, there is published literature on the safety of this procedure in this setting. The four 
liver surgeons at St James’s University Hospital are experienced in both liver resection and 
liver transplantation. It is routine practice in liver transplantation for surgeons to isolate the 
portal vein during liver transplantation surgery. So as to address any learning curve that the 
new procedure will have (portal vein isolation may be different in resectional surgery 
compared to transplant), the first 20 patients in the study will undergo portal vein clamping 
alone (5 per surgeon). In the event of any difficulty encountered during operation, the 
procedure (portal vein clamping alone) will be converted to standard Pringle manoeuvre. You 
will form part of this 20 patients, who will undergo portal vein clamping alone.  
 
10.  What are the possible benefits of taking part?  
It is important for you to understand that the information obtained during this study will be 
crucial in determining whether isolated portal vein clamping is superior to the Pringle 
manoeuvre. The information that you provide as a participant in this study will contribute to a 
body of evidence that will help determine the best direction for future routine practice and 
therefore benefit other patients in the future. However, there is no direct benefit to you in 
taking part in this study 
 11. What happens when the research study stops? 
The duration of participation is 3 months from the day of surgery. At the end of the study 
period, you will continue to receive the same standard of treatment and follow up care as is 
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practiced in the Liver unit of St James’s University Hospital for CRLM (6 monthly follow up 
for the first two years followed by annual follow up thereafter). 
12. What if there is a problem? 
If you have a concern about any aspect of this Trial, you should ask to speak with the 
Screening Practitioner or Research Nurse who will do their best to answer your questions.  If 
you remain unhappy and wish to complain formally, you can do this through the NHS 
Complaints Procedure.  Details can be obtained from the hospital. 
 
In the event that something does go wrong and you are harmed during the research Trial, 
whether or not this is due to someone’s negligence, you may have grounds for a legal action 
for compensation but you may have to pay your legal costs.  The normal National Health 
Service complaints mechanisms will still be available to you. 
 
 
 
13. Contact Details 
Chief Investigator  
Name: Mr K Raj Prasad    Tel. Number: 0113 2066665 
Research Fellow  
Name : Mr Samir Pathak                                           Tel Number: 07779 607659 
Lead Research Nurse 
Name : Ms Catherine Moriarty                                   Tel Number: 0113 2064672 
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This completes Part 1 of the Information Sheet. If the information in Part 1 has interested you 
and you are considering participation, please continue to read the additional information in 
Part 2 before making any decision. 
 
 
 
 
 
 
 
 
PART 2 
 
15.   What if new information becomes available? 
Sometimes during the course of a clinical Trial, new information becomes available on the 
topic being studied. If this happens, we will tell you about it and discuss with you whether 
you want to or should continue in the Trial. If you decide to withdraw, we will make 
arrangements for your care to continue. If you decide to continue in the Trial, you will be 
asked to sign an updated consent form. 
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On receiving new information, we might consider it to be in your best interests to withdraw 
you from the Trial. If so, we will explain the reasons and arrange for your normal care to 
continue. 
If the Trial is stopped for any other reason, you will be told why and your continuing care 
will be arranged. 
16.    What will happen if I don’t want to carry on with the study? 
You can withdraw from participation at any point of time during the study. Your withdrawal 
will not affect your treatment and standard of care in any way. 
17. Will my part in this study be kept confidential? 
If you consent to take part in this Trial, the records obtained while you are in this Trial as 
well as related health records will remain strictly confidential at all times. The information 
will be held securely on paper and electronically at your treating hospital under the provisions 
of the 1998 Data Protection Act. Your name will not be passed to anyone else outside the 
research team or the Sponsor, who is not involved in the Trial. You will be allocated a Trial 
number, which will be used as a code to identify you in all Trial paperwork and samples. 
 
Your anonymised data will be available to people authorised to work on the Trial but may 
also need to be made available to people authorised by the Research Sponsor (Leeds 
Teaching Hospitals NHS Trust), which is the organisation responsible for ensuring that the 
Trial is carried out correctly. By signing the consent form, you agree to this and for any 
further research that may be conducted in relation to it, even if you withdraw from the Trial.  
 
The information collected about you may also be shown to authorised people from the UK 
Regulatory Authority and Independent Ethics Committee; this is to ensure that the Trial is 
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carried out to the highest possible scientific standards.  All will have a duty of 
confidentiality to you as a research participant. 
 
In line with Good Clinical Practice guidelines, at the end of the Trial, your data will be 
securely archived for a minimum of 15 years. Arrangements for confidential destruction will 
then be made.  
18.       Informing your General Practitioner (GP) 
With your permission, your GP will be notified that you are taking part in this study. The 
letter will explain fully what participation in the trial involves. 
19.    What will happen to any samples I give? 
The samples obtained during the course of study will include blood and tissue from liver 
(which are taken as per routine practise). The tumour tissue will be stored in the pathology 
department as per normal clinical practice but the biopsy taken (to assess ischaemia-
reperfusion injury) from the sample will be destroyed after 18 months. 
 The samples will be stored in the Department of Pathology, St James’s University Hospital 
in accordance with the Trust policy of storing and safeguarding of pathological samples. 
20.        Will any Genetic testing be done? 
This study does not involve any genetic testing of samples. 
21.       What will happen to the results of this clinical trial? 
The results of the study will be available after it finishes and will usually be published in a 
medical journal or be presented at a scientific conference. The data will be anonymous and 
none of the patients involved in the trial will be identified in any report or publication.  
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If you wish to receive a copy of these, you should let your study doctor know so that it may 
be sent to you when it is ready. 
22.   Who is organising and funding this study? 
You will not be paid for participation in this study. The study will be funded by the National 
Institute of Health Research (NIHR). The routine costs for this operation and post-operative 
care and follow-up will be billed to the National Health Service as normal. You can ask the 
study co-ordinator for any additional costs as result of your participation in this study. 
23.     Who has reviewed the study? 
The study has been approved by the local research ethics committee responsible for St 
James’s University Hospital. Their role is to check that the study is acceptable from an ethical 
and safety point of view in the interests of the patients participating. 
This study was given favourable ethical opinion for conduct in the NHS by Yorkshire & The 
Humber - Leeds East Research Ethics Committee. 
 
 
 
24.    Contact for further information 
 
You are encouraged to ask any questions you wish, before, during or after your treatment. If 
you have any questions about the study, please speak to your study doctor, who will be able 
to provide you with up to date information about the procedure(s) involved. If you wish to 
read the research on which this study is based, please ask your study doctor. If you require 
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any further information or have any concerns while taking part in the study please contact 
one of the following people: 
Principal Investigator: Mr K Raj Prasad (Tel. Number: 0113 2066665) 
Principal Co-Investigator: Mr Samir Pathak (Tel. Number: 07779 607659) 
Lead Research Nurse:  Ms Catherine Moriarty (Tel Number: 0113 2064672) 
If you decide you would like to take part then please read and sign the consent form. You will 
be given a copy of this information sheet and the consent form to keep. A copy of the consent 
form will be filed in your patient notes, one will be filed with the study records and one may 
be sent to the Research Sponsor. 
Thank you for taking the time to read this information sheet and to consider this study. 
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9.5 Consent Form 
 
 
 
John Goligher Colorectal Unit 
Colorectal & HPB Research Office 
Ground Floor Lincoln Wing 
St James’ University Hospital 
Beckett Street 
Leeds 
LS9 7TF 
                                                Tel: 0113 2064672 / 0113 2069215 
                                                       Catherine Moriarty / Louise Clarke       
 
 
PATIENT CONSENT FORM  
 
Randomised Controlled Trial of Pringle Manoeuvre versus Portal Vein Clamping in Patients 
undergoing Liver Resection for Colorectal Liver Metastasis - A Pilot Study 
 
 
Patient ID: …..………………..  Initials: ………………………..       Date of Birth: 
………………...     
 
                                                                                                                             Patient initials 
 
 
1. I confirm that I have read and understand the information sheet dated 28/10/2013 for the 
above study, and have had the opportunity to ask questions. I understand that my 
participation is voluntary and that I am free to withdraw at any time without my medical 
care or legal rights being affected.  I agree to take part in the study. 
 
2. I understand that my medical records may be looked at by authorised individuals from the 
Sponsor for the study, the UK Regulatory Authority, Independent Ethics Committee or 
from the NHS Trust in order to check that the study is being carried out correctly. I give 
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permission, provided that strict confidentiality is maintained, for these bodies to have 
access to my medical records for the above study and any further research that may be 
conducted in relation to it. I also give permission for a copy of my consent form to be sent 
to the Sponsor for the study. 
 
3. I understand that even if I withdraw from the above study after the surgical procedure, the 
data and samples collected from me will be used in analysing the results of the study. I 
understand that my identity will remain anonymous. 
 
4. I consent to the storage including electronic, of personal information for the purposes of     
      this study. I understand that any information that could identify me will be kept 
 strictly confidential and that no personal information will be included in the study report 
 or other publication. 
 
5.   I consent to receiving a phone call from the research team just before my operation and  
      at 30 days after my operation for purposes of follow up and data collection                                                                                                
        
6. I agree that my GP, or any other doctor treating me, will be notified of my participation 
 in this study. 
 
7. I agree that the samples collected for this study will be stored for potential future research.  
 However any future study will be subject to approval by Research Ethics Committee.             
______ 
      (This is optional and should not hinder your participation in the current study) 
 
____________________________  _________________________________________________ 
Name of the patient    Patient’s signature and the date the patient signed the  
Consent form 
 
_________________________________
 __________________________________________________ 
Name of the Investigator    Investigator’s signature and date the Investigator signed the  
taking written consent    consent form 
 
 
Original to be retained and filed in the site file. 1 copy to patient 
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9.6 Learning Plan  
Please see attached on next page 
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9.7 Published Article 
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